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ABSTRACT
It is now believed that there is a significant association between skeletal blood flow and
the movement ofother ions in and outof bone. Bone is capable of regulation of this flow
but this is affected by factors such as physiological stimuli, arterial blood pressure and
humoral agents which can override this ability. The effects of vasoactive substances,
noradrenaline andATP and calcium regulating hormones,PGE2, PTH andcalcitonin on
bone blood flow and strontium clearance have been investigated in an experimental
model in the rat.
In order to proceed with this work smaller studies were undertaken to develop and
validate the technique used to measure flow and clearance. These included;
1. validation of choice of cannulation site,
2. investigation of rat bone haematocrit,
3. determination of an appropriate withdrawal rate.
Cannulation of the carotid artery and insertion of the cannula into the ventricle provides
adequate mixing of the microspheres, withdrawal at the caudal artery (0.197ml/min) an
adequate reference sample. The haematocrit work suggests that a correction factor may
be required when using this procedure as the haematocrit of rat bone is consistently less
than that of the caudal artery. However the results in this study are too variable to
incorporate this finding in the bone blood flow and clearance work.
The main study involved the use of radioactive microspheres to estimate bone blood flow
and strontium-85 for clearance in rats weighing approximately 350 grammes. This
involved cannulation of the carotid and caudal arteries with injection of the agent and
microspheres via the carotid and reference blood samples withdrawn from the caudal.
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For each animal blood flow and strontium clearance in bone, arterial blood pressure and
blood flow in muscle were measured and from these strontium extraction and vascular
resistance in bone and muscle were calculated.
Infusion of noradrenaline resulted in a significant decrease in blood flow and an increase
in blood pressure, while ATP caused a significant decrease in only blood pressure.
Neither agent had any effect on strontium clearance. Parathyroid hormone produced a
significant decrease in both bone blood flow and blood pressure with a general trend of
decreasing clearance with increasing concentration (not significant). While administra¬
tion of PGE2 significantly reduced blood flow, pressure and strontium clearance.
Calcitonin had no effect on any variable apart from strontium clearance. This was
dependent upon the degree of change at the 50U. dose which represented an increase of
30% while at the other doses clearance remained relatively constant.
With all groups, there was a significant relationship between blood flow and strontium
clearance, but the slope of regression was significantly different from the control group
for PGE2 only. This shows that PGE2 was having a direct effect on bone independent
of its effect on blood flow. In the normal untreated animal a change in flow is reflected
by a change in clearance, indicating that some vascular mechanism is involved. The
PTH, ATP, calcitonin and noradrenaline animals all demonstrate this same pattern
suggesting that these also act through some vascular mechanism, either directly or
indirectly. But PGE2 has a direct effect on strontium clearance indicating that some
othermechanism may be involved, possibly through a non-vascular effect. This would
therefore invalidate the use ofclearance measurements as estimates of bone blood flow.
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INTRODUCTION
1.1. Bone function and cellular composition
Bone is a complex arrangement of cells matrix and mineral which functions as an
accessible mineral store and structural support. Its structural role is obvious: the
skeleton serves as a framework upon which the soft tissue of the body are supported so
that the form of the body and an erect posture can be maintained. The storage ofminerals
in bone is a secondary function and to some extent is incompatible with its structural
role.
The control ofmineral metabolism in the body is dependent on processes occurring in
the kidneys, intestine and bone. Each playing an important role in maintaining the
mineral balance, particularly plasma calcium levels. Within bone, formation and
resorption occur continuously and play an important part in the maintenance of this
balance. Hormones causing resorption bring about the dissolution of both the mineral
and organic phases, affecting the skeletal content and its ability to support the soft tissues
correctly. In fully developed bone there is a balance between bone resorption and bone
formation, while in growing bone an inbalance of these causes remodelling of the bone,
but growth in length is the result ofmore complex processes (Smith 1984). Defects in
any of these processes or metabolic disorders can result in abnormal bone which does
not function efficiently with respect to its role of structural support and mineral storage.
Of the three major components of bone it is the cells which mediate these conflicting
demands. Each cell type is primarily associated with a specific function and together
these are responsible for the formation, mineralisation and remodelling of bone. The
osteoblast's main function is to lay down the osteoid matrix and to some extent play a
part in the mechanism of calcification. An essential role in resorption is played by the
osteoclast, although the mechanism of this action is still today under review. There is
no question however, of the osteoclast's essential part in the process, since so many
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factors, e.g. parathyroid hormone, that affect resorption producemarked changes in this
cell type. Finally with regard to the osteocyte views concerning its function are
controversial. However it, is agreed that this cell is necessary for the maintenance of
bone as a living tissue. The activity ofeach cell is influenced by hormones, local agents
and mechanical factors.
1.2. Vascular supply
Throughout life a two-way chemical traffic between blood stream, cells and matrix is
required to maintain this cellular activity. Thus the vascular supply of bone is important
with respect to this exchange.
The literature cites the long bone as the general model for description of the blood supply
to bone. This represents the chief type ofosseous tissue and is a fundamental component
of the appendicular skeleton. A long bone consists of three regions: the metaphysis at
either end made up of mostly cancellous bone surrounded by a protective layer of
compact bone and the diaphysis, a shaft of compact bone which contains the medullary
cavity (Figure 1.1.). The blood supply consists of three basic components: (a) the
nutrient artery, (b) the metaphyseal combined, after closure of the growth plates, with
the epiphyseal arteries, and (c) the periosteal arteries. Brookes considers the principle
nutrient artery and the metaphyseal arteries to represent the main components of the
bone nutrient system (1971).
Nutrient artery
The nutrient artery and its branches supply at least two thirds of the cortex by a
centrifugal method, from the endosteal to the periosteal surface. This principle of the
nutrient artery system always holds even though there are major anatomical variations
within the mammalian species (Rhinelander 1972). Arising directly from
the systemic circulation, the nutrient artery enters the diaphysis by a distinct foramen.
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Figure 1.1. Osseous tissue
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In the medullary cavity it branches into ascending and descending branches (medullary
arteries) subdividing into radially orientated arterioles. These penetrate the endosteal
surface of the diaphysis where they go into Haversian canals.
Haversian systems tend to develop as animals age i.e. in the young stages bone is mainly
composed of lamellar bone which develops into Haversian systems, the numberof these
systems varying between species (Figure 1.2.). This is to some extent a compromise
since Haversian bone is less efficient in terms of surface area of vascular channels per
cm (Halstead 1974). Additionally the osteocytes can become cut off from the nutrient
source when the cement lines of the new canal is laid down. However the one main
advantage of the Haversian system over the lamellar structure is its ability to be
remodelled. In adult bone a balance is struck between the efficiency and strength of the
lamellar bone with the adaptability of Haversian bone and thus adult cortical bone
contains both lamellar andHaversian systems. The number ofHaversian systems varies
from species to species and is dependent to some extent on how bone is laid down. In
man and dogs there are a large number of these systems while in rodents this number
decreases and the percentage of lamellar bone increases.
Each Haversian canal is contained within an osteon, which is considered to be the basic
morphological unit of compact bone. The degree of mineralisation, size of Haversian
canal and activity of cells in the canal differs between osteons. Unless bone is being
resorbed (combined action ofmany cells including the osteoclast) or formed (osteoblast)
the Haversian canals are lined with 'resting osteoblasts'. The centre of each Haversian
canal contains one, and occasionally two blood vessels which ultrastructurally resemble
capillaries (Cooper et al 1966). These authors noted that where two vessels were seen
one was often smaller and thicker than the other. This confirmed the observations of
Branemark (1959) who remarked that when two vessels were present, the flow of blood
was in opposite directions. An adequate blood supply is maintained by transverse canals
which connect each osteon with the major endosteal and periosteal vasculature.
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A haversian system of cortical bone, between each system there are
interstitial lamella.
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Metaphyseal arteries
The metaphyseal system, as well as supplying the metaphysis, acts as an important
adjunct to the medullary circulation. Within the medullary cavity the metaphyseal
arteries anastomose with the terminal branches of the ascending and descending
medullary arteries, thus providing the medullary cavity with a metaphyseal supply.
Efferent vascular system
Drainage for this extensive capillary network is provided by the components of the
efferent vascular system. This includes (a) in the diaphyseal region the emissary veins
and the vena comitans of the principle nutrient artery, (b) in the epiphyseal region the
veins accompanying the epiphyseal artery, (c) and marrow sinusoids which drain
directly into the central venous sinusoids.
1.3. Regulation of blood flow in bone
In the mid-19th century sympathetic nerves were observed in the blood vessels
supplying bone by M. Gros, this finding to be confirmed by Ottolenghi in the early
1900's (Tendevold 1983). Their activity appears to arise through changes in arterial
blood pressure and denervation or stimulation ofcarotid and aortic baroreceptors. In the
seventies these were demonstrated to affect blood flow, in particular reducing the flow
upon stimulation (Shim et al 1972). Simultaneously measuring systemic blood
pressure, blood flow and intermedullary pressure of bone, these authors found a good
correlation between blood flow and medullary cavity pressure, thereby supporting
Shaw's earlier view that a positive correlation existed (Shaw 1963). This evidence
implies that intramedullary pressure is bone blood flow dependent and reflects the
changes in the haemodynamics of bone.
Tondevold (1983) suggested that medullary pressure therefore reflects the circulatory
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conditions in bone and thatmeasurementof this was a good indicatorofbone blood flow.
Measuring both arterial and intra-osseous pressure in tubular bones in dogs he identified
the "threshold" point at which medullary pressure dropped in response to arterial
pressure. The medullary pressure was constant at all measured sites if the arterial
pressure was kept above 80mmHg. Five to ten mmHg below this critical level there
was a sharp fall in the medullary pressure.
Since medullary pressure reflects changes in blood flow the above suggests that bones
are capable ofmaintaining constant flow rates if the arterial pressure is 80mmHg. Upon
stimulation the sympathetic nerves present in bone blood vessels can affect this flow.
Thus the factors responsible for this action are important when considering bone blood
flow.
1.3.1. Physiological stimuli
Brookes (1971) suggested that venous efflux through the nutrient veins of bone would
be promoted by muscular activity. Using microspheres as indicators ofbone blood flow
Gross etai (1979) investigated this, finding that in conscious dogs exercising caused an
increase in bone vascular resistance as a result of bone vessel constriction, in contrast to
profound vasodilation in the skeletal muscle. This indicates that bone participates in the
redistribution of blood flow during exercise.
A more recent study detected a delayed hyperaemia after submaximal exercise, with the
duration of the exercise possibly important in determining the extent and the time of
blood flow increase (Tendevold 1983). During exercise a steal phenomenon may come
into action, vasodilation of the muscle decreasing the effective inflow to the medullary
region of bone. This delayed hyperaemia could be a repayment response to compensate
the bone for some built up metabolic deficits.
While investigating the relationship between bone blood, flow and the clearance of
labelled substance, Schoutens (1979) found that flow could be modified over a wide
range of physiological values by heating or cooling the limbs. Mean blood flow
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increasing by 88% in the warmed tibiae and decreasing by 66% in the cooled tibiae
compared with the value at rest. During the physiological stresses of exercise bones
appear to participate in the redistribution of blood. Since exercise results in increased
muscle temperature one would expect the heating of a limb to result in similar
vasodilation.
1.3.2. Arterial blood gas composition
Like other tissues bone requires oxygen for the normal metabolic processes. Therefore
the oxygen content of blood and its ability to take up the by-product of these processes
is important when considering blood flow in bone.
Decreasing arterial oxygen tension in the blood supplying dog hind limbs results in
vasodilation causing an increase in blood flow of the femoral artery (Ross et al 1962).
This means that a vasodilation in the tissues of the hind limbs occurs, increasing the
general blood flow, with the presence or absence of oxygen acting as a stimulus. Two
mechanisms could be responsible for this: firstly the cells of the tissues could compete
for the available oxygen limiting the supply to the smooth muscle cells of blood vessels
so they are unable tomaintain constriction. Or secondly, the actual lack ofoxygen could
cause vasodilatory substances to be released. Tendevold (1983) demonstrated that the
relationship between intraosseous pressure and arterial oxygen tension begins to come
into action at an oxygen tension of 75mmHg.Above this point intraosseous pressure is
independent of the arterial oxygen tension. A reduction in bone perfusion occurs which
could be due either to an increased sympathetic tone and/or to steal phenomenon from
other tissues, a shunting of blood from supplying bone to othermore vital organs arising
when the oxygen tension falls. The vasodilation of muscle and surrounding tissue
increasing flow and directing blood from the bone vascular network could give rise to
this phenomenon.
Bone, in particular bone marrow, consumes oxygen and produces carbon dioxide as a
by-product. The process of osteogenesis is dependent on carbon dioxide (C02) tension
Introduction 1 - 8
and is increased by raising this over aminimum (Wilmer 1965). Erickson et al (1979)
have identified a linear relationship between arterial blood gas tension and medullary
blood gas tension, in particular for carbon dioxide. This means that the carbon dioxide
content of bone seems to be correlated to the arterial content. However there appears to
be no active regulation of this.
1.3.3. Hormonal
Research into humoral regulation on blood flow has been extensive. These studies
suggest that as in other vascular beds hormonal production influences bone circulation.
The vasoconstrictive action of adrenaline was demonstrated by Drinker and Drinker
(1916). Using a method of bone marrow perfusion, vasomoter nerves were stimulated
with adrenaline. Extending this study Tran et d (1978) examined the effect of drug
treatment on the intramedullary pressure in dog tibiae. Adrenaline was found to cause
an increase in perfusion pressure and a fall in medullary pressure, consistent with its
action as a vasoconstrictor. The administration of alpha-inhibitors reduced or sup¬
pressed this increase indicating the possibility of intraosseous vasoconstrictor alpha-
receptors.
Noradrenaline has been found to have a direct constrictor effect on bone vessels^ t he
magnitude of this constrictor response being dependent on the initial flow rates (Gross
et al 1979, Driessens and Vanhoutte 1979). The walls of blood vessels serving bone
contain vascular smoothmuscle cells which contract in the presenceof alpha-adrenergic
agonists. Since the action of both adrenaline and noradrenaline is abolished by alpha-
adrenoytic drugs itwould appear that these are acting on the smoothmuscle cells causing
this constriction. McCarthy et al (1985) investigated bone blood flow before and after
infusion ofnoradrenaline or adenosine tri-phosphate (ATP). As expected noradrenaline
decreased bone blood flow and increased bone vascular resistance by acting as a
vasoconstrictor, whereas ATP increased bone blood flow and decreased bone vascular
resistance, implying that ATP dilates resistance vessels. This vasodilatator^ effect of
adenosine on marrow vessels had previously been noted by Gross et al in 1979.
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Itwould appear that the action ofnoradrenaline, adrenaline and ATP is probably a direct
effect of the respective agent on vascular smooth muscle surrounding the arterioles,
mediated through adrenergic receptors present in smooth muscle cells.
Evidence is accumulating that parathyroid hormone (PTH) influences vascular resis¬
tance as well as the rate of bone resorption. In an attempt to separate this hypotensive
property from the hypercalcemic action of PTH Pang et al have conducted a series of
studies. They have identified the possible amino acids involved in each process, the
synthetic fragments of bPTH containing amino acids 24-34 and 24-28 having hypoten¬
sive activity in rats and dogs. Finding that blood flow was increased in renal cortex,
heart, liver and stomach, they concluded that PTH has a direct vasodifatatory action on
vascular smooth muscle (Pang et al 1981,82,84). If this is the case one would expect
bone blood vessels to react in the same manner, thereby increasing blood flow to bone.
However Driessens et al (1981) found that PTH had no direct effect on canine blood
vessels and only increased flow during the hypercalcemic phase of action. Since PTH
was not found to alter significantly the smooth muscle cell response to adrenergic
activation, its action would not appear to be through this mechanism, unlike calcitonin
and hydrocortisone, whose effects on bone is due to some extent on their direct effect
on bone blood vessel smooth muscle cells.
It is therefore apparent that bone is highly responsive to both external and internal
stimuli. These give rise in some cases to vasodilation or vasoconstriction, possibly
through action on the smooth muscle cells of bone blood vessels. The result is control
of blood flow, pressure and to some extent the systemic blood volume. Apart from
affecting the ability of bone to regulate blood flow, some of these factors, in particular
the humoral, can influence the exchange of minerals between blood and bone. Here the
question is can blood flow alone alter this exchange ?
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1.4. Mineral Exchange
Before discussing the control of this process it is important to note that "exchange"
when used to describe the movement of ions has different definitions depending upon
the authors citing the phrase. This can be broken down into two descriptions, firstly
exchange is "any process involving equal and opposite rates of transfer of calcium ions
to and from one microscopic volume of bone" ( a microscopic volume = 10pm cubed)
(Marshal et al 1959, Rowland 1966). Secondly exchange is used to describe the
movement of ions in relation to hydroxyapatite crystals i.e a precise mechanism is
concerned (Groer and Marshal 1973). Here I refer to the later definition, the process of
calcium movement in relation to the bone surface.
As stated in section 1.1. bone has two main functions, mineral storage and structural
support. With reference to these mineral exchange can be discussed under the headings
skeletal andmineral homeostasis. The factors controlling both are complex and to some
extent interrelated.
Skeletal homeostasismay be considered as the maintenance of skeletal integrity through
growth and remodelling of the skeleton. This is affected by hormones, mechanical
stress, pressure and other external factors.
On the other handmineral homeostasis is the control of the level ofminerals throughout
the body. It is maintained by a complex system of controlling factors acting on the
skeleton, absorption process of the gut and excretion by the kidney. The mechanisms
for the exchange of minerals and the factors affecting this in bone are presented here.
1.4.1. Bone-blood barrier ?
Does amembrane exist separating bone fluid from extracellular fluid ? In 1971 Neuman
argued that the circulating fluids could not be in equilibrium with bone surfaces; thus a
membrane must exist separating a perivascular space from the bone fluid. Talmage
(1969) suggested that a layer of cells separates the Haversian capillaries and the
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mineralisedmatrix at the periphery of the canal. This results in two fluid compartments,
one of which is directly associated with mineralised tissue while the other is part of the
body's extracellular fluid reservoir.
Originally the primary characteristics of the bone fluid compartment were considered
to be the low calcium and the high potassium levels in the blood compared to the
extracellular fluid. A calcium pump could account for the low level, the mineral actively
transported against a concentration gradient out of the cell, while the excess potassium
has been suggested to be under cellular control (Geisler 1969, Ramp 1971, Scarpace
1976 a).
Recent work by Pinto and Kelly (1984) argues against this excess potassium, suggesting
that it can all be accounted for by cell volume. The implication is that potassium
exchange is a cell dependent process as other tissues. Therefore arguing that there is not
a barrier controlling the potassium flux. These authors conclude that the there is no
barrier separating the extracellular fluid of bone and like other tissues, that bone has a
vascular space, an interstitial fluid space and an intracellular fluid space. Thus the only
barrier separating the plasma and the interstitial space is the capillary wall. This
however disagree with the findings of Scarpace (1976 b), who investigated the influx
and efflux of calcium and phosphorous across the membrane into calvarial bone. He
found that these fluxes were concentration-dependent, a model of passive diffusion.
This supports the concept of a barrier controlling the fluxes of certain minerals.
However the exact relationship of the osteocytes (the cell type separating two compart¬
ments), the extracellular fluid and the adjacent bonematrix is not known. The proximity
of these suggest the possibility of a close physiological relationship, perhaps that of
mineral homeostasis.
1.4.2. Pathway for exchange
For minerals and ions to pass to the bone matrix they first have to pass through the
capillaries to the interstitial fluid. It is generally accepted that minerals and ions
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exchange by diffusion and water by filtration or osmosis. If it is accepted that there is
some form of control of transport from capillaries, to bone then the structure of this
barrier is important when considering the passage of minerals.
Essentially a capillary is a tube like structure with walls composed of a single layer of
endothelial cells. There are three types: continuous, fenestrated and discontinuous. The
thin-walled nature of the vessels allows lipid soluble substances to pass across the the
capillary by diffusion processes. Numerous authors have investigated this transcapil-
lary exchange, demonstrating that water and water soluble lipids do indeed pass through
pores in the capillary wall by passive diffusion (Pappenheimer 1953, Crone 1963 and
Davies et al 1976). It has been pointed out that this passive diffusion was dependent
uponmolecular size, the larger the molecule the larger the diffusion coefficient and thus
the slower the movement across the capillary wall (Hughes et al 1977). Within the
capillary the blood flow is also important in determining the equilibrium point of this
diffusion. At low flow rates the concentration of solute decreases continually along the
capillary length so that an equilibrium point is reached before the distal end of the
capillary. Thus the transport rate is directly proportional to the flow and is said to be
flow-limited (McCarthy et al 1983). On the other hand at higher flows there is less
chance of this point being reached and extraction becomes diffusion-limited.
Within bone the capillary structure varies depending on the location. Thus this is
important when considering exchange at the different locations i.e. marrow and cortex.
The microvascular networkofmarrow changes with age, in the adult animal themarrow
consists of adipose tissue (yellow marrow) while in the immature animal this is
composedofactive haemopoietic tissue (redmarrow). There is variation in the capillary
type between these two types of marrow the size of vessel varying according to the
functional state. In the active haemopoetic tissue the vessels are small and sinusoid in
nature (Trueta and Harrison 1953). These authors were not able to demonstrate open
fenestrations (pores) between the endothelial cells. But Zamboni and Pease (1961)
found small gaps in the sinusoid wall structure of rat long bone. These could represent
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artifacts and be of no importance to exchange, however the lack ofbasement membrane
underlying the reticular cell cytoplasm means that marrow sinusoids would present
minimal hindrance to exchange.
In cortical bones the capillaries are contained within the Haversian canal (page 2 -1.2.).
Hughes and Blount (1979) have shown that in the rat the cortical capillaries are similar
to those in skeletal muscle, although a basementmembrane surrounding these was not
identified. Cooper etai (1966) noticed that intercellular capillary clefts were present in
cortical capillaries, spaces of 175 A between adjacent endothelial cells could be
measured. Thus the transcapillary movement of substances could occur through two
pathways: 1. passive diffusion of lipophilic substances through these clefts and 2.trans-
port by pinocytic process across the endothelial cells for larger molecules such as
albumin which cannot diffuse through transcapillaiy clefts.
Crone (1963) used amethod ofmulti tracer injection into the vascular system as ameans
of obtaining a ratio of permeabilities for substances e.g. inulin to sucrose in muscle.
When this technique was applied to bone the relationship between permeability and
diffusion coefficients for lipo-insoluble substances (diphosponate, sucrose, sodium,
fluorine and strontium) was established. In this case a linear relationship was demon¬
strated for the lipo-insoluble complexes while the fat-soluble substances showed much
higher permeabilities. This establishes that diffusion through bone capillaries is
dependent on molecular size (Hughes 1980).
Large molecules such as horse radish perioxidase have been observed to penetrate the
canalicular lacunae region of bone after injection intravenously (Doty and Scofield
1972). This supports the findings of Cooper et al (1966) and implies that the transport
of larger molecules is by pinocytic processes.
Thus the normal mechanism of solute uptake in cortical bone appears to be by passive
diffusion through the capillaries of the haversian system. These solutes pass through
capillary clefts to the interstitial fluid and pass on to bone. In the marrow the presence
of clefts has not been proved however the thin-walled nature of the vessels provides
minimal hindrance to passage.
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1.4.3. Biological factors affecting mineral exchange
Bone is a storage site in the body for calcium, phosphate, sodium, carbonate and other
ions. This function, as a reservoir, assists in the maintenance of the concentration of
these ions in the tissue fluids. All are of importance in the metabolic processes of the
body but, with respect to its bone it is the mechanism of calcium homeostasis that has
been widely reviewed. The ways in which calcium is deposited on the organic matrix,
and the mechanisms that control the calcium equilibrium in the body being of particular
influence. Calcium moves in both directions between plasma and bone surfaces, the
quantity exceeding that involved in bone turnover. Thus the extracellular fluid is
constantly replaced. In order to maintain constant plasma levels there must be some
mechanism that keeps these fluxes in equilibrium. One concept involves two linked
mechanisms, firstly hormonal control of skeletal turnover and secondly extracellular
regulation i.e. hormonal action on the gut and kidney, t he linking of the systems
ensuring that the action ofone does not negate the action of the other (Parfitt 1976). Here
it is the hormonal mechanism of control that is discussed.
Hormonal action
It has been demonstrated in vitro that administration ofPTH stimulates bone resorption.
The evidence from work with numerous experimental systems supports the theory that
PTH increases the recruitment of osteoclasts from the osteoprogenitor cells, leading to
the activation of new remodelling cycles and thus to an increase in bone turnover. In the
rat, using scanning electron microscopy Jones et al (1970) found the resorbing surface
of bone to increase after PTH treatment but that the nature of the surface remained the
same. The early action ofPTH appears to be the activation ofcyclic AMP, noradrenaline
inhibits this while propanolol has no effect (Heershe et al 1974).
Apart from this increased resorption PTH administration affects plasma calcium levels.
Webster et al (1974) found that in culture, calcium and phosphate ions are released in
a 2:1 ratio with PTH treatment. The release of calcium is linear and occurs over such
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a wide range of concentrations that this can be used for an assay in vitro. Grubb et al
(1977) demonstrated that in vivo plasma calcium levels are raised with PTH treatment.
The work of Parsons et al suggests that this rise occurs after an initial period of transient
decline. Movement of calcium from the plasma to bone occurring within two minutes
of injection decreasing the plasma calcium levels. Dacke and Shaw (1987) disagreewith
this initial influx of calcium into bone finding that PTH inhibits the exit of acutely
injected 45-Ca from the plasma, thereby supporting the elevation of plasma calcium
through this inhibitorymechanism. The timing of this response is dependent on the dose
and varies in sensitivity between species. Dacke and Shaw (1987) found that 45-Ca
uptake was inhibited within three minutes in chicks with prostaglandin E2 (PGE2) and
PTH treatment, while in rats the timing of the response to PTH was similar but less
sensitive. Unfortunately this study did not allow bone blood flow to be measured
directly.
The timing of these two events i.e. histological changes caused by bone resorption and
the hypercalcemic response have been widely investigated along with the third charac¬
teristic action of PTH, that of a hypotensive response. It appears that these are distinct
actions of the hormone and these occur at different intervals after administration. Raisz
and Niemann (1969) found that changes in plasma calcium could be seen within hours
but that at least 24 hours were required before histological evidence of increased
resorption in response to PTH could be seen. This was confirmed in the work of
Tatevossian (1973) who noted that the hypercalcemic response was rapid and occurred
long before any morphological changes.
With respect to the hypercalcemic action Pang et al (1982, 83) studied this, along with
the hypotensive effect, identifying the portions of the hormone involved in each. The
bPTH 1-34 portion was required for each response but the 24-28 a.a. portion was crucial
for the hypotensive action and the 1-2 a.a. for the hypercalcemic action. These authors
also found that the hypotensive response was immediate, whereas the hypercalcemic
response required time to develop.
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In some respects the effects of prostaglandins are similar to those of PTH, both appear
to act through cAMP and calcitonin inhibits both. The demonstration byKlein andRaisz
(1970) that prostaglandins were able to resorb bone directly in vitro has been confirmed
by several groups. In normal and diseased states of bone prostaglandins are thought to
have important effects on mineral release . However unlike PTH reports on the effects
of PGE2 on plasma calcium levels are conflicting. Several authors have noted that
PGE2 administration to rats and dogs failed to produce a hypercalcemic response (Beliel
et al 1973, Klein et al 1970) while other authors have found that in vivo PGE results in
a similar if generally smaller hypercalcemic responses as PTH (Vanderweil et al 1979,
Voelkel et al 1975). The work of Dacke and Shaw (1987) supports the hypercalcemic
action of the hormone. They suggest that a decrease in clearance of 45-Ca label in
response to PGE2 andPTH could result from inhibition of calcium uptake by bone, this
inhibition representing a mechanism underlying the hypercalcemic action .
It is clear that prostaglandins like,PTH,are potent bone resorbers but that prostaglandins'
role in regulation of calcium release in bone is uncertain. It is possible that the action
ofprostaglandins is through a secondary mechanism where the the action ofother agents
requires the synthesis of prostaglandin (Martin 1983).
Vitamin D is also important in the control ofplasma calcium. Production of this vitamin
appears to be controlled by secretion ofPTH, which then acts on the kidney. Vitamin D3
then moves to the gut and stimulates calcium transport across the intestinal epithelium.
This in effect increases plasma calcium concentration the level acting as a controlling
factor in PTH secretion (Williams 1981) It has also been demonstrated that this vitamin
effects the skeleton, a deficiency affecting calcification (Vaughan 1981). Inhibition of
bone resorption results in a decline in the release of minerals.
Calcitonin, the most potent inhibitor, lowers both calcium and phosphate levels in the
plasma (Tashjian 1965). The greatest effect occurs between 30 minutes and 3 hours.
When ingested the effect on bone cells is immediate (Vaughan 1981). This hypocal-
cemic response ismoremarked in young animals and is greatly reduced in older animals.
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This action however is not just the opposite of PTH but a complex interaction with the
hormone in order to control plasma concentration.Other work shows that calcitonin
probably also plays a vital part in the protection of the skeleton from excessive
osteoclastic resorption (Stevenson et al 1979)
1.5. Theses objectives.
In summary, bone is capable of regulation of blood flow but this is affected by factors
such as physiological stimuli, arterial blood pressure and humoral agents which can
override this ability. Many investigators have shown that vaso-active and calcium
regulating hormones affect flow in bone. However little work has been done to identify
the relationship between drug concentration and response. This study was set up to
identify this relationship. Recent work has shown that PTH and PGE2 have a rapid
inhibitory effect on calcium uptake in bone. Both these substances are known to have
vascular effects. Therefore this study also investigated these vascular effects with
respect to altered uptake of minerals to see if a change in blood flow alone could alter
this uptake by bone.
These factors have direct orthopaedic applications. The technique of skeletal scanning
relies on labelling compounds eg 18-F and Tc-99m that are incorporated into the bony
matrix of hydroxyapatite. Skeletal uptake of these bone seeking radionuclides is flow
dependent (McCarthy et al 1980). If the flow can alter the uptake of minerals then its
suggests that the uptake of the labelled compound will be affected. Similarly if the
metabolic activity of bone itself can affect this extraction process then the use of
clearance measurements as a method of estimating bone blood flow in vivo is question¬
able.
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Rats were chosen as the experimental animals for three reasons.
1. Previous bone blood flow and mineral clearance studies have used this species and
therefore direct comparisons can be made.
2. The rat is amammalian species and thereforemore comparable with human bone then
would be if a non mammalian species was used. Although rat bone is not comparable
in terms of structure i.e. a high percentage of lamellar bone compared to human, the
general blood supply to the bones is similar.
3. The expense and access to large numbers was also a factor in the choice of the
experimental animals. A more comparable bone structure would be provided using a
dog model but this would have involved a high expenditure and have severely limited
the number of animals in each group.
The work fell into three categories.
1. Vascular supply and Histological presentation
The structure and vascular supply to long bone has been well documented. This varies
to some degree from species to species so here the intention was to establish the vascular
supply and examine the Haversian / lamellar content for rat bone. Also to view the bone
types which form the basic unit of long bone i.e.the trabecular and cortical bone. Thereby
enabling a comparison to be made with the findings of others authors in these areas.
2. Development and validation of the technique to measure blood flow and
strontium clearance in the rat
This section reviews the problems in establishing the correct protocol for the measure¬
ment of bone blood flow andmineral clearance in the rat. The results of an initial control
group are presented and the associated problems discussed. These include choice of
cannulation site, pump setting, bone haematocrit, method ofdrug administration and the
error parameters associated with the technique. Each topic is tackled in turn and small
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studies were set up in an attempt to validate each choice. The findings of these are
documented in the conclusion and are discussed with reference to the experimental
protocol.
3. Measurement of blood flow and mineral clearance in a rat
This represents the main point of the work to establish the effects of calcium regulating





The intention was to attempt to quantify effects of these agents creating dose response
curves for each. In addition to examine if a change in blood flow can alter the uptake of
mineral by bone or if mineral exchange can be altered independently of blood flow.
The plasma calcium levels were examined to study whether effects onmineral exchange
in bone could alter these values.
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VASCULAR SUPPLY AND HISTOLOGY
2.1. Introduction
It has been established that bone is provided with an adequate supply of blood by the
nutrient artery, metaphyseal arteries and the epiphyseal arteries. The principle of a
centrifugal method of blood movement from the endosteal to the periosteal surface has
been described by Brookes and Harrison (1957). Methods of investigating the layout of
blood vessels in bone include indian ink perfusion (Irving 1965) and injection of radio-
opaque media into the main vessels followed by x-rays (Rhinelander 1968).
With reference to rat bone the illustration of this vascular network has been well
reviewed by Brookes (1971). This author describes the nutrient arteries as perforating
the cortex of the diaphysis and the bone extremities. These then pass into the bone
marrow and divide to form the medullary arteries, while the compact bone of the
diaphysis is supplied by cortical blood vessels.
The use of barium sulphate (radio-opaque) allows easy visualisation of the nutrient
vessel and its ramifications in long bone. Immediately after removal and cleaning, the
bones can be x-rayed and the vascular network viewed, although decalcification of the
bone can make the vessels appear clearer. The micropaque however is too viscous to fill
any but the larger vessels. The extensive processing that is required to visualise the
vascular network using ink includes clearing of the bone, a time consuming and tedious
technique which limits its use.
Histological preparations allow further detailed examination of the vascular supply and
nature of rat bone . The foundation of all good histological preparations is adequate and
complete fixation. This is required to prevent putrefaction and autolysis of the samples,
without damaging the tissue in any obvious manner. Thus the tissue should be as close
to the living state as possible. With respect to bone the calcium salts present in the matrix
form a barrier to sectioning .
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Once fixed, bone can easily be cut into thick sections (100pm) either transversely or
longitudinally, then x-rayed or stained to examine the bone type i.e. compact or
cancellous bone. Thinner undecalcified sections can be cut however this is more
difficult, but decalcification of bone allows easier examination of the cellular nature.
This involves the dissolving of the calcium salts by treatment with acid leaving behind
the organic matter and cellular components in order to section the tissue. The criteria of
a good decalcifying agent are :
(i) The complete removal of calcium salts.
(ii) The absence of any damage to tissue cells or fibres.
(iii) Non-impairment of subsequent staining processes.
Once cleared the bones are then embeded, sectioned and stained. The above criteria have
been taken into consideration with respect to the processing of rat long bone. EDTA was
used to remove the calcium without damaging the tissue. This allowed basic staining
techniques to then be used ie. Toluidine blue.
In order to visualise the capillary network, blood supply, lamellar /Haversian strucures
and the cellular make up of the rat bone barium sulphate perfusion has been used along
with sectioning of decalcified and calcified bone.
2.2. Barium sulphate perfusion
2.2.1. Methods
A saturated solution of barium sulphate was made by dissolving the powder (Barium
Sulphate Precipitated, Fisons Scientific equipment) in neutral buffer.
After anaesthesia (sodium pentabarbitone 60mg/ml - 0.1ml per lOOg body weight,
injection into the abdominal cavity) the rat was prepared for perfusion. The abdominal
cavity was opened allowing access to the thorax, this was then cut along its length and
the diaphragm retracted displaying the heart. A needle was then inserted into the left
atrium and through this the barium sulphate solution was injected under pressure (20ml
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per 400g animal). Immediately before this the animal was given an overdose of Sagatal.
The vena cava was cut during this procedure to prevent a build up of pressure and to
allow drainage of the circulatory system. Both femora and tibiae were removed and
placed in 10% neutral buffered formalin to be fixed.
After an initial x-ray, to determine the distribution of the barium sulphate (40KV for 4
minutes usingKodak Technical Pan Film 4415 andHCl 100 developer. Figures 2.1. and
2.2.) the bones were decalcified using EDTA (saturated aqueous solution of ethylene-
diamine tetra-acetate 10 per cent). The whole bone required approximately a week but
the end point was determined chemically. The determination of the end point was
important to ensure that the bone was not exposed to the decalcifying agents longer than
necessary. Testing for calcium ions dissolved in the decalcifying fluid adequately
indicates the end-point.
1. 5ml of decalcifying fluid nearly neutralised with Sodium Hydroxide bubbled with
Nitrogen
2. Add 1ml of 5% sodium or ammonium oxalate
Turbidity of the fluid indicates calcium is present, absence of turbidity after fiveminutes
indicates that the fluid is free of calcium.
Once neutralised and washed the decalcified bones were then re-X-rayed (35KV for 4
minutes Figures 2.1. and 2.2.)
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2.2.2. Results
The x-rays of calcified and decalcified tibia and femur are shown in figures 2.1 and 2.2.
The principle nutrient artery with its branches ascending and descending with in the
medulla can be seen in these x-rays (Figs 2.1 and 2.2.). The path of some of the main
medullary branches can be followed to the epiphysis.
Unfortunately in figure 2. there is an area of clouding in the femur head. This is likely
to have been caused by the bursting of the finer blood vessels under the pressure of the
fluid and thus the barium sulphate has escaped the vessels.
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Figure 2.1. X-ray of calcified and decalcified rat tibiae showing
main arteries (scale 2x)
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Figure 2.2. X-ray of calcified and decalcified rat femora showing




2.3. Histology of normal rat bone
Prior to sacrifice an untreated animal was given a bolus of tetracycline (2ml). The rat was
then sacrificed and the femora and tibiae removed.
These were then processed using the following methods.
1. Fixation— The bones were placed in 10% neutral buffered formalin.
Calcified sections were then cut before further processing as this removed the tetracy¬
cline. The remaining bones were then processed as follows.
2. Decalcification— The bones were treatedwith EDTA and tested to ensure complete
decalcification using sodium oxalate.
3. Dehydration— The bones were then taken through alcohol to absolute alcohol to
remove the aqueous fixative and any tissue water. This involved processing in 70%
alcohol, 90% alcohol and finally several changes of absolute alcohol.
4. Clearing— The bones were then placed in histoclear to remove the dehydrating
agent.
5. Embedding — Finally the samples were embedded in paraffin wax to allow
sectioning. The bones were then cut in cross sections (100pm) and stained
6. Staining — Toluidine Blue a general purpose stain used to highlight the cellular
content and structure of the bone.
2.3.1. Results
Figure 2.3 is a cross section of rat tibia showing the general structure of cortical bone.
The particular type of bone in the tibiae can be seen in the following figure (Fig 2.4).
Both Haversian and lamellar bone are present in the rat tibia, these occur in approxi¬
mately a 1:1 ratio. Of particular interest in figures 2.3 and 2.4 is the high proportion of
circumferential lamella on the endosteal surface compared to that of the interstitial
lamella. The section in figure 2.5. shows cells and vascular channels (which are
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probably similar toVolkmans canals). These radial endosteal canals cross the lamellar
bone towards the sites of secondary ossification (Haversian bone). This means that the
bone has a better blood supply than would be expected following secondary osteogen-
isis. This process involves the creation of new cement lines which normally restricts the
Haversian blood supply. These medial canals provide a second blood supply thereby
contributing to the total that the bone receives. Thus even the middle portion of the bone
is fairly vascular.
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Figure 2.3. Cross section of rat tibia, (100pm) stained with toluidine blue
(magnification X40)
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Figure 2.4. Polarised unstained cross section of rat tibia (lOOj^m)
(magnification X 40)
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The x-rays of the tibia and femur are similar if less informative than those of Brookes
(1971). Thus these appear to substantiate* the facts mentioned in the introduction. That
is that the nutrient artery enters the bone then divides into ascending and descending
branches which supply the medulla. These vessels then enter the cortex, supplying at
least two thirds of this area. The vessels which supply the cortex are to small to fill with
the media and therefore this is not actually demonstrated by the figures. Similarly the
x-rays do not provide information on the centrifugalmethod of blood supply, however
the blood vessels can be seen to originate within themedullary canal anddivide outwards
to towards the endosteal surface.
The photographs of the tibial sections highlight the lamellar nature of rat bone.
Although this type of bone exists in approximately the same proportion as the Haversian
type, this is a higher proportion than is found in human bone. The presence of radial
endosteal canals is important since its shows that rat bone is fairly vascular in nature.
However the number of these are less than that seen in human bone.
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DEVELOPMENT AND VALIDATION OF THE TECHNIQUE TO MEASURE
BLOOD FLOW AND STRONTIUM CLEARANCE IN THE RAT
3.1. Introduction
The measurement of bone blood flow is complicated by the nature of the circulation of
bone, the number of capillaries and veins forming a complex network that creates a
multitude of difficulties. Although there are numerous methods for estimating this
variable most involve the use of radioactive labels and fall into one of three categories.
Each of these have certain advantages and disadvantages which are discussed here.
a. Clearance of "bone seeking" tracers as an estimate of bone blood flow
Clearance can be defined as the removal of the tracer from blood during its passage
through the organ of interest. Assuming that in bone the extraction of the tracer is
complete or at least occurs at a constant rate, a fixed proportion thus accumulates in the
bone. It has been claimed that 18-Fluorine is completely extracted in a single circulation
(Van Dyke 1967, Wootton 1978, Humphrey et al 1982). The validity ofWootton's
technique has been questioned with particular reference to the maximum transit time
through bone and the minimum recirculation time (Tothill and Hooper 1984). For the
single passage measurement technique to be valid there must be sufficient time for any
of the tracer that is not taken up to leave the bone (transit time) yet recirculation must
not be allowed to occur. Tothill shows that the maximum transit time through bone is
greater than the minimum systemic recirculation time. Therefore invalidating the use
of this technique to measure extraction ratios in rabbits.
The extraction ratio of unity for 18-Fluorine has been questioned by Brookes (1979)
who states that 'this has never been demonstrated in the case of any bone-seeking
isotope'. Copp and Shim (1965) support this view, at least for strontium-85. These
authors measured the extraction of this isotope with a multiple dilution technique,
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finding that in a five minute period the extraction ratio was 0.76 and not unity. Yet in
1963 Shim assumes an extraction ratio close to unity when estimating the blood flow in
the rabbit humerus and the tibiofibula.
It has in fact been demonstrated that the extraction of diffusible tracers are flow rate
dependent (Crone 1963, Renkin 1959, Tothill et al 1984). At low flow rates this
extraction is said to be flow-limited while at higher rates the extraction becomes
diffusion limited since the transit time is too short for the ion to diffuse sufficiently, the
equilibrium point is not reached.
Therefore the variable levels of clearance means that bone blood flow cannot be
quantitatively measured using this technique. However the non-invasive nature of bone
seeking radionuclides make this the best available method of estimating blood flow in
human studies,
b. Freely diffusible tracers
Although this method has become well established for measurement of blood flow of
specific organs it presents numerous problems in measuring bone blood flow. This
technique is based on the principle that blood flow determines the removal of the
introduced tracer and therefore the characteristics of the tracer are important. These
include; 1. that the tracer be freely soluble thus dissolving in the blood and, 2. that the
tracer flow freely having no haemodynamic effects. The method of introduction of the
tracer, timing of re-circulation and heterogenous nature of bone blood flow all
contribute to the difficulties of using this method to measure bone blood flow.
Lahtinen et al (1981) used 133-Xenon to estimate the washout curves of bone and
marrow. However certain assumptions are included in the paper about the assignment
of the fast and slow portions of the curve without sufficient validation, for example that
the nonhaematopoietic compartment determines the whole washout curve in the cases
where bone contains no marrow. This brings into question themethod ofcalculation and
use of the correction factors in the Lahtinen paper thus suggesting the findings presented
are misinterpreted. Additionally xenon was introduced intravenously leading to label-
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ling of numerous other tissues as well as bone which is not advantageous.
The one advantage of this technique is that the tracers do not have to be radioactive. A
hydrogen washout technique has been used to measure blood flow in cardiac muscle,
skeletal muscle and brain. Using this methodWhiteside et al (19771 have demonstrated
that epiphyseal and trabecular bone have approximately two fold higher rates than that
of diaphyseal cortex. These regional differences in blood flow have also been
demonstrated by Shim et al (197T) using a bone seeking radioisotope, and by Brookes
(1967) using labelled red blood cells.
This procedure is however invasive, the bone is drilled and the electrodes placed in the
holes. Therefore this method is unsuitable for use in human studies,
c. Arteriolar blockage
This method is dependent upon the blockage of arterioles by labelled tracer introduced
into the arterial circulation in one passage, thus no re-circulation of the tracer should
occur.
The technique involves mixing radioactive microspheres with the blood supply allow¬
ing the particles to circulate in the systemic circulation and these then trap in capillaries
and arterioles in proportion to the blood flowing through the vessels. The microspheres
reach their final destination in the capillary bed in one passage of blood through an
organ. Arterial blood is withdrawn at a known rate before, during and for a short time
after the injection of the microspheres. This gives a reference sample of mean blood
radioactive concentration during the withdrawal period to compare with the activity of
the tissue under investigation. After sacrificing the animals the tissue of interest is
removed, weighed and then alongwith the reference blood sample counted for activity.
From these counts the Tissue Blood Flow can be estimated,
Tissue count - Background
Tissue Blood Flow X Rate of withdrawal
Reference blood count - Background
This can then be divided by the weight of the tissue to give the results in the form
ofml/min/g.
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Additionally if the activity of the micropheres is measured before injection the
proportion of cardie output flowing to reference organs can also be calculated.
The following guide lines should be followed for the use of this technique if the
estimation of blood flow is to be valid.
1. The microspheres must be well mixed and evenly suspended in the blood.
2. The microspheres must be of a size to ensure entrapment in the system during the first
passage in the circulation.
3. There must be sufficient numbers of microspheres to satisfy the requirements of
statistical treatments.
4. The microspheres must be of a uniform size and no preferential arterio-venous
shunting should occur.
The above produces conflicting requirements. Firstly microsphere size; these have to
be large enough to trap in the systemic system yet small enough to give realistic values
of blood flow. Furthermore, the microspheres must not have haemodynamic effects
which would alter this blood flow. However numerous studies have established the
requirements which fit these criteria i.e. injection of spheres into the heart (Tondevold
1983), optimum size of 15pm diameter (Gross et al 1979), minimum number of
microspheres (393) in a sample (Buckberg et al 1971).
This technique has some advantages over (a) and (b). Firstly it allows blood flow to
be estimated in the whole skeleton, individual bones and portions of bones in the same
animal. Any changes in flow due to some intervention can be followed using multiple
injections ofdifferent labelledmicrospheres. And the use ofmicrospheres with mineral
analogues allows bone clearances and blood flow to be simultaneously measured.
Therefore the relationship between flow and clearance can be interpreted and drug
response can be examined. It is important to note that the microspheres must not have
any haemodynamic effect themselves or the use of the technique in assessing drug effect
is inappropriate. This method is unsuitable however for human studies due to the
radioactive nature of the microspheres and the invasive procedures involved in the
technique.
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3.2. General methods
3.2.1 The microspheres and isotope
This study measured both bone blood flow and mineral clearance in the same animal.
Thus changes in flow as a result of treatment could be related to changes in clearance.
Microspheres with different labels allows two separate measurements of bone blood
flow to be made and compared. Cobalt-57 andTin-113 (New England Nuclear) were
selected because these gamma emitters have completely different energies and long half
lives.
Principal Photon Energy Half Life
Cobalt-57 122-136 keV 271 days
Tin-113 393 keV 115 days
Thus the counts from the two sources could easily be distinguished in the gamma
counter, crossover only occurring downwards i.e. tin into cobalt, simplifying the
calculations. Also the long half life of these two isotopes meant that counting could be
delayed when necessary, without significantly affecting the counts. This long half life
ensured that the microspheres were still relatively active in the later days of dispensing
when the bottles of microspheres could be months old.
Strontium-85 was chosen to estimate mineral clearance in bone. This is a calcium
analogue and exchanges directly with calcium hydroxapatite crystal in the bone and
therefore its clearance is representative of calcium exchange. Although calcium-45 is
available this is a beta emitter and when used with gamma emitters the emissions of this
isotope are difficult to distinguish. Strontium-85 is a gammaemitter the energy ofwhich
is higher than both cobalt and tin, therefore cross over occurs into both of these.
Principal Photon Energy Half Life
Strontium-85 514 keV 60 days
Before dispensing the microspheres the syringes were coated with silicon (Sigma). This
involved drawing the silicon into each syringe and then emptying it. These syringes
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were allowed todry out before use. This was done tominimise the extentof microspehre
adhesion to syringe walls. Approximately 0.2ml each of cobalt-57 and tin-113 labelled
microspheres were drawn into separate siliconised syringes. This represented about
200,000microspheres with an estimated activity of5pCi (NEN; 0.5mCi in 20ml physiol
solution). A third syringe was used to dispense 0.05ml of 85-SrCl solution, this volume
has an approximate activity of 5pCi (Amersham lmCi in physiol solution, made up to
10ml using saline).
Activity per microsphere
Before using a new source ofmicrospheres the activity of individual microspheres was
estimated (CPM = counts per microsphere) and then compared with the manufacturers
specific activity (DPM = disintegrations perminute). This allowed the calculation of the
number of microspheres to be made in each sample and acted as a secondary check
ensuring that the minimum number (393) for 95% confidence limits were met.
The process involved dispensing a diluted solution of each microsphere type onto cm2
pieces of graph paper on microscope slides. This was then covered with selotape and
the slides viewed at lOx magnification in order to see the actual microspheres (Figure
3.1.). Approximately 200 microspheres were on each slide and could be easily counted
by eye and three counts were made on each slide. These counts were averaged and the
activity of each counted along with the standard for each isotope. The activity of each
microsphere type was then estimated from the total number of spheres and the activity
count.
Thus for two sources the counts per microsphere from new bottles were;
Standard
1. Cobalt-57 66 counts per microsphere 16/11/88, 22085
2. Tin-113 116 counts per microsphere 16/11/88. 43155
The information sheet from the manufacturer details the specific activity at their
calibration date e.g.3/11/88
Cobalt-57 3/11/88 55DPM microsphere
Tin-113 81DPM "
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Figure 3.1. An example of the 15p diameter spheres on graph paper
(magnification X 100)
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These two values can be compared since "count" refers to a detected "disintegration".
As it is unlikely that all disintegrations would be reflected in the "count", CPM should
be less than DPM. This is not the case here and could have occurred because the number
ofmicrospheres on the slides was underestimated. The microspheres were some times
crushed when the Selotape was added to the slide and these could have been mistaken
for artifacts and not included in the count. Additionally the presense of the Selotape
occasionally made it difficult to focus, thus microspheres could have remained
undetected. These figures did however allow the counts perminute to be related to the
standard. In each case the counts per microsphere is over estimated, therefore the use
of these values ensured that the number of microspheres in each sample was under
estimated rather than overestimated. Thus a cutoff level of400 actually reflects a higher
number ofmicrospheres, ensuring that the criteria necessary for 95% confidence limits
were met.
The activity per microsphere decreases with time (radioactive decay) but the standards
were made from the same source and on the same date as the slides used to calculate the
CPM. This means that an estimate of counts per microsphere in the standard can be
adjusted each time it is counted in the gamma counter. Thus the decay can be taken into
consideration and the specific activity of the microspheres can be estimated throughout
the period any one bottle is used. Therefore an approximate number of counts per
sample could be calculated as a check that at least 400 microspheres were present in the
measured samples.
3.2.2. Dissection and cannulation
Before beginning the dissection the cannula were prepared. This involved filling the
cannula with heparin (Evans 5000U in 1ml) to coat the cannula and prevent blood clots
blocking the cannula. This cannula was then flushing with saline containing 0.05%
heparin and connected to a syringe containing this solution.
Adult male Sprague Dawley rats weighing approximately 300-400 grammes were
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anaesthetised using sodium pentabarbitone (60mg/ml) at a concentration of 0.1ml per
lOOg body weight. This was injected into the abdominal cavity. The response of the
animal was tested by strong squeezing of its hind foot pads. When fully anaesthetised
the rat was placed on an electric heating pad covered with Benchkote.
An incision was made in the top portion of the tail, only deep enough to penetrate the
skin. Using forceps this was widened to expose the connective tissue, and by cutting
through this the artery below was uncovered. Once the artery was identified a pair of
tweezers were passed under, to allow a loop of suture (Ethicon) to be pulled through.
During this procedure it was important to ensure that the vessel did not become twisted.
The suture was cut in two, the lower portion of the vessel was tied off and the suture held
with a pair of artery forceps. The upper tie was looped and also secured with a pair of
forceps. These were either held by an assistant or latched so as to apply pressure to the
artery thus cutting off the blood flow. A lateral cut was then made in the artery and a
cannula (0.63mm outside diameter, Portex), was gently pushed into the artery. Once
again it was essential that neither the artery or the cannula twisted. The top suture was
then released and the cannula pushed until 2cm was in the artery. This was then secured
using the suture to tie the vessel to the cannula. Bloodwas drawn up the cannula to check
for adequate withdrawal and then the cannula flushed using the saline filled syringe
(Figure 3.2.)
Using forceps and scissors a cut 2cm long was made in the mid line of the neck. The
forceps were then used to widen this, exposing the subcutaneous tissue underneath. This
fat, and associated connective tissue were teased away from this area using tweezers,
thereby exposing the underlying muscle. Themuscle to the left of themidline (Musculus
Sternohyoideus) was gently teased away from the remaining muscle creating a 'win¬
dow' access to the artery. After clearing the remaining connective tissue the artery was
lifted and a suture passed underneath. This was then cut in two and the suture furthest
from the heart tied, while the other was looped. The cannulation procedure was similar
to that for the tail. However we attempted to insert the cannula (0.75mm outside
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diameter, Portex) into the left ventricle pushing approximately 2cm into the vessel and
pulling the cannula back slightly once it came into contactwith the ventriclewall (Figure
3.3.).
In some of the control animals the femoral artery was also cannulated. A 2cm cut was
made in the groin region of either side of the animal and opened using forceps. The
connective tissue was teased away from the medial surface of the thigh and overlying
muscles separated (adductor brevis and caudo-femoralis)to expose the femoral artery.
The artery along with the associated nerve and vein was traced to the point where forms
aY-shaped branch incorporating the external iliac artery. A suture was passed under the
vessel prior to this branching and the vessel cannulated (0.75mm outside diameter,
Portex) using the method already described. Approximately 2cm of the cannula was
inserted into the vessel before tieing it off (Figure 3.2.).
In each animal a control blood flow was established using 57-Cobalt microspheres,
blood withdrawn from the tail artery at0.197ml/min/g (and in some animals the femoral
cannula) and thirty seconds later 200,000 microspheres injected via the carotid cannula.
Blood withdrawal ceased after a total of twominutes. Next the agent was either injected
or infused, withdrawal commenced, followed thirty seconds later with an injection of
Tin-113 microspheres and85-Sr. Blood withdrawal ceased after a further four minutes.
At the end of the experiments the animals were sacrificed using KC1, injected via the tail
cannula. Both tibiae and femora were removed quickly to minimise post-mortem
migration of ions into bone (Tothill and MacPherson 1978). A muscle sample from the
upper quadriceps was also removed.
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Figure 3.2. Photograph showing cannulation of both the femoral
and caudal arteries
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Figure 3.3. Photograph showing cannulation of the carotid artery
Validation 3
The samples were then prepared for counting. The bones were stripped of all muscle
and scraped with a scalpel blade thereby ensuring all tissue was removed and so also
removing the periosteum. These were weighed and placed in a test tube with a small
quantity of formalin.
The muscle sample was weighed and treated in a similar manner. The syringes
containing the blood samples were also weighed in order to calculate the actual
withdrawal rate.
These samples were then counted on aWallac L.K.B. gamma counter for 300 seconds.
Standards of the isotopes were used to determine the crossover factors. The long half-
lives of the isotopes meant that no allowance had to be made for decay in the count
period.
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3.2.3. Measurement of arterial blood pressure
A measurementof arterial pressure was made in each animal. This involved connecting
aHarvardPhysiological recorder (Figure 3.4.) to the carotid cannula via a three way tap.
This tap was connected to a second tap on the syringe used for infusion (on the infusion
pump). Therefore the carotid cannula was connected to an infusion pump and a pressure
recorder.
Bymeasuring arterial pressure constantly any effect of the agents under investigation on
blood pressure could be seen immediately and quantified after the experiment by
examining the traces provided. This allowed ameasurement of change in pressure to be
calculated.
Before the experimental procedures the Harvard recording equipmentwas calibrated. A
sealed bottle connected to a pressure transducer (Elecomatic) via a three way tap was
pressurised using a Sphygmomanometer. The minimum pressure was then established
and depending on the agent used this was set at 40mmHg (vasodilators) and 60mmHg
(vasoconstrictors). From other workers the mean arterial pressure was approximately
80mmHg and these two settings were chosen to allow the pressure to decrease or
increase from this level and still remain on the trace. The pressure was then increased
to the maximum which represented lOOmmHg above the minimum i.e. 140mmHg and
160mmHg and the highest point set. After these were set the 0.1V calibration button
was used to give a fixed reference sign; this remained constant even when the pen zero
was adjusted to increase or decrease the minimum or maximum point. Thus if the
pressure trace started to rise above the maximum setting, the pen zero was adjusted to
maintain a constant reading and 0.1V button used to re-calibrate the system.
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Figure 3.4. Photograph showing the Harvard Physiological Recorder
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3.3. Method of calculation
a) Tissue flow rate, strontium clearance and extraction ratio.
Crossoveroccurs when two ormore isotopes ofdifferent energies are present in the same
sample, in this case cobalt-57, tin-113 and strontium-85. For each standard a spectrum
plot, a plot of the energy against intensity of emissions, was produced (Figures
3.5,3.6,3.7). From these the optimum windows were calculated.These represent the
windows whichminimises the crossover from one isotope into the other whilemaximis¬
ing the percentage of total counts within the window (level number).
Table 3.1. Windows selected and % of total counts
Window KeV % of counts
Cobalt 115-135 122 85%
Tin 172-184 392 23%
Strontium 186-198 514 55%
The setting of these windows reduced the spillover of the lower energies into the higher
energy tracer. Cobalt-57 has a low energy and the percentage ofcounts spilling over into
the strontium window is less than 0.02% when the standards are used. This was ignored
when estimating the strontium activity of the samples thereby simplifying the calcula¬
tions. Approximately 0.06% of the counts from the tin standard spectrum plot are found
in the window selected for strontium. This small spillover of tin into the strontium
channel was also ignored when estimating the strontium tissue activity.
Although the spillover from tin into cobalt window is low, less than 3%, this is sufficient
to require a spillover factor. Similarly the strontium spillover into cobalt (7%) and tin
(4.8%) also requires calculation of a spillover factors. These were calculated using the
following equations.The calculations assume that there is no spillover up from the lower
energy tracer into the window for the higher energy.
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Figure 3.5. Spectrum plot of 57-Cobalt standard
LEVEL NO % OT CRM 0 195000 390000 585000 7B0000
035-040 0, 01 151 I
040-045 0.01 95 I
045-050 0.01 189 I
050-055 0.02 •2' I
055-060 0. 04 596 I
060-065 0.04 682 I
065-070 0. 03 578 I
070-075 0.03 512 I
075-080 0.03 578 I
080-085 0.05 872 I
0:90 0.06 946 Ti.
090-095 0.09 1560 1
095-100 0.21 3499 I




■JJL i -J .2. I-
110-115 2. 37 39121 I-
115-120 7.29 120399 I-
120-125 47.21 780187 I-
125-130 31. 18 515272 I —
130-135 4.75 78479 I-
135-140 0.57 9413 I*
140-145 0.55 9063 I*
145-150 0.67 11011 I*
150-155 0.89 14720 I*
155-160 0.94 15505 I*
160-165 0. 19 3177 I
165-170 0.02 I
170-175 0.03 492 I
175-180 0.01 236 I
180-185 0.01 104 I
185-190 0. 01 142 I
190-195 0.0 i. 113 I
195-200 0.01 95 I
200-205 0.02 388 X
205-71 0 03 ~r :_j TX
210-215 0.00 19 I
215-220 0.00 9 I
220-225 0. 00 19 I
4^. X- -U_ V 0. 00 19 I
0. 00 9 I
235-240 0.00 9 I
035-245 100.00 1652667
Selected window 115-135 represents 85% of total counts
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Figure 3.6. Spectrum plot of 113-Tin standard
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090-095 0.38 1204
095-100 0. 43 1342
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135-140 1.11 3476
140-145 0.87 2739






175-180 20. 96 65863
180-185 4.76 14960
185-190 0.05 145
190-195 0. 03 99
195-200 0.02 66
200-205 0. 02 59
205-210 0.01 39
210-215 0. 02 66
215-220 0.01 46
~
__ <"7: l~ 0. 00 /
























Selected window 172-184 represents 23% of total counts
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Figure 3.7. Spectrum plot of 85-Strontium standard
LEVEL NO % 01 uPM 0 1900 3800 5/00 760
035-040
~ ~ ~ HZ ~ ™ —
0.54 115
___ -j- — _______ — . — — ■—
I*
040-045 0.37 79 I
045-050 0.31 67 I
050-055 0. 46 97 I *
055-060 0.37 79
060-065 0.57 121 I*
065-070 0.77 164 J*
070-075 0.69 146 I*
075-080 0.77 164 I*
080-085 0. 89 188 I *
085-090 1.00 '"•i -j r"iji. i X- I*
090-095 1.14 243 I *
095-100 1. 14 243 I #
100-105 1.54 328 J -*
105-110 1.77 376 I ~*r
110-115 1.66 7C";•-> -_J JU. I~*
115-120 1.31 279 I-#
120-125 1.57 334 I-*
125-130 2.00 425 J
130-135 2.03 431 I *
135-140 2.91 619 J 44
140-145 2.89 613 I ■£
145-150 3. 11 661 J -
150-155 2.69 570 I
155-160 2.31 491 I ¥.
160-165 2.06 437 7 *
165-170 1.57 334 I~*
170-175 1.37 291
175-180 1.23 261 r~-M
180-185 1.39 400 i -*
185-190 19.92 4229 i *
190-195 35. 90 7621 i
i YD-^OU 0. 71 152 i*
200-205 0.03 6 T
205-210 0.03 6
2io -215 0. 06 12 I
215-220 0.06 12 I
~i(_ ~ •— cr 0. 14 30 I
225-230 0. 03 6 I
230-235 0. 06 12 I
235-240 0. 06 12 I
240-245 0.06
—- — — — —
12 I
035-245 100.00 21231
Selected window 186-200 represents 55% of total counts
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i. Spillover factor 1 for strontium into the tin channel
Sr standard counts in the Tin channel
Sr standard counts in the Sr channel
ii. Spillover factor 2 for strontium into cobalt channel
Sr standard counts in the Cobalt channel
Sr standard counts in the Sr channel
iii. Spillover factor 3 for tin into cobalt channel
Sn standard counts in the cobalt channel




Examples of these spillover factors are;
1. Strontium into tin - 0.06
2. Strontium into cobalt - 0.13
3. Tin into cobalt - 0.084
These spillover factors are then used in the calculation of true count for the tissue and
blood samples.
1. Strontium
True count = sample count - background (13)
2. Tin
True Count = sample count - background - (Sr spillover factor 1 x Sr count) (14)
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3.Cobalt
A = sample count - background
B = (Sr spillover factor 2 x Sr count)
C = (Sn spillover factor 3 x True count Tin)
True Co Count = A - B - C (15)
The cobalt blood sample is obtained before the other isotope are added therefore there
is no spillover from the other sources. Thus calculationof true blood count is simplified.
1. Strontium and 3. Cobalt
True blood = sample count - background (13)
2. Tin
True blood = count - background - (spillover factor 1 x Sr count)
(16)
In each case the tissue flow can now be calculated using the following equation:
True Microsphere count in tissue x pump rate (ml/min)
BLOOD FLOW =
True microsphere count blood
(17)
These results are then divided by weight of tissue to give values in ml/minute/g.
The removal of strontium from blood during its passage through bone is defined in
terms of clearance.
The exact relationship between clearance and flow can be explained in algebraic terms,
bringing in the additional variable of extraction.
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e.g. If Ca(t) = Quantity entering the system with time
and Cv(t) = Quantity leaving the system with time
then Extraction = i Ca -fcv
I Ca
Then letting the change in quantity = dM
and the change in time = dt
with flow represented by f. a change in quantity overtime can be described as
dM = f.jca(t) -|f. Cv(t)
dt
therefore M = F. [Jca(t)dt - Jcv(t)dt] at time T
Thus clearance, which is the quantity not deposited in the tissue over the time period of
the experiment
ie. Total Quantity (Ml
Quantity entering the system with time [Ca(t)dt]
Thus Clearance equals Flow times Extraction
Strontium clearance can be calculated using the following equation:
True Sr activity in sample x pump rate (ml/min)
CLEARANCE = (18)
True Sr activity in blood
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This value for clearance is then divided by the weight of tissue to give the results in the
form ofml/min/g.
Strontium-85 can only be partially cleared during its passage through bone and
therefore it can be assumed that the value for bone blood flow is greater than that of
clearance. The extraction ratio which represents the proportion of strontium deposited
is calculated from the values of flow and clearance.
Extraction = Clearance / Flow rate (19)
(b) Change in arterial blood pressure.
The arterial blood pressure was measured during the entire procedure, although each
animal was connected to a perfusion pump the perfusion did not alter the pressure
reading to any extent so this recording was accepted as arterial trace. I was therefore
able to note the pressure at specific points in the experiment. These were;
B1 blood pressure at point of cobalt microsphere injection,
B2 blood pressure at beginning of experimental run,
B3 blood pressure at point of tin microsphere injection,
B4 blood pressure at point of maximum drug effect.
Therefore the extent of the action of the administered agents on pressure could be
established. The change in arterial pressure as a result of any treatment is calculated
from B2 and B4.
i.e. Change in blood pressure = B4 - B2. (20)
In some cases B3 and B4 are the same value so this one value is used in the calculation
of the change in blood pressure and the vascular resistance during the Tin blood flow
measurements.
In the untreated animals i.e. controls the the values for B1, B2, B3 and B4 are all similar
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and no statistical difference is found. However for some of the experimental animals the
difference between B2 and B3 is significant as is the difference between B2 and B4. In
all cases B1 and B2 are similar, but for the calculation of pressure change the value at
the beginning of the experimental run is used to ensure that the administration of cobalt
microspheres has no direct effect on the arterial pressure.
(c) Vascular resistance.
Vascular resistance can be defined as the impediment of blood flow through a given
portion of the circulation. To calculate it the formula shown below is used;
arterial blood pressure - venous blood pressure
V.R. = (21)
Blood flow
In practice the venous blood pressure from the systemic circulation is so small in relation
to the mean arterial pressure that this can be disregarded and the mean arterial pressure








The method of analysis used throughout this document are:
1 the Student t-test; paired for flow, pressure and vascular resistance change and
unpaired used to test for significant differences from control values,
2. regression analysis (X variable i.e. drug dose is fixed) to test the significance of trends
in bone blood flow etc. This identifies the correlation between the concentration ofdrug
and the variable examined. A form of the t-test was then used to see if the slopes of
regression are significantly different from one another.
For example, the regression lines for :
1 Control Animals — dose versus strontium clearance.
2 PGE2
i.e bl - b2
t= on (nl + n2) - 4 D.F. (23)
{var bl - b2}
Where b = the slope of the line of regression and the standard error of the slope is the
square root of its variance.
3. correlation (X and Y variables are random), thus viewing the relation of one variable
to the other.
In the case of the paired t-test i.e. for flow, arterial pressure and vascular resistance
change, the assumption is that a correlation exists between pre and post treated
measurements. The magnitude of this change dependent upon the concentration of
administered drug not the initial baseline. Thus animals within any dose group should
exhibit changes of the same degree irrespective of the base line and the two measure¬
ments should be correlated. The extent of this association is discussed with respect to
the control animals in this chapter (3.5.6).
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3.5. Development of procedure
This will be divided into 6 sections.
The first section includes the initial study to identify potential problems associatedwith
the technique. These problems are then studied in greaterdetail in the following sections
which attempt to identify the cause and suggest changes to the protocol to rectify the
situation. The discussed areas ofdifficulty include choice of cannulation site, assumed
haematocrit values, choice of pump setting andmethod of randomising the selection of
drug and the dose used.
Finally the last section dealswith the degree ofassociation between pairedmeasurements
with respect to the control animals for the experimental data (i.e. control group 3)
3.5.1. Control animals
Study one — Control group 1
An initial study was conducted on eighteen animals to see if the injection of micro-
r
spheres had an adverse effect on blood pressure and also if a time delay between two
measurements of blood flow resulted in any change. The data of two animals are not
included because insufficient blood was collected during the first blood flow measure¬
ment to establish an estimate of bone blood flow. The results for the remaining sixteen
Sprague Dawley rats are presented in Table 3.2. (control group 1).
a). Method
1. The animals were dissected and cannulated as set out in section 3.2.2. This study was
set up to view the efficiency of the suggested protocol therefore only the carotid and
caudal arteries were cannulated.
2. Measurement of blood flow
The choice, dose and supplier of the microspheres is detailed in section 3.2.1.
In each case two separate measurements of flow were made using two different labelled
sets of spheres.Thus for each animal two blood samples were obtained.
Thirty seconds before themicrospheres were injected blood withdrawal from the caudal
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cannula commenced and this ceased after a total of two minutes (0.197ml/min).
Approximately 200 000 cobalt-57 and 113-tin microspheres were injected via the
carotid cannula. These injections were separated by about two minutes and during the
entire test period the rats were infused with buffer via the carotid cannula at 6ml/hour.
This was done to ensure that the cannula remained patent so that the microspheres could
be injected and to replace some of the blood lost by the animal. Therefore over each test
measurement 0.2ml of buffer was infused.
3. Arterial blood pressure was also monitered during the experimental period, the
recorder connected to the animal via a tap attached to the carotid cannula.
4. The animals were sacrificed and both femora and tibia removed and all samples
measured for activity.
b). Results
Table 3.2 highlights the variation in the difference between the two flow measurements
that can occur in any individual animal, however as a group this difference is low and
is not significant (t=l.59 D.F.=13).
The mean values for flow for this group
i.e. Flow 1 Flow 2
0.386 ± 0.193 (SD) 0.305 ± 0.131 (SD)
are higher than those ofmost other authors (Hruza et al 1969, MacPherson and Tothill
1978, Schoutens et al 1979). This could have arisen through differences in either the
technique or the age and species of the animal used.
eg. Hruza - blood clearance measurements using Calcium-45, male and female rats
sampling the tibia.
MacPherson - microsphere technique, Wistar rats, 2-17 months old sampling tibia
and fibula.
Schoutens - bone plasma flow using red blood cell labelling in female Sprague
Dawley rats.
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Table 3.2. Control group 1, infusion of saline over the test period at
6ml/hour (Flow measurements separated by 2 minutes)
Flow* #
Rat no. 57-Co 113-Sn Sn-Co Sn/Co
1 0.231 0.287 0.056 1.24
2 0.160 0.087 -0.073 0.54
3 0.121 0.111 -0.01 0.92
4 0.412 0.307 -0.106 0.74
5 0.643 0.357 -0.286 0.55
7 0.579 0.172 -0.407 0.30
9 0.441 0.314 -0.127 0.71
10 0.457 0.254 -0.203 0.56
11 0.131 0.541 0.41 4.13
12 0.698 0.522 -0.177 0.75
13 0.462 0.407 -0.055 0.88
14 0.310 0.306 -0.004 0.99
15 0.220 0.271 0.051 1.2
16 0.543 0.328 -0.215 0.6
X 0.386 0.305 -0.082 1.0
SD 0.193 0.131 0.192 0.94
* Flow is measured in ml/min/g
# Students paired t-test, t =1.59 D.F.= 13 Not significant,
x = mean. SD = standard deviation
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These values are however similar to the top range of the values of Fredrickson et al
(1955),who cite a range of 0.1 - 0.3 ml/min/g of tissue for bone blood flow.
The arterial pressure traces during these tests were unaffected by injection of the
microspheres, indicating that any effect found after injection of test drug should be due
to the test solution.
Study two — control group 2
A second control group was then studied. Control group 2 consists of eight rats with
similar injections of tracer separated by a time period. The procedure was changed to
incorporate a 2ml bolus injection ofbuffer, representing injection ofsome of the agents.
Unfortunatly two rats were of theWistar variety and these are not included in the results
a). Methods
1. The dissection and cannulation method was the same as the control group 1 animals.
2. Measurement of control blood flow - Cobalt-57 (0.2ml of 20ml saline solution, NEN
0.5mCi)
Thirty seconds after begining withdrawal (0.197ml/min) from the caudal artery Cobalt-
57 was injected via the carotid cannula. Blood withdrawal ceased after a total of two
minutes.
3. Measurement of test blood flow - Tin-113 (0.2ml of 20ml saline solution, NEN
0.5mCi)
Prior to the second measurement of flow a 2ml bolus of buffer was injected via the
carotid cannula, approximately two minutes after stopping the withdrawal for the first
measurement. The cannula was reconnected to the infusion pump. Thirty seconds after
this withdrawal from the caudal artery was begun. After a further 30 seconds the tin-
113 microspheres were administered via the carotid cannula followed by injection of
strontium-85. Thus in addition to flow, clearance was measured.




The difference between the two flows in any particular rat is small apart from numbers
2 and 8, and as a whole this difference is insignificant (Table 3.3.).
The mean values of flow are once again higher than those of the authors cited in study
1 but agree with those of Fredrickson et al (1955).
Thus the evidence shows that a time lapse (approximately 2 minutes) between the two
determinations of flow does not result in any loss ofaccuracy and that any change in flow
is caused by the substance injected not the microspheres.
Using the flow and clearance values extraction has been calculated (column 6). All but
one value is greater than one. As explained in section 3.3. extraction is an indication of
the proportion of strontium deposited and reflects the quantity of strontium that remains
in the system i.e. is not cleared by the blood. Extraction is dependant on both flow and
clearance and since it is unlikely that all strontium entering the system is deposited,
clearance should be less than flow. Here clearance is greater than flow suggesting that
strontium is actively deposited. This discrepancy could have arisen through either an
underestimation of flow or an overestimation of clearance.
Thus before proceeding further the problem associated with the extraction ratio had to
be identified and an attemptmade to rectify the situation or a correction factor calculated
that could be incorporated into the drug study. The sources of error which could give
rise to either an underestimation of flow or overestimation of clearance could arise from
the actual microsphere technique. As clearance cannot be greater than flow this would
suggest that the problem is related to an underestimation of flow. Therefore a review
of the technique was undertaken. Firstly the cannulation sites were considered compar¬
ing withdrawl at the femoral and caudal sites. Next the haematocrit of the bone and
caudal arteries were investigated to see if either plasma of microsphere streaming
occured. Finally the rate of withdrawal was reviewed to see if this was inappropriate,
possibly causing the vessel to clamp down and thus not allowing collection of sufficient
microspheres.
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Table 3.3. Control group 2, injection of buffer as 2ml bolus before second
batch ofmicrospheres
Flow* # Strontium
Rat no. 57-Co 113-Sn Sn-Co Clearance* Extraction
1 0.127 0.266 0.099 0.353 1.56
2 0.199 0.404 0.205 0.316 0.78
3 0.205 0.237 0.032 0.365 1.54
6 0.278 0.297 0.019 0.725 2.44
7 0.443 0.351 -0.092 0.369 1.05
8 0.554 0.286 -0.268 0.65 2.27
x 0.301 0.3 0.001 0.46 1.61
SD. 0.164 0.07 0.163 0.18 0.65
* Flow is measured in ml/min/g
# Students paired t-test, t = 0.01 D.F.= 5 Not significant,




Study three. — Withdrawal from the caudal and femoral arteries simultaneously
1. Choice of the caudal artery.
It is accepted that cannulation of the carotid artery allows an entry point into the left
ventricle of the heart, providing optimummixing of the microspheres. The choice of the
caudal artery as a reference sampling point is disputed, Brookes (1971) feels that the
caudal artery, with its caudal glomeruli is more representative of a mixed supply than
an arterial source. Therefore the use of this vessel would not supply an arterial blood
sample required for the calculation of bone blood flow.
Although the femoral artery can be cannulated this is not as easy a process as cannulation
of the caudal artery. In order to locate the femoral artery extensive dissection of the groin
region may be required, while location of the caudal artery only really requires an
opening to be made in the upper portion of the tail. Also use of the femoral artery limits
the useful bones to only one side meaning that the number of injectedmicrospheres has
to be increased to ensure that the two bones contain a sufficient number to allow 95%
error limits.




1. The syringes used for withdrawal were weighed prior to the experiment so that the
actual withdrawal rate could be calculated.
2. Investigating this, I conducted a series ofexperiments in which both both the femoral
and caudal arteries were cannulated (3.2.).
3. Measurement of flow.
The choice, dose and supplier of the microspheres is detailed in section 3.2.1.
Both cobalt-57 and tin-113 were used to establish bone blood flow measurements. The
injection of the two tracers, via the carotid cannula was separated by a few minutes
allowing the animal to recover and to establish two flow measurements for comparison.
Over the entire test period buffer was infused via the carotid cannula at 6ml/hour .This
ensured that the cannula remained patentWithdrawals of reference blood samples were
made from both the femoral and caudal arteries simultaneously (0.197ml/min for two
minutes).
4. The animals were sacrificed and both femora and tibia removed and all samples
measured for activity.
5. The syringes were weighed after collection and the actual withdrawal rate calculated.
i.e. (Weight 2 - Weight 1) / S.G.B.
Withdrawal = (24)
Time of withdrawal
S.G.B. = Specific Gravity of Blood — 1.05
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b). Results
There is no significant difference in the flow values obtained from the two sources
(Table 3.4.). The mean values for the cobalt measurement is almost identical at the two
sources i.e. 0.19 and 0.187 ml/min/g. And although the two femoral measurement are
slightly different, i.e.0.05 ml.min/g difference, this is not significant.
Table 3.4. Comparison of blood flow using two sampling sites in the
same animal
Cobalt-57* Tin -113*
Caudal Femoral Caudal Femoral
0.213 0.164 0.114 0.132
0.05 0.108 0.05 0.08
0.19 0.144 0.134 0.198
0.292 0.344 0.105 0.128
0.134
0.048
* Flow is measured in ml/min/g
Number of animals (n) = 4.
None of the paired t-tests are significant,










Study four. — Withdrawal from the caudal artery followed by dual sampling
The flows estimatedof study three (Table 3.4.) are lower than thosemeasured in animals
where only the caudal artery has been used for withdrawal (Table 3.2. and 3.3.). This
may have arisen because blood has been withdrawn at two sources in study three,
possible causing the vessels to clamp down or streaming of the microspheres to occur.
In study four the procedure has been changed to allow a comparison between single
cannulation and sampling (carotid artery) and dual cannulation with sampling of blood
at two sites (carotid and femoral arteries). This should identify if it is the effect of
sampling at two reference points that reduces the measured blood flow in study three.
a). Methods
1. The animals were prepared as detailed in section 3.2. cannulating the carotid and
caudal arteries. The choice, dose and supplier of themicrospheres is detailed in section
3.2.1.
2. The animal was connected to the pressure recorder and infusion pump (6ml/hour) via
two three-way taps attatched to the carotid cannula.
3. Blood withdrawal from the caudal cannula was started and after 30 seconds
Cobalt-57 microspheres were injected via the carotid cannula. (Withdrawal 0.197ml/
min for 2 minutes).
4. The femoral artery was then cannulated and a second flow rate established using tin-
113 microspheres. The blood was sampled at both the caudal and femoral cannula
simultaneously, the withdrawal begining thirty seconds before injecting the micro¬
spheres (0.197ml/min for two minutes).
5. The blood samples were weighed to calculate the actual withdrawal rates.
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b). Results
Withdrawal from the caudal artery has been compared with withdrawal at both femoral
and caudal sites during run two in Table 3.5.. Although there is a change in the two
caudal flow measurements this is not significant (students t-test). Statistical analysis of
the mean difference in the two tin measurements i.e. Caudal 0.707 and Femoral 0.567
shows that there is no significant difference.
Thus there is no difference in the flow estimates between the two sites (femoral and
caudal) or between the runs (cobalt and tin).
These flow estimates are well above the values for the previous study i.e. over 0.5
compared with 0.29 (maximum value in Table 3.4). These are also higher than the
values of the control group, being almost double the mean values.
Each study represented animals chosen from separate sibling groups i.e. control group
1 represented one group of sibling animals, control group two a second sibling group etc.
This therefore suggests that there is a large variation in animals between separate sibling
groups which could result in these different flow measurement groups. The variation
(standard deviation) with in any group is low indicating that the flow measurements are
acceptable. Thus a review of the selection of rats was required to examine this with in
group variation compared with the between group variation. The study is presented in
a further section.
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Table 3.5. Withdrawal from the caudal artery (run 1) compared with
withdrawal from the caudal and femoral arteries (run 2)
Caudal* Femoral * (Tin)
Cobalt Tin Tin Fem - Cau
0.904 1.007 0.986 -0.021
1.364 0.860 0.613 -0.247
0.373 0.522 0.372 -0.15
0.208 0.606 0.397 -0.209
0.465 0.502 0.569 0.067
0.440 0.743 0.466 -0.277
x 0.626 0.707 0.567 -0.14
SD. 0.429 0.201 0.225 0.139
* Flow is measured in ml/min/g
Number of animals (n) = 6.
None of the paired t-tests are significant,
x = mean. SD = standard deviation
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2. Assumed haematocrit
Study 5. Measurement of bone and caudal haematocrit
Assuming that the caudal artery is an adequate source ofarterial blood, the next question i s
whether the haematocrit of the reference sample is the sameasthe bone haematocrit. In
the control animals it is assumed that the labelled blood flowing to bone has a similar
microsphere concentration to the blood collected. If this is not the case then this could
result in the under or over estimation of bone blood flow.
Blood flow and blood volume are easy to define and possible to measure. The
measurement of tissue haematocrit involves the principle ofdilution analysis. The most
practical method ofmeasurement of red cell volume involves the use of radionuclides,
labelling a small volume of the animal's blood cells with either radioactive chromium,
technetium (pertechnate) or indium. From the dilution of the labelled cells in the
circulation of the animal the red cell volume can be calculated. Using a similar
procedure the plasma volume can be measured directly by injecting 125-1 labelled
albumin. Ameasurementofred cell and plasma volume can be made in the same animal
and the haematocrit of a selected circulation can then be calculated.
The use of red blood cell and plasma labelling allows a comparison of the haematocrit
of bone and caudal artery to be made. Therefore the results can be assessed to see if a
correction factor for either blood flow or strontium clearance is required.
a) Methods and materials
1. The animal was anaesthetised and the carotid and tail arteries cannulated following
the procedure set out in 3.2.2.
2. Red blood cell and plasma labelling
(a) 1-125 labelled Albumin and Technetium (Amerscan Stannous Agent)
A 0.01ml solution of stannous salts was injected via the tail cannula (4.0mg stannous
fluoride and 6.8mg sodium medronate in 6ml saline). Twenty to thirty minutes after the
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injection of the stannous salts a 1ml blood sample was withdrawn from the tail artery.
This sample was incubated with technetium (10-13mCi sterile eluate from Technetium-
99m generator) for ten minutes. Next the sample was centrifuged at 500g for ten
minutes, the supernatant removed and the cells resuspended in saline. This was then
injected back into the rat via the carotid cannula along with 1-125 labelled albumin
(human labelled albumin, Amersham).
(b) Chromium, Indium and 1-125 labelled Albumin (Amersham)
A 1 ml sample ofblood was withdrawn and to this 0.15ml ofacid citrate dextrose solution
(ACD) was added, this was made up to 15ml using saline and the solution centrifuged
to sediment the red blood cells (lOOOg for 5 minutes). The supernatant was then
removed and type cells resuspended in saline. One drop of indium oxine-111 (sterile
isotonic aqueous solution of indium oxine complex) and three drops of 51-Cr chromate
(sterile solution of sodium chromate in isotonic solution) were added to this and the
mixture incubated at room temperature for 15 minutes. A further 5ml of saline was
added to wash the cells before a second centrifuging, the supernatant was once again
removed and the cells resuspended in 1ml saline. This was then injected via the carotid
cannula into the rat at the same time as the 125-1 labelled albumin.
(a) and (b)
After two minutes, to allow the red blood cells to mix in the circulation, withdrawal of
blood from the tail cannula commenced. Ceasing after two minutes.(0.197ml/minute.)
The animal was then sacrificed and the femora and tibiae removed. After the collected
blood sample was centrifuged (5 minute 3600rpm) the volume of supernatant and red
blood cells was estimated, the supernatant removed and the samples then analysed for
radioactivity.
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The energies ofeach label used determines the settings for each window, (level number)
each is set to minimise the amount of spillover between isotopes.
Label Window KeV




b). Method of calculation
For each animal we have a value for :
(1) Bone weight.
(2) Bone count (99-Tc or 111-In and 51-Cr. 125-1).
(3) Blood sample weight ( x specific density of 1.05, to give blood volume ).
(4) Blood count (99-Tc or 111-In and 51-Cr. 125-1).
(5) Measured volume of sedimented blood cells.
(6) Measured volume of centrifuged blood sample.
and using an approximate value for tail haematocrit of 45% (Brookes 1965) we can
calculate the bone haematocrit for the experimental animals.
Technetium and 1-125 labelled animals.
The spilloverof technetium into the iodine counts was small because there was a two day
delay in counting for 125-1 to allow the technetium to decay.
From each of the counts the background is subtracted.
Measured volume of R.B.C.
True Tail Haematocrit = (25)
Measured total volume.
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Bone 111-In
Volume of R.B.C. = x (blood volume x 0.45) (26)
Blood 111-In
Bone 125-1
Volume of Plasma = x (blood volume x 0.55) (27)
Blood 125-1
Volume of R.B.C.
True Bone Haematocrit x 100 (28)
(Volume of R.B.C. + Volume of Plasma)
Chromium, Indium and 125-1 labelled albumen.
This presents more complicated calculations since the 111-In and 57-Cr not only
spillover into 125-1 but into each other (Figure 3.8.).
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Figure 3.8. Diagram showing the overlapping spectrum plots of
111-In and 51-Cr
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Thus four spillover factors must be calculated before the true counts for the samples can
be obtained;
1. 51-Cr spillover into 111-In (i)
i.e. 51-Cr standard in 111-In channel
51-Cr standard in 51-Cr channel
2.111-In spillover into 51-Cr (ii)
i.e. 111-In standard in 51-Cr channel
111-In standard counts in 111-In channel
3. 51-Cr spillover into 125-1 (iii)
i.e. 125-1 standard in 51-Cr channel
51-Cr standard in 51-Cr channel
4.111-In spillover into 125-1 (iv)
i.e. 125-1 standard in 111 -In channel
111-In standard in 111-In channel
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Calculation of true chromium and indium counts
For the purpose of the calculation ;
let X = 111-In counts in A
let Y = 51-Cr counts in B
Thus X + (i)Y = Measured 111-In counts (29)
(ii)X + Y = Measured 51-Cr counts (30)
If equation (30) is multiplied by the spillover factor (i) (31)
We can calculate true X by subtracting this new equation from equation (29).
Thus (29) - X
Y = (32)
(i)
Calculation of true Iodine counts.
True count = 1-125 counts - ( Y x (iii)) -( X x (iv)) (33)
Once these "true count" values have been calculated the haematocrit of bone and tail
can be calculated as for technetium,
c). Results
The use of three separate red blood cell labels provide different estimates for the bone
haematocrit, ranging from 47 to 100 % of the assumed arterial haematocrit. The actual
values and the associated mean and standard deviations are shown in Table 3.6. The
haematocrit using 99-Tc differs significantly from the means when the other labels are
used (p<0.02 d.f.=4). Similarly the plasma and erythrocyte volumes for the three labels
differ, the 99-TC label giving higher estimates in both cases although in neither case are
these differences significant.
In the table all values are calculated using an assumed arterial haematocrit of 45%. This
is obtained from the work of Brookes(1965). However the measured arterial haemato¬
crit varied from 40-59% in the four animals where the tail haematocrit was calculated.
This represents only two measurements of tail haematocrit for each technique and the
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range may result from variation between animals or experimental variation. The study
does not allow this to be fully investigated or any statistical analysis to be made. If the
range does reflect natural variation in the haematocrit between animals this will affect,
to some extent, the variation in the tissue haematocrit. Thus the use of an assumed
haematocrit of45% would incorporate a degree of variation into the calculation of bone
and caudal haematocrit values. The use of actual measured haematocrits is considered
in the discussion but because of the degree of variation in the measured values there are
problems in the calculation of any correction factor.
d). Conclusions
This work therefore points to a difference in the haematocrit of bone and the caudal
artery. However the actual extent of this difference cannot be successfully estimated
from this study because of the extent of variation and lack of animals. The possible
causes of this difference are assessed later in this chapter, including evidence that
supports the suggestion that bone is richer in plasma and poorer in blood corpuscles than
the caudal blood. This would cause a decrease in the micropheres entering the bone
while increasing the strontium portion of labelled blood, thus giving rise to an under
estimation of flow or overestimation of clearance.
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Table 3.6. The distribution of three blood cell labels and 125-1 labelled
albumin as a plasma indicator in rat bone, assuming an arterial
haematocrit of 45%
Volume (ml/lOOg) Haematocrit R.B.C %
Technique Plasma Erythrocyte Bone Tail
99-TC 3.89 1.23 24 /
2.17 0.58 21 /
3.56 1.13 24 51
2.71 1.07 28 59
n=4 3.08 + 0.78 1.0 + 0.3 24 + 3





1.3 + 0.86 49 + '
51-Cr 0.35 34
1.10 37
n»2 0.72 ± 0.5 35 + 2
Mean ± standard deviation
* Two techniques were carried out simultaneously on the same rat thus plasma volume and
tail haematocrit are the same for the two procedures.
Validation 3-46
3. Pump setting.
Next I investigated the effects of the pump rate on flow withdrawal.
Study six. « Withdrawal rate
a). Methods
1. The animals were prepared using the same method as for study group 4.
Reviewing the estimates for femoral withdrawal rates of this group of animals it was
decided to increase the rate ofwithdrawal at the femoral cannula to 0.492ml/min which
represented the actual rate better.
2. Measurement of blood flow.
Cobalt and tin microspheres were used to measure bone blood, the same method as in
the previous studies was used i.e. injection via the carotid cannula with a short time
period between the two injections.
Using the femoral as a reference organ and the withdrawal at a constant rate the setting
of the caudal pump was varied ie.0.079, 0.197 and 0.393 ml/min.
After collection the blood samples were weighed to calculate the actual flow compared
with pump setting. The samples were then analysed for radioactivity and the data then
converted into two ratios to allow analysis.
b). Method of calculation
i. Measured withdrawal rate Caudal
Ratio of Flow (34)
Measured withdrawal rate Femoral
11. Caudal sample Ms count
Ratio ofMs count = (35)
Femoral sample Ms count
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c). Results
At none of the pump speeds do the flow and count ratios different drastically (Table
3.7.). The small numbers i.e. three animals in each group negates the use of the paired
t-test. However comparing the two ratios within each group it appears that the 0.197ml/
minute setting provides the most reproducible results, showing the least variation
between the two ratios. The ratio ofmicrosphere counts is higher than that for the flow
at the lowest setting and since the number of microspheres in the femoral blood is
relatively constant in each sample this indicates a high level of microspheres in the
caudal blood compared with the femoral, possibly caused by pooling or streaming at this
pump setting. The lower ratio for microsphere count found at the 0.393 ml/minute
setting could be caused by streaming of themicrospheres. At the higher flow rate results
suggest that the vessels remains patent during the withdrawal although on numerous
separate occasions during other flowmeasurements the vessel was seen to clamp down.
This clamping reduces flow and thus the number of microspheres collecte and makes
this withdrawal rate unsuitable.
c). Conclusion
The 0.197ml/min rate appears to be the best withdrawal rate for blood collection, since
the results are reproducible as indicated by the low standard deviation value. Although
the other two rates have similar standard deviation values there is some indication of
streaming of the microspheres and clamping down of the vessel at the higher rate, thus
making these settings less suitable.
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Table 3.7. Comparison of three pump settings on withdrawal of blood at
two sites in three animals
Rat




* a 0.09 0.17 0.19
b 0.107 0.2 0.4










b 0.29 0.56 0.55










b 0.47 0.9 0.66









# Femoral withdrawal constant— 0.492 ml/min.
* Caudal withdrawal constant — 0.079 ml/min.
** " " " —0.197 ml/min.
*** " " "
— 0.393 ml/min.
x = mean. SD = standard deviation
Validation 3-49
4. Administration of drug and experimental variation
The choice of administration was determined by the half life of the drug used and this
section reviews the control animals (group 1 and 2) to establish if injection or infusion
of the test compounds had any direct effect. The variation caused by selection of animals
from one sibling group is then compared with the degree of variation when the animals
are chosen at random from more numerous sibling groups.
Studies 1 and 2 Infusion or injection
The procedures followed and results are detailed in section 3.5.1.
Table 3.8. The mean flows and associated standard deviation values for study
group 1 and 2
Flow 1 Flow 2 Number
Control 1 0.386 ±0.193 0.305 ±0.131 n=14
Control 2 0.298 ±0.16 0.3 ±0.07 n=6
Comparison of the two methods of administration involve only flow 2, as the injection
of the bolus occurs thirty seconds before withdrawal for the second flow estimate began.
However here both flow 1 and flow 2 (Table 3.8.) are compared using an unpaired t-test.
There is no significant difference between the infusion of Krebs Ringer buffer (0.2ml)
over the test period or injection of a 2ml bolus following injection (Flow 2 t = 1.5
D.F.=18). There is also no significant difference between the two flow 1 means (t =
0.721 D.F.=18). Therefore it is acceptable to combine infusion and injection control
animals to establish the errorparameters associated with this method ofmeasuring blood
flow and clearance.This gives a control group of twenty animals.
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Table 3.9. Mean flows and standard deviations for the ail combined group
Flow 1 Flow 2 F 2 - F 1
x 0.36 0.30 -0.06
SD. 0.184 0.114 0.183
Paired t-test t = 0.63, degrees of freedom = 19 Not Significant.
These values are higher than those of Schoutens (1979) andTothill (1986).
Systemic preference ?
Control Group three— Left or right systemic preference
A review of the evidence concerning any systemic increase to one side or the other is of
relevance to the haematocrit study where because of cannulation of the femoral artery
only one set of femora and tibiae were available for counting. Using control group three
(see Section 4', Table 3.11.) the flow values have been calculated in the form of left and
right side (Table 3.10.). This table highlights the analysis of the paired data, none of the
groupings are significant when a students t-test is used (p<0.1). Thus there is no
preference for the microspheres to accumulate on either side and this evidence supports
the assumption that the microspheres have been adequately mixed in the circulation.
Table 3.10. Comparison of flow to the left and right hind limbs in control
group three animals
Left Right L - R
Cobalt 0.33 ±0.14 0.29 + 0.13 *0.03 + 0.07
Tin 0.37 ±0.16 0.33 ±0.16 *0.04 ±0.09
Tin - Co *0.03 ±0.11 *0.009 ± 0.09
All values represent mean ± standard deviation.
Number of animals (n) = 20
* paired t-test in all cases p < 0.1 i.e. not significant.
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Experimental 0 dose animals
The first two control groups (Table 3.8.) were drawn from animals which were delivered
in sibling groups, 6 to 8 animals at a time. This would decrease the variation between
animals in any one group but would increase variation between groups. Therefore
before tackling this study the procedure for selection of animals, drug and dosage was
changed. The numberof animals were ordered in larger quantities, 16-24 at any one time
and in any one day the number used was increased in an attempt to minimise
experimental variation. The drug choice was randomised, for example in the case of
PTH the 0, 4, 8 and 12pg doses were given in any order to animals from more than one
sibling group. Thus the results of any complete drug trial are gathered from animals of
different sibling groups in an attempt tominimise the variation between groups, perhaps
at the expense of increasing the variation within a group.
This third control group represents all animals given 0 drug, the animals are selected
from numerous sibling groups and the total number gathered from experiments
performed over a long time (approx 18 months). Using the mean and standard
deviations for the flow measurements the variation due to the technique can be
calculated (Table 3. I I1.).
Experimental variation
Before discussing the calculation of experimental variation some knowledge on the
types of variation in the above data is essential.
a). Firstly there is the variation within the population i.e. the spread of the values of
interest . This will therefore reflect the population variation and thus be free of any
differential treatment effect and is therefore a measure of error variance.
i.e. Var (between animals) + Var (technique).
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b) From the subtraction of two measurements made with in the same animal i.e. F2 - F1
a value for the experimental variation can be estimated, assuming that the variation
between animals has been cancelled,
i.e. Var (technique).
Using these definitions the extent of the variation resulting from the experimental
technique can be calculated.
Method of calculating experimental variation (Table 3.11)
1. Variation due to experimental technique.
F2-F1 =0.006 ±0.053
Var (F2 -Fl) = Standard deviation2
= 0.05 32
= 0.0028
= Var (Fl technique ) + Var (F2 technique)
Var (technique) of one measurement
= Var (Fl technique ) + Var (F2 technique)4-2
= 0.0028 4-2
= 0.0014
Standard deviation (technique) =10.0014
= 0.037
This is the standard deviation associated with the experimental technique for one
measurement of blood flow.
2. Variation due to experimental technique and variation between animals.
In this case we have two measurements, Fl and F2, to calculate the mean variance the
values are added then divided by two.
i.e. Var Fl = Standard deviation2 Var F2 = Standard deviation2
= 0.1242 = 0.1252
= 0.015 =0.016
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Fraction of overall =
error due to tech. [Var (between animals) + Var (technique)] {2}
In this case 0.0014-f 0.015 =0.093
Therefore the error associated with the technique is approximately 9% of the overall
error, an acceptable value. Thus increased randomness of animal and drug choice
minimises the errors associated with the technique and reduces the variation between
groups at the expense of increasing the overall group variation.
The error parameters associated with strontium clearance (Table 3.11.) cannot be
calculated in this manner. However the variation in flow caused by the experimental
technique should be the upper limit of the variation effect on clearance. The estimates
of flow and strontium clearance are measured at the same time. A plot of flow versus
clearance demonstrates that a significant relationship between these two variables exists
(Figure 3.9.). Strontium clearance appears to vary directly with flow.
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Table 3.11. Control animals from the drug treated rats
1. Vasoactive Agents
Flow Sr Clearance
Drug 57-Co 113-Sn Sn - Co
ATP 0.234 + 0.092 0.22 + 0.036 -0.014 + 0.035 0.16 + 0.05
Nor. 0.352 + 0.197 0.27 + 0.07 -0.082 + 0.175 0.24 + 0.09
2. Calcium Regulating Hormones
PTH 0.232 + 0.098 0.332 + 0.055 0.087 + 0.105 0.17 + 0.02
PGE2 0.49 ±0.115 0.497 + 0.098 0.007 + 0.072 0.20 + 0.02
Cal. 0.297 + 0.041 0.215 + 0.036 -0.102 + 0.106 0.32 + 0.02
Combined (n) = 21
0.324 + 0.124 0.33 + 0.125 0.006 + 0.053 0.24 + 0.07
All values represent mean ± standard deviation, with drug referring to the group that the
control (0) dose animals are included in.
Flow and clearance are measured in ml/min/g.
Nor. = Noradrenaline. Cal = Calcitonin.
An important point to note in this table is that the mean clearance values are less than the
mean flow values in each respective group.
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Flow 2 ml/min/g
Significance of the regression , p < 0.0001
Correlation coefficient (r) = 0.89
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5. Degree of association between paired measurements
As outlined in section 3.4. the pre and post treated measurements should be related in
order to use a paired students t-test.
i.e. Paired data = Blood flow measurements
Arterial pressure
Vascular resistance
The paired data from control group three were treated using regression analysis, in each
case the significance of the slope was 0, the correlation coefficient greater than 0.9 and
the percentage variation in the second measurement due to its relationship with the first
greater than 82%. Thus there is a high association between the two measurements made
in the control animals and therefore the use of microspheres to measure flow does not
significantly affect this variable. I would assume that this relationship would hold in the
experimental animals and therefore any significant difference found would be a result
of the drug treatment.
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3.6. Discussion
3.6.1. Cannulation site and microsphere technique
1. Carotid site
In order for the microsphere technique to be successful, immediately after injection into
the circulation the spheres have to be adequately mixed and evenly distributed in the
blood stream. Here the cannulation procedure followed involves insertion of a cannula
into the left ventricle. Heyman et al (1977) noted that although the injection should be
made into the left atrium, the left ventricle provided accurate measurement of systemic
blood flow. Additional support for this method is given by the work of Tondevold
(1983) and Schoutens (1979) who use a similar procedure. Thus injection of the
microspheres into the left ventricle should provide adequate mixing and this view is
confirmed in the presented results.
2. Caudal site
The choice of caudal artery is queried, although a similar method was used by and
Schoutens et al (1979) who cannulated the "ventral artery" stating that an arterial
sample was withdrawn from the tail. Murray Brookes has pointed out that the rat tail
contains "caudal glomeruli", arteriovenous anastomoses occurring between themedial
caudal artery and the vein. Thus withdrawn blood from the caudal artery could contain
mixed blood therefore dilution of the microspheres would arise because of the addition
of the venous supply. This dilution however depends on the withdrawal rate and the
arterial blood pressure. If the rate ofwithdrawal is too high then venous bloodmay enter
the vessel to compensate for the sampled arterial quantity, and a lowering of the arterial
blood pressure below that of the venous side would allow venous blood to seep into the
arterial supply. Kondo (1972) confirmed the presence of these glomeruli. However in
establishing the general fine structure this author only mentions the distal third portion
of the medial caudal artery as a location. No statement is made to say that glomeruli
occur out with this area. The upper portion of the caudal artery may however contain
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these. As long as the arterial pressure in the caudal artery is not adversely lowered there
may not be any effect even if glomeruli are present. This is supported by the lack of any
statistical difference between sampling at the caudal and femoral sources (3.5.2.). Other
authors have used the femoral as a withdrawal site (Tothill etal 1980) so if this source
of arterial blood is adequate then the caudal arterymust give a similar acceptable supply.
3. Microspheres number and evenness of mix
The number ofmicrospheres also affects measurement of blood flow. Buckberg et al
(197J) have calculated that 393 microspheres are required in the tissue sample to
measure a 10% difference with 95% confidence. Here each injection of radionuclide
contained approximately 200 000microspheres. A level of400 or more, estimated from
the count per sphere made for each microsphere batch, was obtained in all the samples
used. This therefore acted as a secondary check on the distribution of the microspheres.
The evenness of mixing can be assessed by injecting two sets of microspheres a few
minutes apart; the patterns ofdistribution should be similar for each injection (Heymann
et al 1977). Although here I do not have data on the distribution pattern the degree of
association between the cobalt and tin measurements (section 3.5.1.) suggest that these
are similar. A comparison of flow to left and right hind limbs (3.5.5.) shows that no
systemic preference for microsphere collection occurs supporting the view that the
microspheres have been sufficiently mixed in the blood thus representing the the actual
flow.
4. Microsphere size
The size of the microspheres is important when considering entrapment and arterio¬
venous shunting. This method of measuring blood flow assumes that the microspheres
entrap completely in one passage but do not have haemodynamic effects. Few studies
however have investigated this complete entrapment with regard to bone.
Gross etal (1979) evaluated arteriovenous shunting in bone blood vessels using different
sized microspheres. Blood flows measured using 7-10pm diameter spheres were 35%
lower than those made with 15pm and 25pm spheres. Further comparison of micro-
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sphere concentration in the arterial blood and nutrient venous blood from the dog tibia
indicated that the 15pm diameter spheres did not shunt through the bone significantly.
However the use of the nutrient vein as a venous source of blood was questioned by
Cofield etal (1975) who have stated that this vein drains only 10% of the tibial vascular
bed. If this is the case then the findings ofGross et almust underestimate the percentage
ofmicrospheres non-entrapped when the venous sampling method is employed.
The problem of non entrapment has also been investigated by Tothill et al (1987) who
examined the concentration of microspheres in the femoral venous blood after the
spheres were injected into the tibial nutrient arteries ofdogs. In this study the entrapment
ofonly 15 ± 5pm diameter spheres was investigated. They found little evidence ofnon-
entrapment, only 1.7% ± 2.6% (mean ± SD for 10 perfusions) of the administered
activity found in the venous blood. However these authors suggest that dilation of
vessels or opening of non-nutrient arteriovenous bypasses can lead to shunting of
microspheres.
Thus, arterio-venous shunting does occur but the limited evidence suggests that 15pm
diameter spheres are shunted only to a minimum extent. In general this size of
microsphere is mostly trapped in bone but adverse conditions such as dilation of the
vessels can lead to shunting and non-entrapment. Since the size of the rat prevents this
type of study it has been assumed that from this evidence the 15pm diameter micro¬
spheres are best suited for the measurement of bone blood flow, the percentage of non-
entrapment low and thus not an important factor in the estimation of flow. This was
confirmed to some extent by analysing the lung ofone animal, the percentage ofactivity
in this tissue representing a very small proportion of the actual dose (less than 2%).
However if all these microspheres pass through bone, this would be a very high
proportion of the bone microspheres.
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3.6.2. Control values for bone blood flow and mineral clearance
Assuming that the choice of cannulation site, microsphere size and number adequately
fulfils the criteria for the use this method to measure bone blood flow the next topic to
be considered is the control values of flow and clearance and how these compare with
the findings of other authors.
1. Bone blood flow
These values fall into two groups for flow.
Table 3.12. Control blood flow, mean ± standard deviation
Combined flow for infusion or injected animals
Flow 1 0.36 ± 0.184 (SD) Flow 2 0.30 ± 0.114 (SD) n=20
Control group 3
Flow 1 0.32 ± 0.124 (SD) Flow 2 0.33 ± 0.125 (SD) n=21
Range of all measurements 0.087 - 0.698
Both these groups have mean flow values that are greater than the findings of other
authors. However the range ofmeasurements does include those of other investigators
e.g. Fredrickson et al (1955) bone blood flow at least 0.1 - 0.3 ml/min/g of tissue.
Thestudyof Hruza et al (1969)givesacontrolvaluefortibiabloodflow,ofatenweek
rat weighing 250g of 0.14ml/min/g, half that of the mean values presented in this work.
However bone blood flow was measured using the bone clearance technique of Copp
and Shim (1965) and as pointed out in the introduction this method assumes complete
extraction (which is not the case) and thus this value can be questioned. In this respect
the value is most likely to be an underestimation.
Schoutens et al (1979) compared the measurement of bone blood flow using strontium-
85 microspheres and clearance of calcium-45. Although the results are in the form of
plasma flow in bone ml/min/lOOg by using a mean figure for the haematocrit (46%)
these can be converted in to flow in bone per gramme of tissue. That is multiply the
plasma flow by 1.85 [1 -r (1-0.46)]
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Table 3.13. The plasma flow values from Schoutens (1979) converted to bone blood
flow
Plasma flow ml/min/g Bone blood flow ml/min/g
Femur 0.058 to 0.135 0.107 to 0.25
Tibia 0.051 to 0.114 0.094 to 0.21
These values are similar to that of the Hruza study but the estimates of flow using 45-
Calcium are lower, in the femur clearance is 0.061 to 0.103 ml/mim/g and in the tibia
this is 0.056 to 0.104 ml/min/g. As a result these authors suggest that bone clearance
measurements are inadequate to monitor bone blood flow. If this is the case either the
measurements of flow in this study are low or the method used by Hruza is more
efficient as both papers give similar ranges of measurements for flow using the
microsphere and clearance methods.
This however does not account for the higher blood flow estimates found in the present
study. In the study of Schoutens the microspheres are injected directly into the left
ventricle and blood samples withdrawn from the tail at a constant rate (figure not given
*
in paper ), thus the main difference between this study and the work of Schoutens is the
weight and age of the animals. This however should not give rise to these differences
in flow in fact Hruza andWachtlova (1969) found that blood flow in bone dropped with
increasing age (accompanied by an increase in weight). Similarly MacPherson and
Tothill (1978) found a significant negative correlation for the blood flow of the tibia-
fibula, jaw and femur. They did not however find a significant change in skeletal blood
flow in the conscious rat with an increase in age or weight.
It is difficult to say why the results of this study are higher than those of the above
authors. Possibly the age of the animals was of importance, some animals in the others
studies may be immature thus having a slightly different blood supply because fusion of
the metaphysis has not yet occurred however.'this is unlikely. The quantity and method
of anaesthesia could have a part to play in these findings, Schoutens uses pentobarbital,
12mg ip. for a 240-260g animal, roughly 5mg per lOOg. In this study the concentration
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per lOOg was 6mg ip. The animals are sensitive to the levels of anaesthesia and possibly
the higher flow values reflects the effect of the anaesthetic.
A plot of all the control blood flows i.e. the cobalt flow of all the 'bone blood flow
animals' shows that the blood flows are relatively normally distributed (Figure 3.10.).
The mean of these 93 values is 0.33 with a standard deviation of 0.11. The distribution
is slightly skewed (0.361) but this is not to a large degree so it is acceptable to say that
the flowmeasurements ofthis study are normally distributedwith a small plateau around
the mean (indicated by a negative kurtosis, -0.15).
2. Strontium clearance
There are also two control groups in which strontium clearance has been estimated.
Control group 2 Sr clearance 0.46 ±0.18 n=20
Control group 3 Sr clearance 0.22 ± 0.072 n=21
These two groups are significantly different and so are treated as two separate mean
values in this discussion unlike the mean flow values which are similar enough to be
grouped into one range.
Control group 2 represents animals where in all but one strontium extraction is greater
than one. Strontium extraction is calculated from clearance and flow, thus a value of
greater than one means that clearance is greater than flow, as clearance is dependant on
flow this should not be possible in any animal. The possible reasons for this include over
estimation of clearance through post mortem migration of strontium or because of
streaming of microspheres, leading to under estimation of flow.
The post mortem migration of strontium has been investigated by by Tothill and
MacPherson (1978). These authors found an approximately linear uptake of of bone
radioactivity in the post mortem animal with time. The proportion of this increase
depended upon the initial concentration of the bone-seeking nuclide, and ranged from
a factor of 1.5 to 4.5 over a one hour period. Thus the effect of post mortem migration
of strontium-85 from the soft tissue to bone can affect the accuracy of uptake measure¬
ments if there is any delay in removal of the bones. This post mortem uptake has been
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Figure 3.10 Histogram of all the flow 1 values for the experimental rats




confirmed by Dacke and Shaw (1987) who compared the uptake of strontium in non-
microwaved and microwaved groups, finding it to occur in the untreated group.
In this study post mortem migration is negligible as the bones are removed and cleaned
of all soft tissue immediately after sacrifice so this cannot be a factor in the calculation
of strontium clearance. Thus the next consideration is the underestimation of flow
possible through streaming ofmicrospheres. This is discussed in the section investigat¬
ing bone and caudal haematocrit.
Before looking at the possibility of streaming the values for control group three will be
considered. In this case the strontium extraction values are all less than one, the range
is 0.48 to 0.943 with a mean of 0.68 ± 0.11 (SD). Thus the randomness of animal choice
or the shortening of the procedure time because of familiarity with the technique has
removed the problem of high clearance values. The actual values for clearance are
higher than those of Schoutens et al (1979). However the standard deviation of 0.072 is
small indicating little variation occurring but, the small numbers make it difficult to
compare this group with the of distribution of a normal population.
Thus although the values in this study are higher than those of other authors the results
of flow and clearance are of an acceptable level with minimal variation to allow a
comparison of drug effect on these variables to be made.
3.6.3. Caudal and bone haematocrit
Although the experimental control group do not have clearance values greater than flow
this does not explain why such a problem occurred consistently in the original control
group. In an attempt to explain this problem the haematocrit of bone and caudal arteries
were examined.
Brookes (1965) and Tendevold et al (1982) found that in long bone there are regional
differences in plasma and erythrocyte volumes. This gives rise to associated regional
differences in tissue haematocrit. Neither however have assessed the whole bone, thus
making comparison of these results and those presented here difficult. Apart from the
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femoral neck the values estimated in Tendevolds' paper are all less than those presented
in Table 3.6. Tondevold has stated that although the haematocrit in bone depends on the
location of measurement it is in the range of 50-75% of the arterial haematocrit. Here
the values range from 47 to 100% with the two values obtained using the 111-In label
greater than the 75% value. Although the paper of Tendevold and Erickson involves
work in dogs, assuming an arterial haematocrit of 40% this alone does not account for
the degree of variation between this and the results of my study.
Brookes also found the haematocrit of bone to be proportionally less than the arterial
haematocrit. The reason for this was outlined by Fahraeus in 1929 who found that the
blood streaming in narrow tubes had a higher plasma content and lower corpuscle
content than that streaming in larger tubes. He also found that the layer of fluid next to
the vessel wall is mainly stationary and consists largely of the plasma fraction while the
axial fast flowing stream contains a large percentage of the corpuscle fraction. Thus with
decreasing tube diameter there is an associated decrease in haematocrit. These findings
account for the decreased haematocrit in bone found in most of the animals in this study
but does not shed any light on the difference in the estimates when different labels are
used. Some factors which could give rise to this are discussed in the following pages.
1.Albumin egress
Tendevold (1983) suggests that the egress of albumin occurs in the first few minutes the
concentration leveling off to that of other markers 5-6 minutes. This would invalidate
the use ofalbumin as a plasmamarker. In this study the withdrawal of blood commenced
within three minutes of marker injection, ceasing after a further two minutes. Thus the
maximum time for albumin to egress is five minutes. The same method is used in all six
animals therefore any over-estimation of plasma volume should be consistent and this
egress of albumin is unlikely to be the cause of the different plasma erythrocyte volumes
obtained.
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2.Plasma labelling with red blood cell label
An over estimation of erythrocyte volume (99-Tc) could have been caused by the
labelling of the plasma with the red cell label. The % of label in the supernatant
indicating to what extent this occurred. When analysed the supernatant was found to
contain less than 1% of any of the labels when compared to the content of the corpuscle
fraction. Thus this was not an important consideration and insufficient to cause high
haematocrit volumes.
3.Blood sample volume
A small blood samplemay provide spurious counts resulting in invalid volumes. All the
samples collectedwere in the range 3-4.5ml, and sufficient to provide acceptable counts.
The blood samples were therefore not a problem in the calculations.
4. Assumed haematocrit
As stated in the results the haematocrit used in the calculations was assumed to be 45%
but in reality this varied from animal to animal. The blood samples used to estimate the
tail haematocrit gave similar values of total volume 0.97 ± 8E-3, as expected since 1ml was
used each time, but varied in their red cell content from 0.38 - 0.57. Thus accounting for
the variation in the measured tail haematocrit. This variation in the arterial haematocrit
therefore affects the calculated tissue haematocrit. Using the tail values to calculate the
bone haematocrit the situation changes. Firstly there are only two animals in each group,
and secondly the mean haematocrit is now in the range 32-38 instead of 24-41 but with
an increase in two of the standard deviations.
i.e. 99-Tc 34.5 ±9
111 -In 38 ±3
51-Cr 32.5 ±5
This suggests that the assumed haematocrit of 45% played an important part in the
variation and the significance if the difference between the results when different labels
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are used. This statistical significance is now lost. However this does not change the %
value with reference to the arterial haematocrit.
Using these values themean for the three labels is 35 ± 4. This value represents only 71%
of the arterial mean which is within the limits suggested by Tondevold. Therefore the
useof the caudal artery as a reference organ in the estimation ofbone blood flow appears
to require a correction factor. However before stating that such a factor should be
incorporated into the calculations note should be taken of how inconclusive the results
are: the extent of the plasma volume variation and the variation in the measured arterial
haematocrit the main problems.
The use of albumin as a plasma indicator is questionable. Its ability to pass to the
extravascular space has been noted by many authors, but the extent of this over
estimation when using this indicator is unknown. Thus measurement ofplasma volume
can only be an approximation and difficult to reproduce since plasma volume is capable
of rapid fluctuations.
Measurement of red blood cell volume, on the other hand, is usually accurate and gives
reproducible results. Here when 51-Cr and 111-In have been used, in one animal the
measured volume is low. Since the number of animals used is only two this could have
lead to a lowering of the mean erythrocyte volume. Only an increase in the number of
animals used would allow this to be confirmed. Thus here animal number not method
creates a difficulty in interpretation of the data.
The use of an assumed arterial haematocrit, such as 45% (Brookes) incorporates a
degree of variation into the calculation. Removal of this by using the measured arterial
haematocrit limits the extent of this variation therefore highlighting the difficulty ofcal¬
culating a correction factor which could incorporate this. Here the arterial haematocrit
ranges from 40-59% with the arterial percentage ranging from 47-100%. Themean value
for all six animals allows a correction factor of 30% to be calculated. However this
would cause a variation, the degreeofwhich is represented in the variation in the arterial
percentage.
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Thus although this work points to a difference in the haematocrit of bone and caudal
artery the actual degree of this difference is not conclusive. The study would have to be
repeated incorporating other plasma labels i.e. 125-1 fibrinogen and increasing the
number of animals. The suggested cause of the different haematocrits is that bone is
richer in plasma and poorer in corpuscles than the caudal blood supply. To what extent
this occurs I am not certain but this could give rise to an over estimation of strontium and
an under estimate of the microsphere counts. This could account for the strontium
extraction values that are greater than one in control group two.
3.6.4. Pump setting
Withdrawal ofblood at a constant rate is a requirement of this procedure. Unfortunately
the actual withdrawal rate is not cited in the methods of any of the comparable papers
making it impossible to draw any comparison between these and the present study
(Schoutens et al 1979. Tothill and MacPherson 1980). However this study suggests that
the 0.197ml/min rate is the most suitable withdrawal setting for the rat producing the
most reproducible results. At higher rates the vessel tends to clamp down restricting the
collection.
The actual withdrawal rate varies around this setting. In some cases blood collection is
sluggish and the rate is less than this while in other animal the flow is so great that the
collection rate is above this value. Thus to minimise this variation the actual flow rate
is estimated by weighing the syringes before and after collection then dividing the
weight of the sample by the specific gravity of blood. The per minute rate is then
estimated by dividing this weight by the time of collection i.e. 2 minutes or 4.5 minutes.
The withdrawal timing is not begun until the blood appears in the syringe to ensure that
the time period represents actual withdrawal of blood. This value is then used as the
pump rate in the calculation of bone blood flow.
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3.6.5. Administration of drug and experimental variation
The chosen method of administration depends on the half life of the drug under
investigation. This study has confirmed that neithermethod has any direct effect on the
animal (3.5.4.).
The degree of experimental variation is important in determining the reproducibility of
the results. As stated in 3.5.4. the high percentage of variation in the combined control
group is unacceptable. Randomness of selection of animals, drug choice and dose
minimise this experimental variation to an acceptable level. Therefore this method of
selection of animal and drug has been incorporated in the protocol of bone blood flow
measurement and the animals were ordered in large sibling groups i.e. 16-24 animals
in one group.
3.7. Conclusions
These are presented in the form of the selected protocol. Further details of the specific
methods are included in the approprite chapters i.e. chapter 4 vasoactive agents.
PROTOCOL
1. Dissect and cannulate the carotid and caudal arteries (3.2.2.).
2. Connect animal to infusion pump via the carotid cannula - 6ml/hour.
3. Inject 57-Cobalt microspheres via the carotid cannula.
Begin withdrawal after thirty seconds (0.197ml/min), ceasing after ninety seconds.
4. Inject or infuse the test solution (Random choice of dose and drug).
The time period between administration of drug and the withdrawal begining depends
on the agent. Begin withdrawl (0.197ml/min) and thirty seconds later injectTin-113 and
Sr-85. Cease withdrawal after a total of 4.5 minutes.
5. Scarifice animal with a saturated KC1 solution via the tail cannula and immediately
remove tibiae and femora and a sample of the upper quadriceps.
Weigh all samples, including blood samples and analyse for radioactivity.
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A correction factor for the difference between caudal and bone haematocrit cannot be





Vasoactive agents are known to affect blood flow through action on bloodvessels. This
takes two forms: 1. vasoconstriction and 2.vasodilatation,With respect to these the action
a variety of agents have been investigated, these include noradrenaline, adenosine,
isopropaline and adrenaline.
Noradrenaline is a neurotransmitter of the sympathetic nervous system, through
stimulation of the alpha-adrenergic receptors it produces vasoconstriction. Gross et al
(1979) found that noradrenaline had a direct constrictor effect on bone and marrow,
increasing arterial pressure and decreasing bone blood flow. These authors also
examined the vasodilator responses in bone blood vessels to the effects of adenosine.
Both arterial pressure and vascular resistance was decreased with adenosine treatment.
It is suggested that these act through a direct effect on the vascular smooth muscle.In
bone vessels the response is of a similarmagnitude to that of skeletal muscle. In addition
to investigating the effect of noradrenaline and ATP on the exchange processes in bone
McCarthy and Hughes (1985) also examined bone blood flow and arterial blood
pressure. During infusion of noradrenaline flow decreased significantly while vascular
resistance increased. The reverse occurred during ATP infusion. This supports the
vasoconstrictor effect of noradrenaline and suggests that ATP acts as a vasodilator
thereby allowing blood flow to increase and reducing vascular resistance. Driessens and
Vanhoutte (1981) also assessed the responsiveness of bone to vasoactive agents. By
measuring the perfusion pressure of an isolated tibiae following administration of the
agents they confirmed that noradrenaline caused constriction of bone blood vessels.
Vasoactive Agents 4 - 1
4.2, Choice of Drug and dosage
The effects of noradrenaline and adenosine in terms of vascular response has been well
detailed. However few of these studies have related this action to a change in blood flow
or clearance ofminerals in bone. This knowledge of the vascular action of these agents
allowed some prediction of their effect on bone blood flow to be made in advance. Thus
the work of previous workers provided a good foundation for this choice and ensured
that drugs with opposite vascular effects were compared.
The choice of dosage was made on the bases of earlier work carried out in this
department (Davies 1986). Here noradrenaline at doses of 0.57 and 1.24pg/Kg/minute
(over 5 minutes) were found to significantly reduce blood flow and increase arterial
blood pressure. In a 350g rat these doses were equivalent to 1 and 2pg of noradrenaline
per animal. In order to plot a dose response curve an intermediate dose of 1.5pg per
animal was also chosen. Thus the selected noradrenaline doses were 0.2,0.3 and 0.4pg
/minute. These representedpharmacologically active levels: in humans about 2-4pg per
minute of norepinephrine bitartate is used in treatment of hypotension (Goodman and
Gilman 1980). Thus, assuming an average weight of 70Kg for a human, the dose
administered to a rat represents about 40-80pg in a human perminute over a five minute
period. The choice of infusion of this drug was due to its rapid inactivation by the same
enzymes that methylate and oxidatively deaminate epinephrine. Test injections of 2pg
bolus noradrenaline (equivalent to 0.4pg/minute) had no apparenteffect on either blood
flow or blood pressure suggesting that the agent is quickly inactivated. However
infusion of the same dose resulted in an effect on arterial pressure after about thirty
seconds which remained until the end of the experiment. Thus it was decided to infuse
the solutions and wait 30 seconds before begining withdrawal to allow the drug to have
an effect. The above study also included ATP. At the highest dose i.e. 0.724 mg/Kg/
minute an increase in blood flow and a decrease in blood pressure was observed. This
dose represents 1.25mg/350g animal infused over a total of five minutes. Other doses
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in this study were equivalent to 0.25,0.45 and 0.80 mg/ animal. The 0.25mg dose was
then selected as the lowest dose and 0.75mg selected as an intermediate dose to complete
the dose curve. Since the effects ofATP has not been as extensively studied the literature
does not appear to cite basal levels of this agent thus it was difficult to find out if these
representedpharmacological orphysiological levels. In order to compare the two agents
ATP was made in similar solution to noradrenaline and infused at the same rate.
4.3. Preparation of injected dose
Both noradrenaline and ATP were bought in powdered form; the required concentration
was achieved by weighing out some of this and dissolving it in buffer. In each case 10ml
of the solution was made up at any one time, this ensured that the 25ml syringe contained
a large enough volume to allow the infusion pump to function correctly. Thus on
occasions the same batch of solution was used in more than one animal.
a) Noradrenaline ("Sigma - lg.) — 1,1.5 and 2pg per rat, 0 C°< .
These dose are equivalent to 5,7.5 and lOpM. infused over five minutes.
Over the infusion period 0.5ml was infused. Thus for a 10ml solution of the correct
concentration 20, 30 and 40pg of noradrenaline was required. The balance however
could notweigh such small quantities so a concentrated solution was made up using 2mg
dissolved in about 1ml saline and made up to 10ml using buffer. For the lpg dose 0.1ml
of this concentrated solution was then made up to 10ml using buffer (0.15 for the 1.5pg
and 0.2 for the 2pg doses).
b) ATP (Sigma: 500mg Vanadium free from Equine muscle)
— 0.25,0.75 and 1.25mg per rat, 0 C°<.
These doses are equivalent to 0.32,0.96 and 1.6mM. infused over fiveminutes. ATP was
also made up in 10 ml quantities, 5,15 and 25mg were required for each respective dose.
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These were then dissolved in small quantities of buffer before being made up to a 10ml
volume.
In both cases it was important to ensure that the powder was completely dissolved
especially at the higher doses, efficient mixing in the 10ml volume was usually
sufficient. The solutions were made up when required and the choice of dose
randomised tominimise variation between dose groups. Thus in any one sibling group
a variety of doses or drugs were used.
4.4, Experimental procedure
a) Noradrenaline and ATP (Figure 4.1)
The prepared animal (see 3.2.2.) was connected via the carotid cannula to an infusion
pump and the pressure recorder. This was achieved using two three-way taps, to the first
a Braun infusion pump was connected and to the second a pressure transducer. Lost
blood was replaced by the pump which infused buffer or the test solution at a constant
rate (6 ml/hour). This infusion also ensured that the carotid cannula remained patent.
Needles were pushed under the skin of the animal at both fore paws and one hind paw
in order to obtain an electro cardiograph (ECG) and average heart rate. The blood
pressure of the animal was allowed to stabilise, and then the tail cannula was connected
to a withdrawal pump set at 0.197ml/minute, the syringes used for collection had been
previously weighed so that the of actual collection rate could be calculated.
1. Control blood flow.
Bufferwas infused over the control flow period. Blood collection commenced and thirty
seconds laterCo-57microspheres were injected into the heart via the first tap. Bloodwas
withdrawn for a further ninety seconds.
2. Test blood flow.
After ensuring that the pressure was stable the test run was begun. The syringe
containing buffer was replaced with a syringe containing the test drug, blood was
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allowed to come back into the carotid cannula and the syringe and cannula then
reconnected. Thus the start of infusion could be visualised through clearing of the
cannula. After thirty seconds blood withdrawal began into a second syringe. At one
minute Tin-113 and Strontium-85 were injected. Blood withdrawal ceased after 4.5
minutes.
At the end of the experiments the animals were sacrificed using KC1 injected via the tail
cannula. Both tibiae and femora were removed quickly to minimise post-mortem
migration of ions to the bone. A muscle sample from the upper quadriceps was also
taken. The bone, muscle and blood samples were then weighed before counting.
b) Control animals
In these animals the same method was followed but during the test run a solution
equivalent to the test solution minus the drug was infused i.e. Krebs Ringer buffer.
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4.1. Schematic Presentation of Procedure
To carotid artery:
1. Co-57 jjspheres.
2. Drug (per animal
a. INFUSION
ATP 0, 0.15,0.75 and 1.5mg





1. 2 minutes collection







This group was composed of twenty six animals, in eight there were insufficient micro¬
spheres in either of the blood samples and two died during the procedure. The results
of the remaining sixteen animals are shown in tables 4.1 - 4.4. These include details of
blood flow in bone and muscle (Tables 4.1. and 4.4.), strontium clearance in rat bone
(Table 4.1.), arterial blood pressure (Table 4.3.) and vascular resistance in bone and
muscle (Tables 4.2. and 4.4.).
Noradrenaline treatment causes a dose dependent reduction in blood flow with a rise in
arterial blood pressure, strontium extraction and vascular resistance (Figures 4.2.,4.4,
4.6. and 4.7.).
The change in blood flow is significant at the 1.5 and 2.0pg levels (p<0.05). A
comparison of the mean Flow 2 with mean Flow 1 at each dose shows that the
experimental flow is reduced compared with the control (Table 4.1.).
i.e. Dose % of Flow 1
l.Opg Flow 2 = 77%
1.5pg Flow 2 = 56%
2.0pg Flow 2 = 62%
The line of regression for this change in flow is significant and negative, this implies
that it is the increasing noradrenaline concentration that is responsible for the degree of
change. In fact the r squared value suggests that this is the cause of some 30% of this
variation.
Accompanying this change in flow is a change in arterial blood pressure. Blood pressure
significantly increases with dose (ie. the slope of the regression is significantly different
from 0, Figure 4.4.). The arterial blood pressure is measured at four points which are
detailed in table 4.3. The pressures at B1 (point of Co microsphere injection) and at B2
(the begining of the test blood flow) should be relatively similar, and in all but the 1 .Opg
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dose this is the case. But even the difference at this dose is not significant. However B2
is used as the arterial pressure level in the calculation of a change in pressure in case the
use ofcobaltmicrospheres has in some way affected the pressure (although this does not
appear to be the case). The arterial pressure at the point of tin microsphere injection is
represented by the B3 measurement while the point of maximum drug effect is repre¬
sented by B4. Although none of the B3 or B4 measurements are significantly different
within each dose group the differences in the values are important in the calculation of
arterial pressure change. Therefore in each case B4 is used in this calculation and
pressure change is calculated as follows; B4 - B2.
The arterial pressure rises almost immediately after infusion has begun and although the
degree of change is similar for each dose the length of this effect is subject to the
concentration of noradrenaline (Figure 4.5). Thus at l.Opg the pressure returns to the
original level by five minutes while at 2.0pg pressure is still at a high at three minutes
and is only beginning to decline at five minutes.
Vascular resistance displays the same pattern as blood pressure i.e. there is an increase
with increasing concentration, the 2.0pg tin value is 220% of the cobalt value (Table
4.2.). This effect could be expected from the decrease in flow ie. a vasoconstrictory
response reducing the flow through increased vascular resistance. Once again the
response is caused by the concentration of noradrenaline, indicated by the regression
value, r squared being 0.35 (Figure 4.7).
Strontium clearance is unaffected by noradrenaline treatment (Figure 4.3.). At no dose
is there any significant difference from the control value (Table 4.1.). On the other hand
strontium extraction increases significantly with a significance difference from the
control group found at the 1.5 and 2.0pg doses (Table 4.2.). Extraction is dependent on
both flow and clearance thus if clearance is relatively constant, as is the case here, it is
the change in flow that gives rise to the effect on extraction. Comparison of the slopes
of figures 2 and 3 confirms that the lines of regression are significantly different (t=2.12,
d.f.=28 p<0.05) supporting the view that the change in flow that gives rise to the change
in extraction.
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Neither muscle flow or vascular resistance appear to be significantly affected by
noradrenaline. The standard deviations for vascular resistance are high illustrating the
range of the individual values (Table 4.4.).
Noradrenaline therefore causes a significant reduction in bone blood flow but has no
effect on strontium clearance. Thus the drug does not alter clearance independantly of
it s action on flow. The two variables have been plotted against one another in figure 4.8.
Comparision of this figure with the control animal plot (figure 3.9) shows that the two
are similar statistically ie. t=l.35, D.F. = 26. These results indicate that there is some
relationship between flow and clearance however a significant decrease in flow need not
give rise to a similar significant decrease in clearance.
Finally flow 2 is plotted against blood pressure in the noradrenaline treated animals
(figure 4.9). As the correlation is low (0.33) this suggests that the relationship between
the two is weak.
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Table 4.1. Effect of noradrenaline on blood flow, strontium clearance and
blood pressure in rat bone
Noradrenaline us/animal
Control 1.0 1.5 2.0
Flow
Cobalt 0.34 + 0.13 0.35 + 0.19 0.34 + 0.11 0.32 + 0.03
Tin 0.36 + 0.12 0.27 + 0.07 0.19 + 0.04 0.20 + 0.07
@Sn - Co 0.02 + 0.04 -0.08 + 0.17 -0.15 + 0.09 -0.13 + 0.04
* Sr clearance
0.24 + 0.09 0.20 + 0.03 0.17+ 0.05 0.19 + 0.09
Blood Pressure Change
(B4-B2) -2.50 + 3 40 + 26 39 + 8 39 + 13
@ Paired t-test— 1.5pg p<0.05; 2.0pg p<0.01.
* Unpaired t-test (comparison with 0 dose) — All N.S.
All values represent mean ± standard deviation.
Number of animals in each group (n) = 4.
Flow and clearance are measured in ml/min/g.
Blood pressure is measured in mmHg; at two points;
(B2) at the begining of the experimental run,
(B4) at point of maximum effect.
Sn = Tin. Co - Cobalt.
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Table 4.2. Effect of noradrenaline on strontium extraction and vascular
resistance in rat bone
Noradrenaline fig/animal
Control 1.0 1.5 2.0
*Strontium Extraction
0.66 + 0.08 0.75+0.18 0.90 ± 0.06 0.94 + 0.21
Vascular Resistance
Cobalt 425 + 265 570 ± 554 498+ 187 367+ 176
Tin 390 ± 207 585 ± 250 1025 + 331 809 ± 354
@Sn - Co -36± 87 15 + 496 528 + 190 442 + 208
@ Paired t-test — 1.5pg p< 0.02 ; 2.0pg p< 0.05.
* Unpaired t-test (comparison with 0 dose) — 1.5 pg p < 0.01 ; 2.0 pg p < 0.05.
All values represent mean ± standard deviation.
Number of animals in each group (n) = 4.
Vascular resistance is measured in mmHg/min/g( using B1 for calculating the cobalt value
ad B3 the tin value).
Sn = Tin. Co = Cobalt.
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Table 4.3. Mean and standard deviation of blood pressure measured at the
four reference points in noradrenaline treated animals
Noradrenaline ug/animal
Control 1.0 1.5 2.0
Blood pressure
Cobalt B1 119 + 26 129 ± 29 155 ± 29 115 + 46
Tin B2 118 + 26 140 ± 37 152 ± 86 114 + 36
B3 106 + 30 146 + 42 185 + 35 144+ 32
B4 109 ± 27 151+37 197 + 29 142 ± 34
Number of animals in each group (n) = 4.
Blood pressure is measured in mmHg.
B1 and B3 Blood pressure at point of microsphere injection used for calculation of
vascular resistance.
B2 Blood pressure at the begining of the experimental run, used for the
calculation of blood pressure change (B4 - B2).
B4 blood pressure at the point ofmaximum drug effect.
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Table 4.4. Effect of noradrenaline on blood flow, and vascular resistance
in rat muscle
Noradrenaline ug/animal




















@Sn - Co -80 ±634 260 ± 476 1371 ±3991 -446 ± 400
@ Paired t-test — Flow 2.0jag p< 0.05.
All values represent mean ± standard deviation.
Number of animals in each control group (n) = 3.
Noradrenaline treated group (n) = 4.
Flow is measured in ml/min/g.
Vascular resistance is measured in mmHg/min/g (using B1 for calculation of cobalt value
and B3 for calculation of tin value)
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Figure 4.2. Effect of Noradrenaline on Bone Blood Flow
fig /animal
F1 = Control Blood Flow — using Co microspheres.
F2 = Experimental Blood Flow — using tin microspheres.
Significance of the regression , p<0.03
Correlation coefficient (r) = - 0.55
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Figure 4.3. Effect of Noradrenaline on Strontium clearance
0.4
Significance of the regression, p < 0.2
Correlation coefficient (r) = -0.34
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Figure 4.4. Effect of Noradrenaline on Arterial Blood Pressure
jug /animal
■ Two points
B2 = Arterial Pressure measured at begining of experimental period .
B4 = Arterial Pressure measured at point ofmaximum drug effect.
Significance of regression, p < 0.003
Correlation coefficient (r) = 0.7
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V.R.I = Vascular Resistance as estimated from cobalt flow and blood pressure (B1.)
V.R.2 = Vascular Resistance as estimated from tin flow and blood pressure (B3).
Significance of the regression, p< 0.015
Correlation coefficient (r) = 0.59
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Figure 4.8. Flow Versus Strontium Clearance in the Noradrenaline
Treated Animals
Significance of the regression p < 0.033
Correlation coefficient (r) = 0.73
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Signifiacnce of the regression p < 0.001
Corelation coefficient (r) = - 0.33!
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b) ATP
In total twenty seven animals were treated with 0,0.25,0.75 and 1.25mg ATP. Of these
two died during the procedure, in four there was a problem with collection of the cobalt
blood samples, either an insufficient volume or the number of microspheres was
inadequate; in another the collection of blood commenced after the addition of tin
microspheres and finally in one animal their was insufficient ATP administered to meet
the required dose. The effect of ATP treatment in the remaining nineteen animals on
blood flow and vascular resistance in rat bone and muscle are dealt with in tables 4.5.,
4.6. and 4.7. Table 4.5. also includes the drugs effect on clearance and the change in
arterial pressure as a result of treatment. The actual values for arterial pressure are
detailed in table 4.8.
In all but one area, ATP had no significant action. Arterial blood pressure was
significantly decreased by drug treatment, this decrease was dose dependent (Figure
4.12). The arterial pressure of the test period drops in relation to the initial pressure in
each case (Table 4.8.)
i.e. B4 as a percentage of B2
0.25mg Pressure = 66%
0.75mg Pressure = 70%
1.25mg Pressure = 59%
Table 4.8. itemises the arterial pressure at the four points of interest. There is no
significant difference between the B1 and B2 values indicating that the injection of
cobalt microspheres did not have any effect on arterial pressure. The timing of the
response to ATP is highlighted by this table. At thirty seconds (B3) the blood pressure
is falling but at no dose has reached its lowest value. Reviewing the traces allows this
timing of the maximum drop for each dose to be identified (Figure 4.13.). The
maximum drop in pressure occurs after 1.5 minutes for the lowest dose (i.e. 0.25mg) and
after two minutes for the other doses. By the end of the five minute period the pressure
has returned to normal for all of the 0.25mg treated animals and for most of the 0.75mg
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animals but is still low for the 1.25mg dose. Thus the length of the change in pressure
is dependent upon the dose of ATP administered, the duration of effect increases with
increasing dose.
Although ATP was selected because it was though it would increase blood flow this is
not the case. Bone blood flow actually exhibits a negative trend, a decrease in flow with
increased dose, but the line of regression is not significant (Figure 4.10.). At the 0.75mg
dose this fall is over 50% of the initial level but only 25% at the 1.25mg dose (Table 4.5.).
Although there are some differences in the mean values for strontium clearance this is
not reflected in the regression line where r is virtually 0 and clearance remains constant
(Figure 4.11.). As there is no change in clearance and little change in flow one would
expect little change in strontium extraction. This is demonstrated in figure 14 the line
of regression for extraction having a shallow slope (b=0.13) and is also not significantly
different from zero. At no dose was any significant difference from the 0 group found
when the mean extraction values were analysed using a students t-test (Table 4.6.).
Bone vascular resistance shows no change, the slope being shallow and the line of
regression is not significantly different from zero (Figure 4.15.). Infact the values are
widely spread with a large variation about the mean. Table 4.6 highlights this,the mean
values for resistance change alternating between the negative and positive with, large
standard deviations.
Administration of ATP does effectmuscle vascular resistance, however only at the 1.25
dose (Table 4.7). A plot of the line of regression for this is not significant. Similarly
in no respect does muscle flow show a significant trend with respect to the regression
line.
Figure 16 is a plot of flow versus strontium clearance in the drug treated animals only.
This line is not significant different when compared to figure 3.9. (control animals) (t
= 0.46, D.F = 29). Thus the ATP animals show the same relationship between flow and
clearance demonstrated by the normal untreated animals.
Finally in figure 4.17 flow 2 is plotted against blood pressure, like the noradrenaline
animals there is a low correlation value (0.55) indicating only a weak relationship.
Vasoactive Agents 4 - 23
Table 4.5. Effect of ATP infusion on blood flow, strontium clearance and
blood pressure in rat bone
ATP mg/animal
Control 0.25 0.75 1.25
Flow
Cobalt 0.23 ±0.09 0.27 ±0.07 0.36 ±0.15 0.40 ±0.17
Tin 0.22 ± 0.09 0.24 ±0.08 0.17 ±0.06 0.30 + 0.06
@Sn - Co -0.01 ± 0.03 -0.02 ±0.11 -0.19 ±0.10 -0.11 ±0.14
* Sr clearance
0.16 ± 0.05 0.21 ±0.07 0.12 ± 0.02 0.19 ±0.04
Blood Pressure Change
(B4-B2) 0 -40 ±34 -41 ±23 -55 ±16
@ Paired t-test— 0.75mg p<0.05
* Unpaired t-test (comparison with 0 dose) — All N.S.
All values represent mean ± standard deviation.
Number of animals in each group: Control (n) = 4.
ATP (n) = 5.
Flow and clearance are measured in ml/min/g.
Blood pressure is measured in mmHg; at two points;
(B2) at the begining of the experimental run,
(B4) at point of maximum effect.
Sn = Tin. Co = Cobalt.
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Table 4.6. Effect of ATP on strontium extraction and vascular resistance
in rat bone
ATP mg/animal
Control 0.25 0.75 1.25
*Strontium Extraction
0.77 ±0.12 0.89 ±0.19 0.78 ±0.41 0.66 ±0.13
Vascular Resistance
Cobalt 647 ±315 483 ±143 464 ± 257 434 ± 254
Tin 685 ±186 482 ±217 750 ± 354 354 ± 52
@Sn - Co 38 ±136 -1 ±210 285 ±129 -80 ±250
@ Paired t-test — All N.S.
* Unpaired t-test (comparison with 0 dose) —All N.S.
All values represent mean ± standard deviation.
Number of animals in control group (n) = 4.
Each ATP group (n) = 5.
Vascular resistance is measured in mmHg/min/g (using B1 for calculating the cobalt value
and B3 the tin value).
Sn = Tin. Co = Cobalt.
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Table 4.7. Effect of ATP infusion on blood flow, and vascular resistance
in rat muscle
ATP mg/animal






















@2Sn - Co 760 ±1538 -1384 ±2190 42 ± 898 -282±195
@ Paired t-test — 1.A11N.S.
2. 1.25mg p< 0.05
All values represent mean ± standard deviation.
Number of animals in control group (n) = 4
Each ATP group (n) = 5
Flow is measured in ml/min/g.
Vascular resistance is measured in mmHg/min/g (using B1 for calculation of the cobalt
value and B3 for calculation of tin value).
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Table 4.8. Mean and standard deviation of blood pressure measured at the
four reference points in ATP animals
ATP ug/animal
Control 0.25 0.75 1.25
Blood pressure
Cobalt B1 149 ± 57 123 ±24 144 ±29 143 ±15
Tin B2 155 ±57 117 ± 18 137 ± 28 144 ± 9
B3 155 ±57 107 ± 14 117 ±22 100 ± 8
B4 155 ±57 77 ±24 96 ± 9 85 ±11
Number of animals in control group (n) = 4.
Each ATP group (n) = 5.
Blood pressure is measured in mmHg.
B1 and B3 Blood pressure at point of microsphere injection used for calculation of
vascular resistance.
B2 Blood pressure at the begining of the experimental run, used for the
calculation of blood pressure change (B4 - B2).
B4 Blood pressure at the point of maximum drug effect.
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Figure 4.10. Change in Bone Blood Flow with ATP Treatment
0.2 i
y= - 2.5619e-2 - 0.10704x RA2 = 0.176
F2-F1
ml/min/g
0.0 0.25 0.50 0.75
mg/animal
1.50
F1 = Control Blood Flow — using Co mocrospheres.
F2 = Experimental Blood Flow — using Tin microspheres.
Significance of the Regression, p< 0.09
Correlation coefficient (r) = - 0.41
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0.00 0.25 0.50 0.75 1.00 1.25 1.50
mg/nimal
Significance of the Regression, p < 0.9
Correlation coefficient (r) = - 0.03
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Figure 4.12. Change in Blood Pressure in response to ATP
y= -15.731 -33.877X RA2 = 0.334
mg/animal
Four points
B2 = Arterial Pressure measured at begining of experimental point.
B4 = Arterial Pressure measured at point ofmaximum drug effect.
Significance of the Regression, p< 0.01
Correlation coefficient (r) = - 0.58
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Figure 4.14. Effect of ATP on Strontium Extraction.
Strontium
Extraction
Significance of the regression, p < 0.3
Correlation coefficient (r) = - 0.265
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V.R.1. = Vascular Resistance as estimated from cobalt flow and blood pressure (Bl).
V.R.2. = Vascular Resistance as estimated from tin flow and blood pressure (B3)
Significance of the Regression, p < 0.8
Correlation coefficient (r) = - 0.063
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Figure 4.16. Flow Versus Strontium Clearance in ATP Treated Animals
0.4
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Significance of the regression, p< 0.001
Correlation coefficient (r) = 0.69
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Significance of the regression, p < 0.03
Correlation coefficient (r) = - 0.55
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4.6. Discussion
4.6.1. Effect of vasoactive agents
Noradrenaline
In summary administration of noradrenaline resulted in four significant trends.
1. A decrease in bone blood flow with increasing concentration. At the maximum dose
this flow is reduced by 48%.
2. An increase in arterial pressure with increasing noradrenaline concentration.
3. A similar increasing dose response in bone vascular resistance.
4. An increase in strontium extraction with increased dose of noradrenaline.
Noradrenaline appears to have no effect on the clearance of strontium.
Hypertensive action of noradrenaline
These findings are similar to those of Gross et al (1979) who noted that intravenous
infusion of noradrenaline increased arterial pressure from lll±4tol36± 5mmHg in
the dog. This change in arterial pressure represented a 25% increase and is similar to the
mean percentage increase shown at the maximum dose of noradrenaline used in this
study. Gross found that blood flow to bone and marrow was decreased and vascular
resistance significantly affected at the same time as this pressure effect. Vascular
resistance in the diaphysis of the femur increasedto 237% when a 25pg/min dose was
used and this is slightly higher than the increase when the 2.0pg dose was used in the rat
(220%). These authors suggest that the constrictor response was a direct effect of the
agent on vascular smooth muscle.
The results of this study are also similar to earlier work by McCarthy et al (1985).
Noradrenaline infusion increased bone vascular resistance in a dose dependent fashion
while significantly decreasing blood flow andy despite these changes there was no
significant change in strontium clearance.
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In an earlier paperMichelsen (1968) found flow and intramedullary venous pressure to
decreasemarkedly in response to noradrenaline (1.6 to 4.8pg/10 sec), this resulted in an
increase in the arterial resistance within the bone marrow. This author also noted that
the duration and magnitude of these responses increased with infusion dose, similar to
the findings of this study.
Driessens and Vanhoutte (1981) have also demonstrated that noradrenaline (2pg/ml
whole bone) affects bone vasculature, the administration of the endogenous solution
giving rise to constriction of the blood vessels within the perfused tibiae. A previous
study by these authors (1979) examined the flow pressure relationship in an isolated dog
tibiae. Injections of 0.5pg boluses of noradrenaline caused a dose dependent increase
in perfusion pressure. This response was abolished by phenatolamine an alpha-
adrenolytic drug, suggesting that this constriction was a result of exposure to alpha-
adrenergic agonists.
Therefore the results of this work, ie. the increase in bone vascular resistance could be
expected from the findings of these studies. An increase in vascular resistance would
reduce blood flow and this is seen in the measured bone blood flow of the animals used
here.
Effect of noradrenaline on mineral exchange
Noradrenaline does not however significantly affect strontium clearance. Clearance is
dependent upon the surface area available for exchange thus the lack of effect implies
that the capillary surface area remains constant. That is noradrenaline does not increase
the number ofpatent capillaries. The extraction of strontium is however affected by no¬
radrenaline, and is significantly increased. This variable is dependent on flow and
clearance and although clearance remains relatively constant, bone blood flow is
significantly decreased with increasing doses. Thus the rate of blood flowing through
the patent capillaries is reduced increasing the time taken for minerals to diffuse across
the walls. Thereforemore strontium is extracted from the blood, although the rate of this
clearance remains constant.
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In summary, noradrenaline acts by increasing peripheral vascular resistance and
reducing blood flow without producing changes in the functional properties of the
microcirculation in bone. Its effect on strontium extraction is dependent on the change
in bone blood flow and does not represent a direct action on the exchange process.
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ATP
The administration of ATP resulted in one significant trend, arterial blood pressure was
decreased in a dose dependent manner. The other variables, such as flow, did display
dose dependent trends although none of these were statistically significant from zero.
Hypotensive action of Adenosine and ATP
It is accepted that adenosine is vasodilatator but there are few references that investigate
this property in bone. Gross et al (1979) concluded, from their study of neurohumoral.
regulation of bone blood flow, that adenosine dilates bone and marrow vessels, thus
indicating a dilatory capacity in bone andmarrow smooth muscle. These authors found
that in conscious and anaesthetised dogs adenosine reduced arterial pressure and
significantly lowered vascular resistance while blood flow to muscle was significantly
increased. In the anaesthetised animal the decrease in arterial pressure was approxi¬
mately 55%, which is similar to the percentage reduction shown at the 1.25mg dose of
ATP used in this study. The effect on vascular resistance demonstrated by these authors
in response to adenosine was not found following ATP treatment in the rat, in fact in this
study bone vascular resistance varies to a large degree with large standard deviations for
the means.
McCarthy et al 1985 found a similar significant decrease in bone vascular resistance
with an accompanied increase in flow in response to ATP. Strontium clearance was also
included in this study and was found to remain constant during the infusion of ATP.
The present results contradict to some extent the findings of other authors, a decrease
is found in arterial blood pressure but no significant trend is shown in vascular resistance
or bone blood flow. Thus in the ratATP causes vasodilatation of blood vessels thereby
reducing peripheral blood pressure but this is not of a sufficent magnitude to affect
vascular resistance or flow. Infact in bone vascular resistance and flow remain
unchanged. Analysis of flow and blood pressure shows that these variables are not
correlated to any degree (r=0.55 Figure 4.17.), as was found in the animals administered
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noradrenaline (r=0.3 Figure 4.9.). Vascular resistance in bone is calculated from both
bone blood flow and arterial blood pressure. Here flow does decrease to some extent in
response to ATP, although not significantly and this reduces the change in vascular
resistance that would arise ifpressure dropped and flow remained constant. The lack of
significant effects on bone vascular resistance and on bone blood flow suggests that the
dilatory effect of ATP is mainly on the peripheral circulation with little dilatation
occurring in bone vessels. Thus the systemic vascular resistance appears to be affected
by ATP but the values for muscle vascular resistance are too variable to allow any real
conclusions to be drawn about its systemic effects.
Effect of ATP on mineral exchange
Like noradrenaline ATP has no significant effect on strontium clearance. This is in
agreement with the work ofMcCarthy et al (1985). Unlike noradrenaline the admini¬
stration ofATP does not however affect strontium extraction, bone blood flow remains
relatively constant and therefore extraction which is calculated from both flow and
clearance remains constant as well.
In summary, ATP acts on the systemic circulation reducing arterial blood pressure. It
has no effect on bone blood flow or strontium clearance. Therefore in a similar way to
noradrenaline, ATP does not appear to change the functional propertiesof the bone
vascular bed.
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4.6.2. Mechanism of action
Noradrenaline
The nature of the blood vessels in bone obviously plays a vital part in the response to no¬
radrenaline. The anatomy of the blood vessels supplying the skeleton is well docu¬
mented (Brookes 1971, Rhinelander 1972). The blood vessels supplying the marrow,
the intramedullary arteries, have an endothelial, a muscular and an adventitial layer.
After further branching within the marrow vascular bed the arteries lose theirmuscular
component and the walls consist of only an endothelial and adventitial layer branching
off into sinusoids (Michelson 1968). The active constrictor effect of noradrenaline
appears to be through action on this smooth muscle component as the response of bone
vessels is of similar magnitude to that of skeletal muscle (Gross et al 1979). The
presence of these smooth muscle cells has been confirmed by Driessens and Vanhoutte
(1979).
This study shows that bone vasculature is responsive to noradrenaline over a range of
concentrations and that this is in a dose dependentmanner. Several workers suggest the
presence of intraosseous vascular alpha receptors (Yu et al 1972) and the study ofTran
et al (1978) agrees with these findings highlighting the presence of alpha-adrenorecep-
tors. ilere noradrenaline reduced blood flow and simultaneously increased arterial
blood pressure and bone vascular resistance, the most obvious conclusion is that it acts
directly on the bone vasculature, possibly at local receptor sites, to reduce bone blood
flow through an increase in resistance. It appears that the constrictor effect of noradre¬
naline opposes or masks any increase in flow that would normally arise through an
increase in arterial perfusion stimulating the arterial baroreceptors. This further supports
the theory of local receptor sites for noradrenaline which controls its action in bone.
Analysis of flow and blood pressure shows that the two variables are to a limited extent
correlated (Figure 4.9.), though the actual values are scattered. This suggests that
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a change in flow does cause a change in arterial blood pressure and the drug appears
to be responsible for both actions. The use of alpha-adrenolytic drugs confirms that the
action of noradrenaline is through adrenergic receptors present locally in the smooth
muscle cells of the arteries.
ATP
The vasodilatory action ofATP is probably through its action on the smooth muscle cells
of blood vessels, like noradrenaline the magnitude of the response of bone vessels is
similar to that of smooth muscle Gross et al( 19791. McCarthy et al(1985) found that
bone did respond to ATP, vasodilatation reducing bone vascular resistance. This
however was not seen in the presented results. It has however been shown that alkaline
phosphatase is present in the bone osteoblasts. This enzyme may have been hydrolyzing
ATP before the bone vascular bed could respond, thus no dilatatory response was seen.
Malik (1987) advanced the theory that stimulation of the sympathetic nerves can result
in a the release of adenine nuclides, these in turn enhance the synthesis and release of
prostaglandins from several tissues. Thus the action ofATP on vascular smooth muscle
may be influenced by these prostaglandins.
4.6.3. The relationship between flow and clearance
The plot and analysis of flow versus strontium clearance in the drug treated animals
compared with the control group shows that neither noradrenaline nor ATP are
statistically different from the control or from one another. Since clearance appears to
be related to flow this suggests that these act through a vascular mechanism either
directly or indirectly, any change in flow reflected by a change in clearance. The
presence of intraosseous alpha-adrenoreceptors and the inhibition of noradrenaline
action by an alpha-adrenolytic drug suggests that a direct vascular mechanism is
involved in the constrictor response. The action of ATP appears to be on the general
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circulation, no effect is shown on bone blood flow or bone vascular resistance even
though arterial blood pressure is reduced. This effect may be influenced by the release
of prostaglandins that occurs after stimulation of the sympathetic nerves.
The lack of a change in strontium clearance indicates that this constrictor/dilator action
does not involve increasing the number of patent capillaries.
4.7. Conclusion
Noradrenaline reduces blood flow by increasing the peripheral vascular resistance,
vascular receptors present in blood vessels respond to the drug resulting in vasoconstric¬
tion. Although bone vessels appear to respond in a similarmanner no significant effect
is shown on strontium clearance suggesting that the number ofpatent capillaries remains
the same i.e. the surface area for diffusion is constant. The small changes in clearance
reflect the relationship between flow and mineral transport rather than a direct action of
drug on exchange. On the other handATPreduces arterial pressure through vasodilatation
of the general circulation but has no effect on blood flow or vascular resistance in bone.
Like noradrenaline it has no effect on strontium clearance and similarly ATP does not
change the functional properties of the vascular bed.
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CALCIUM REGULATING HORMONES
5.1. Introduction
The calcium regulating hormones have been shown to control calcium and other ion
levels in the plasma through their action on bone. The movement of these ions i.e.
calcium, phosphorus and magnesium in and out of the skeleton has been extensively
studied. The use of isotopic tracers such as 47-Ca allows attempts to be made at
quantifying intestinal absorption, skeletal accretion and resorption rates. However little .
work has been attempted to identify how agents affecting mineral levels in the blood act
on the vascular bed of bone, even though studies of circulation in other beds suggest that
bone circulation is in some way influenced.
Both PTH and PGE2 have been demonstrated to have hypotensive action in vascular
beds,vasodilatation of vessels reducing blood pressure (Charbon 1968, Messina et al
1976). Evidence is also accumulating that PTH influences bone vascular resistance,
Pang et al (1980a) found that bPTH had a hypotensive effect in the rat. Additionally
these agents have been shown to have rapid inhibitor effects on calcium uptake (Dacke
and Shaw 1987), the authors suggesting that a vascular response to PTH and PGE2 may
be involved in this inhibition mechanism. Elevation of plasma calcium levels above the
normal range is referred to as hypercalcemia. Several authors have investigated this
action with respect to PTH and PGE2, in particular examining the timing of the response
(Boelkins et al 1976. Beliel et al 1973). Both the hypercalcemic and the histological
effect of PTH and PGE2 have been more extensively studied than the vascular action.
Thus there are few studies which detail the vascular effect of these agent with respect to
mineral movement in bone.
Calcitonin has been shown to have opposite action to that ofPTH and PGE2 i.e. causing
hypocalcemia (a reduction in plasma calcium levels below normal). Johnston and Deiss
(1966) established that this agent has inhibitory effects on elevated plasma calcium
levels. This is through complex interactions between the agents rather than inhibition
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of the PTH or PGE2 function. There is ample evidence that calcitonin inhibits bone
resorption ("Foster et al 19661 however like PTH and PGE2 its effect on blood flow is
not so well documented.
5.2. Choice of drug and dosage.
The general action ofPTH, PGE2 and calcitonin has been well documented however the
papers are often contradictory, especially in the case of PGE2, and few have included
a study of their effects on blood flow and mineral clearance in bone. These papers
provide details of effective doses that are suitable for use in the rat thus allowing
selection of doses which should have some effect either on the arterial pressure or
strontium clearance.
It has been established that PTH induces hypercalcemia and it seemed appropriate to
investigate the action of this on bone blood flow as well as calcitonin, whose effects
oppose PTH's action. PGE2 has also been included because it has been shown to have
a rapid inhibitory effect on calcium uptake in bone. The doses of PTH and PGE2 were
selected from work by Dacke and Shaw (1987). The doses of PGE2 used by these
authors are comparable with the lowest doses of native PGE2 found to produce
osteolytic responses in vitro (Raisz andMartin, 1984— l-10nmol/l). The administration
of approximately 2,10 and 20pg/100g body weight of rat decreased net uptake of 45-
Ca in the femur in a dose dependent manner. Only at the highest dose was a significant
difference found from the control values. In a 350g animal these doses are equivalent
to 7,35 and 70pg respectively. For ease in preparation and in the creation of a dose curve
the lowest selected dose in this study was chosen as 20pg increasing to 80pg in
increments of 20. Thus doses similar to these authors were used but the highest dose
increased by lOpg.
In investigating the effects of bPTH( 1-34) these authors used approximately 0.3,1.5 and
3.3pg/100g (Dacke and Shaw 1987 Figure 1.). These caused a decrease in calcium-45
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uptake which was significantly different at all doses. The doses are equivalent to 1,5.25
and 12pg in a 350g rat. As all the doses were statistically significant it was decided to
select doses which fell within this range i.e. l-12pg and create a dose response curve
from these. Once again for ease in preparation whole microgrammme quantities were
selected thus the doses chosen were 4, 8, and 12pg per animal.
The doses of calcitonin were selected from a study conducted by Driessens and
Vanhoutte (1979). These authors used doses ranging from 0.001 to lmU. of salmon
calcitonin perfused over 15 minutes into a dog tibia . They found at all doses the results
were statistically different from the control results. The two highest doses were
equivalent to 10U. and 100U. and it was decided to select 10U. as the starting dose for
infusion into the rat (This was the same as the selected dose ofPorter et al, per gramme
of bone). The next dose of 50U. was then chosen. Then a 25U. dose was selected as a
intermediate point to give a dose response pattern. Thus the three selected doses would
hopefully cause some effect on vascular perfusion pressure which Driessens et al found
to be affected in the isolated bone.
Circulating levels of the hormones
Little is known about the basal secretion of the endocrine glands in situ since the
procedures tend to involve tropic stimulation to some extent thus upsetting the secretion
rates. The measurement of circulating basal levels of these hormones is also hard to
establish but has been attempted through histochemical bisoassays and radioimmunoas¬
says. However PGE2 is secreted locally, the level changing to suit the required needs.
Using histochemical bioassays the circulating concentration ofPTH in the human was
found to be approximately 5 - 15pg/ml of plasma (Williams 1981a). Another method
(cytochemical bioassay) found that the mean value for a normal subject was 16.8 ±
3.6pg/ml ofplasma. The lower values of this study would therefore fall within the range
of the histochemical assay. However this method (cytochemical) measures all the
immunoreactive PTH in the peripheral plasma i.e. the inert metabolites as well as the
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active portion. The histochemical assay is more representative of the circulating level
of the active form ofPTH and since bPTH (1-34,) the active portion is used in this study
this quantity would reflect the dose better. Thus assuming a 30ml plasma volume for
the rat the doses used in this study range from 0.13pg to 0.4pg and represent pharma¬
cological levels.
Calcitonin levels have been measured successfully with numerous techniques but the ra¬
dioimmunoassay method is the most accurate and sensitive reflecting the specificity of
the hormone. Parthemore et al (1978) have found that in a normal male the mean value.
for plasma calcitonin is 24pg/ml ± 18pg with a range of <10 - 75 pg/ml for 55 males.
These findings agree with those of other laboratories, thus the basal circulating levels of
calcitonin in normal adults are low. Although other authors have found higher levels
(Heynen et al 1976) this could arise because of the immunochemical heterogeneity of
calcitonin or the method of measurement (i.e. histochemical assays). Therefore in the
normal rat (30ml plasma) the doses administered represent pharmacological levels i.e.
0.08pg - 4.2pg
5.3. Preparation of Drug
Before the experimental procedure the various drugs used were prepared to ensure
activity and 'freshness'. In each drug group the dose used was randomly chosen to try
to reduce variation due to different sibling groups. In all cases a stock solution of the drug
was either bought or made up and then stored at the appropriate temperature. An
appropriate volume was then removed when required and diluted with Krebs Ringer
buffer to give the necessary concentration.
a) Parathyroid Hormone (Sigma bPTH(l-34) O.lmg.)— 4,8 and 12ug per rat 2ml bolus.
Since the structural requirements for most of the biological activities of parathyroid
hormone (PTH(l-84)) are virtually satisfied by the amino-terminal 34 amino acid
fragment, PTH(l-34) this study use bPTH(l-34) to investigate the action on bone
(Tregear et al 1973).
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The stock solution was made up by dissolving 0.1mg bPTH 1-34 in 2ml saline which
was then stored at <0°C. For each animal the test solution was made up when required.
Thus for a dose of 4pg, 0.08ml of the stock solution was dispensed and this was made
up to a volume of 2ml using buffer. (8pg — 0.16ml, 12pg —0.24ml).
b) Prostaglandin E2 (Sigma) — 20,40,60 and 80ug per rat 2ml bolus.
Using lOOOpg PGE2 and 0.5ml ethanol a stock solution was made. This was stored at
less than 0°C and the appropriate volume dispensed when required. Thus for the 20pg
dose 0.02ml of the stock solution was required with 0.04,0.06 and 0.08ml required for
the other doses. These quantities were then made up to 2ml with buffer containing 0.1%
albumin.
Since more than one animal was experimented on in any one day larger volumes than
these were actually dispensed i.e. for required doses of 20,40 and 60pg 0.12ml were
measured. These were then made in to the 60pg concentration using buffer i.e. made
up to 4ml volume. Two ml of this solution was then dispensed for the 60pg dose, 1.33ml
for the 40pg dose and 0.66ml for the 20pg dose both of these then made up to 2ml using
buffer.
The quantity of ethanol therefore varied depending on dose but this addition was
essential, as the ethanol acted as a 'carrier' for PGE2. To ensure that it was not the
ethanol that caused any effect the control animals also received ethanol in the injected
buffer at the same concentration as that of the 80pg animals i.e. 0.04ml/ml of buffer.
c) Calcitonin (Rorer; Calvsnar 400U. of Salmon Calcitonin in 2ml of saline actate
diluent) — 10,25 and 50U. per rat infusion, stored between 2°C and 8°C.
After a test injection of Calysnar 10U. which displayed no effect on flow or arterial
pressure the protocol was changed to incorporate infusion of the drug. This was
therefore similar to the method used in the perfusion ofa dog tibiae (Driessensetal 1979,
Porter et al 1986)
To ensure that the animal received the same quantity of solution as for PTH and PGE2
the pump rate was increased to 15ml/hour and the period extended to eightminutes. Test
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infusions ofbuffer over this period and at this rate showed no difference when compared
to the other control animals.
The Calysnar solution was 200IU.per ml. Thus to obtain the correct concentration for
the test animal quantities of this was dispensed and diluted with buffer. To maintain
efficient infusion rates more than 2ml of the solution was made up i.e. 6ml quantities
were for two rats. Thus for the 10U. dose 0.15ml was dispensed and made to six ml.
(0.375 in 6ml for two doses of 25U. and 0.75ml in 6ml for two doses at 50U)
5.4, Experimental procedure (Figure 5.10
The animal was prepared for the experiment as detailed in section 4.4.
a) PTH and PGE2
1. Control blood flow.
Buffer was infused at 6ml/hour over the control flow period, this ensured that the carotid
cannula remained patent over the experimental period. Withdrawal of blood com¬
menced (caudal cannula 0.197m/min) and thirty seconds laterCo-57 microspheres were
injected into the heart via the first tap. Blood was withdrawn for a further ninety seconds.
2. Test blood flow
After ensuring that arterial blood pressure was stable the test run was begun. The test
solution was injected via the carotid cannula and thirty seconds after this was begun
blood collection was commenced. After a further thirty seconds tin-113 microspheres
and strontium-85 were injected. Blood withdrawal ceased after a total of 4.5 minutes.
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b) Calcitonin
1. Control blood flow
The same procedure was followed however buffer was infused at 15ml/hour.
2. Test blood flow
The bufferwas replaced with the test solution and infusion begun (carotid cannula 15ml/
hour). After three and a half minutes the pump for withdrawing blood was started
(caudal cannula 0.197ml/min). Thirty seconds later the microspheres and strontium
were injected. Blood withdrawal ceased four minutes later.
c) Control
1) PTH and PGE2
The same procedure was followed except that a bolus injection of buffer,via the
carotid cannula, was used insteadof the test solution. Ethanol and albumin was included
in the buffer for the PGE2 animals.
2) Calcitonin
The same procedure was followed as for the calcitonin treated animals i.e. infusion of
buffer over eight minutes at 15ml/minute.
At the end of the experiments the animals were sacrificed using KC1 injected via the tail
cannula. Both tibiae and femora were removed quickly to minimise post-mortem
migration of ions to the bone. A muscle sample from the upper quadriceps was also
taken. The bone, muscle and blood samples were then weighed before counting.
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2. Drug (per animal)
a. INFUSION
Calcitonin 0, 10, 25 and 50U.
(0, 0.74, 1.8, and 3.6mM..)
b. INJECTION
PTH 0,4, 8 or 12pg
(0,1,2, and 3pM.)






1. 2 minutes collection
2. 4.5 minutes collection
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5.5. Results
a) Parathyroid hormone
This group consisted of 22 animalspnjected with 0, 4, 8, or 12pg parathyroid hormone.
The effect of this administration on seventeen animals is detailed in tables 5.1-5.4..
Table 5.1. includes the effect of infusion on bone blood flow, strontium clearance and
arterial blood pressure. While Table 5.2. gives details of strontium extraction and
vascular resistance in bone. The actual measurements of arterial blood pressure are
outlined in Table 5.3. Finally the action of PTH on muscle are included in Table 5.4.
Of the remaining five animals one died during the experiment, in three there were
insufficient microspheres collected in either of the blood samples, and in another the
withdrawal pump setting was found to be too high.
The administration of parathyroid hormone causes a significant decrease in both bone
blood flow and arterial blood pressure (Figures 5.2. and 5.4.) with an associated
decrease in bone vascular resistance at the first two doses. The general trend is of a
decrease in both flow and pressure with increasing drug concentration. In the case of
flow, at none of the individual doses is there a significant change in flow when compared
to the zero dose, although the line of regression for all the values is significantly
decreased from zero. The mean tin flow at 4 and 8pg are actually greater than the control
mean value (Table 5.1.). Thus the plot of these means would initially rise then fall, but
the values are not significantly different from the control so the general trend still stands.
Blood pressure changes significantly at each dose (p<0.02), falling to 68% at 4pg, 55%
at 8pg and 52% at 12pg (Table 5.3.).Seventy five percent (r2=0.75) of the variation can
be accounted for by the changing dose of PTH, indicating the extent of the relationship
between the two. Table 5.3 outlines the actual values for arterial pressure measured at
the four points of interest. Although B1 and B2 vary to some extent this is not
statistically significant at any dose. The change in arterial pressure is immediate and still
present at the point of microsphere injection (Figure 5.5. ). Thus the values for B3 and
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B4 are the same. Apart from the degree of change, the period of recovery varies
according to dose. Examination of the pressure traces for the individual animals reveals
that at 4pg the trace has returned to normal by about three minutes, this is extended to
four and a half minutes for the 8pg dose and in the case of 12pg the pressure does not
return to normal levels before the end of the experiment. This systemic pressure
decrease points towards the 'vasodilatator action of the hormone, which causes a decrease
in the total peripheral resistance. At 12pg the ECG trace and cardiotac, (Figure 5.6.. )
show changes which represent an increase in the heart rate. From this increase in heart
rate and arterial pressure an increase in cardiac output can be inferred. However the
radioactivity of the microspheres were notmeasured before injection thus cardiac output
could not be estimated. This change in heart rate is in no way sufficient to compensate
for the pressure drop, though there is a small increase in the pressure over the
experimental period.
Bone vascular resistance shows a different pattern, the mean values suggest an initial
decrease at 4 and 8pg followed by a return to approximately normal at the 12pg dose
(Table 5.2.). Indeed at both 4 and 8pg there is a significant difference when analysed
using a un-paired t-test. Using the line of linear regression the two variables are not
correlated (r=-0.39), the injections causing only 15% of the variation in vascular
resistance.
Like noradrenaline, PTH significantly reduced flow but had no significant effect on
clearance. The line of regression for strontium clearance (Figure 5.3.) is not signifi¬
cantly different from zero and at no particular dose is any statistical difference found
between the control and experimental flows (Table 5.1.). Similarly at no dose group
is strontium extraction significant from the control group indicating that, although flow
is decreased, this is insufficient to affect strontium extraction while strontium clearance
remains relatively constant (Table 5.2.). This is, however, different to noradrenaline.
Extraction is dependent on flow and clearance and a comparison of the lines of
regression for flow change (Figures '5.2. and 4.2) shows that the two are significantly
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different (t= 2.1 DF=29 p<0.5). The slope of the regression line for noradrenaline is
steeper than that for PTH and since, in neither case is strontium clearance significantly
affected, this would indicate that with PTH the decrease in flow is insufficient to
significantly increase the quantity of strontium removed in the passage ofblood through
the bone capillary bed. However the greater reduction in flow following noradrenaline
is sufficient to increase the extraction of strontium.
Neither muscle flow or vascular resistance are affected by parathyroid hormone. Both
change in response to treatment but the standard deviations of the means are high and
so no dose is significantly different statistically (Table 5.4.).
Finally, analysis of flow versus strontium clearance in the 4-12 pg animals (Figure 5.9.).
There is a high correlation between the two variables, with some clumping at the lower
values. Comparison of the slope with that of the control group produces a non significant
t value (Figure 3.9.). Thus this relationship is only the same as that shown by normal
animals and not the result ofparathyroid treatment. A change in flow causes a respective
change in strontium clearance, but this change in clearance need not be significant if the
reduction in flow, although significant, is not too great.
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Table 5.1. Effect of parathyroid hormone on blood flow, strontium
clearance and blood pressure in rat bone
PTH pg/animal
Control 4 8 12 #
Flow
Cobalt 0.27 ±0.08 0.23 ±0.10 0.31 ±0.07 0.33 ±0.08
Tin 0.30 ±0.09 0.33 ±0.06 0.31 ±0.015 0.17 ±0.12
@Sn - Co 0.02 ±0.01 0.09 ±0.11 -0.01 ±0.08 -0.16 ±0.16
* Sr clearance
0.17 ±0.02 0.19 ±0.03 0.21 ±0.05 0.12 ±0.06
Blood Pressure Change
(B4-B2) 0 -42 ±13 -60 ±8 -64 ±15
@ Paired t-test— 0 p< 0.05
* Unpaired t-test (comparison with 0 dose) — All N.S.
All values represent mean ± standard deviation.
Number of animals in each group (n) = 4.
# (n) = 5.
Flow and clearance are measured in ml/min/g.
Blood pressure is measured in mmHg; at two points;
(B2) at the begining of the experimetal run,
(B4) at point ofmaximum effect.
Sn = Tin. Co = Cobalt.
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Table 5.2. Effect of parathyroid hormone on strontium extraction and
vascular resistance in rat bone
PTH |ug/animal
Control 4 8 12#
*Strontium Extraction










@Sn - Co -106 ± 78 -368 ± 345 -205 ± 72 129 ± 297
@ Paired t-test — 8|ig p< 0.02
* Unpaired t-test (comparison with 0 dose) — All N.S.
All values represent mean ± standard deviation.
Number of animals in each group (n) = 4.
# (n) = 5
Vascular resistance is measured in mmHg/min/g (using B1 for calculating the cobalt value
and B3 the tin value).
Sn = Tin. Co = Cobalt.
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Table 5.3. Mean and standard deviation of blood pressure measured at the
four reference points in parathyroid hormone treated animals
PTH |ug/animal
Control 4 8 12#
Blood pressure
Cobalt B1 130 ±12 132 ±21 137 ±10 132 ±18
Tin B2 119 ±29 135 ±18 135 ±10 136 ±22
* B3}
} 119 ±29 92 ±25 75 ± 13 72 ±10
B4}
Number of animals in each group (n) = 4.
# (n) = 5.
Blood pressure is measured in mmHg.
B1 and B3 Blood pressure at point ofmicrosphere injection used for calculation of
vascular resistance.
B2 Blood pressure at the begining of the experimental run, used for the
calculation of blood pressure change (B4 - B2).
B4 blood pressure at the point of maximum drug effect.
* Blood pressure at microsphere injection is equivalent to point ofmaximum drug effect.
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Table 5.4. Effect of parathyroid hormone on blood flow, and vascular
resistance in rat muscle
PTH ug/animal






















@Sn - Co -686 ± 395 -668 ± 848 -1131 ±798 -762 ± 542
@ Paired t-test— Vascular resistance I2gg p ^ 0.05.
All values represent mean ± standard deviation.
Number of animals in control group (n) = 3.
PTH treated group + (n) = 4.
# (n) = 5.
Flow is measured in ml/min/g.
Vascular resistance is measured in mmHg/min/g (using B1 for calculation of cobalt value
and B3 for calculation of tin value)
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F1 = Control Blood Flow — using Co microspheres.
F2 = Experimental Blood Flow — using tin microspheres.
Significance of the regression , p<0.02
Correlation coefficient (r) = - 0.56
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Figure 5.3 Effect of PTH on Strontium Clearance.
jug/animal
Significance of the regression, p <0.18
Correlation coefficient (r) = - 0.34
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Significance of the regression, p < 0.0001
Correlation coefficient (r) = - 0.87
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Significance of the regression, p<0.07.
Correlation coefficient (r) = 0.448.
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Figure 5.8. Change in Vascular Resistance in Response to PTH
Hg/animal
V.R. 1 = Vascular Resistance as estimated from cobalt flow and blood pressure (B1.)
V.R.2 = Vascular Resistance as estimated from tin flow and blood pressure (B3).
Significance of regression, p < 0.12
Correlation coefficient (r) = 0.39
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y = 4.7154e-2 + 0.46898x RA2 = 0.686




Significance of the regression, p < 0.0005
Correlation coefficient (r) = 0.83
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y = 76.723 + 9.5417x RA2 = 0.003
0.1




Significance of the regression, p < 0.85
Correlation coefficient (r) = 0.06
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b) Prostaglandin E2
In total twenty nine animals were treated with 0, 20, 40, 60 or 80 pg prostaglandin E2.
However in nine of these insufficient cobalt microspheres were collected in the blood
samples (less than 300). At this time the microsphere supply was nearly finished and
diluting may have meant that an insufficient number was used; also it was noticed that
the microspheres tended to clump. The effects on the remaining twenty animals are
summarised in tables 5.5.-5.8. These include mean values for bone blood flow,
strontium clearance and change in arterial pressure (Table 5.5.), strontium extraction
and bone vascular resistance (Table 5.6.) and blood flow and vascular resistance in
muscle in Table 5.7. The last table gives full details of arterial blood pressure at the four
points of interest (Table 5.8.).
Prostaglandin E2 produced a significant effect on bone blood flow, clearance, extrac¬
tion, vascular resistance and arterial blood pressure. Treatment with this hormone
resulted in a dose dependent decrease in bone blood flow (Figure 5.11.). In all cases the
mean flow 2 values are statistically different from the control mean (p<0.02) and each
is lower than their respective flow 1 values (Table 5.5.).
i.e. 20pg Flow 2 = 71% of Flow 1
40pg Flow 2 = 55% "
60pg Flow 2 = 42% "
80pg Flow 2 = 47%
The effect on bone blood flow is significant at 20, 40 and 80pg (Table 5.5.). The
correlation between the two variables is in the region of 0.68 indicating the extent to
which the two are related, with the drug responsible for some 45% of the variation,
calculated from the r squared value of 0.45 (Figure 5.11.).
Similarly strontium clearance is reduced with increasing dose of PGE2 (Figure 5.1.2)
and this is statistically significant, p<0.001 (DF=20). Comparison with the control
mean values shows that in each case clearance is less than that of the control (85%, 73%
65% and 65% respectively). The extent of variation that the drug is responsible for is
approximately 46%, (r2= 0.46) but the value for correlation i.e. -0.68confirms that the
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two are related to some extent. The mean values for clearance are statistically different
from that of the control at the 40, 60 and 80pg doses (Table 5.5.).
Prostaglandin E2 treatment also decreases arterial pressure in a dose dependent fashion
(Figure 5.13.). The mean percentage decrease ranges from 47% at 20pg to 43% at 80pg
indicating that the initial effect is similar at all doses. However it is the duration of this
arterial pressure decrease that varies with increasing dose. Like the other agents used
in this study the time taken to recover increases with increasing dose (Figure 5.14.).
Both vascular resistance and strontium extraction increase significantly (the line of
regression is significantly different from zero) in a dose dependent fashion (Figures 5.14
and 5.16.). A change in vascular resistance can be anticipated as PGE2 acts on bone
reducing flow. Vascular resistance is calculated by dividing bone blood flow by blood
pressure thus this increase infers that flow is decreased to a greater degree than blood
pressure. A plot of these two variables confirms this to be the case (Figure 5.18).
The increase in extraction can be inferred from the decrease in clearance however this
increase need not be significant as extraction is also dependent on flow, which in this
case also decreases. However the change in extraction is significant (Figure 5.14.) thus
the decrease in clearance and flow cannot be of the same degree. This is demonstrated
in figures 11 and 12, the slope (b) is steeper for change in flow than strontium clearance.
Correlation and regression analysis of flow versus strontium clearance in the 20 - 80pg
animals shows that the two variables are highly correlated (r=0.76), 59% of the variation
found in clearance resulting from a variation in flow (Figure 5.17.). The significance
of the regression is 0.0008 with a slope of 0.78 (s.e. 0.096). Comparing this value with
that of the control data results in a significant t-value (p<0.01). This suggests that PGE2
treatment affects clearance in some way independent of its action on bone blood flow.
Inmuscle the flow is not significantly affected by PGE2 treatment, although, like PTH,
this does change, but the standard deviation of the means are high and at no dose are the
changes significant (Table 8). Similarly the change in muscle vascular resistance at any
one dose is not significant and neither is the regression analysis.
1
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Table 5.5. Effect of prostaglandin E2 on blood flow, strontium clearance and
blood pressure in rat bone
PGE2 fig/animal
Control 20 40 60 80
Flow
Cobalt 0.49 ±0.11 0.32 + 0.04 0.31 +0.13 0.33 + 0.14 0.36 + 0.06
Tin 0.50+ 0.1 0.23 + 0.03 0.17 + 0.05 0.14 + 0.03 0.17 + 0.03
@Sn - Co 0.01 +0.07 -0.09 + 0.05 -0.14 + 0.09 -0.20 + 0.14 -0.19 + 0.06
*Sr Clear 0.32 + 0.02 0.28+0.06 0.25 + 0.04 0.22 + 0.04 0.22 + 0.04
Blood Pressure
(B4-B2) 5 + 7 -57+40 -52 + 3 -77+ 17 -55+4
@ Paired t-test — 20, 40pg p< 0.05
80pg p< 0.01
* Unpaired t-test (comparison with 0 dose) — 40pg p < 0.05
60, 80pg p< 0.01
All values represent mean ± standard deviation.
Number of animals in each group (n) = 4.
Flow is measured in ml/min/g.
Blood pressure is measured in mmHg/min/g ; at two points.
(B2) at begining of experimental run,
(B4) at point of maximum effect.
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Table 5.6. Effect of prostaglandin E2 on strontium extraction and vascular
resistance in rat bone
PGE2 fig/animal
Control 20 40 60 80
*Strontium Extraction
0.66 + 0.11 1.23 + 0.18 1.6 + 0.29 1.6 + 0.19 1.36 + 0.33
Vascular Resistance
Cobalt 249 ± 46









@Sn - Co 7 ±26 -35 + 48 8 ± 198 157+ 108 201 + 177
@ Paired t-test — All N.S.
* Unpaired t-test (comparison with 0 dose) — All p < 0.002
All values represent mean ± standard deviation.
Number of animals in each group (n) = 4.
Vascular resistance is measured in mmHg/min/g (using B1 for calculating the cobalt value and B3
the tin value).
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Table 5.7. Effect of prostaglandin E2
rat muscle
on blood flow and vascular resistance in
PGE2 ue/animal
Control 20 40 60 80+
Flow
Cobalt 0.21 ±0.20





















@Sn - Co 252 ±277 -523 ± 249 -1388 ±1361 -209 ± 293 -65 ± 495
@ Paired t-test — All N.S.
All values represent mean ± standard deviation.
Number of animals in each group (n) = 4.
+ (n) = 3.
Vascular resistance is measured in mmHg/min/g (using B1 for calculating the cobalt value and B3
the tin value)
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Table 5.8. Mean and standard deviation of blood pressure measured at the four
reference points for prostaglandin E2 animals
PGE2 fig/animal
Control 20 40 60 80
Blood pressure
Cobalt B1 120 ±25 126 ± 14 122 ± 10 141 ± 13 129 ± 9
Tin B2 119 ±24 129 ± 16 120 ± 8 149 ± 13 125 ± 4
B3 124 ±18 82 ± 9 75 ± 13 81 ± 8 90 ±21
B4 126 ± 18 62 ± 10 68 ± 6 71 ± 10 70 ± 4
@ Paired t-test — All N.S.
All values represent mean ± standard deviation.
Number of animals in each group (n) = 4.
Blood pressure is measured in mmHg.
B1 and B3 Blood pressure at point ofmicrosphere injection used for calculation of
vascular resistance.
B2 Blood pressure at the begining of the experimental run, used for the
calculation of blood pressure change (B4 - B2).
B4 Blood pressure at the point of maximum drug effect.
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Figure 5.11. Change in Bone Blood Flow After Injection of PGE2.
|ug/animal
F1 = Control Blood Flow — using Co microspheres.
F2 = Experimental Blood Flow — using tin microspheres.
Significance of regression , p<0.001
Correlation coefficient (r) = - 0.67
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Significance of the regression, p<0.001
Correlation coefficient (r) = - 0.68.
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Figure 5.13 Change in Blood Pressure With PGE2 Treatment
0 20 40 60 80
lug/animal
■ Two points
B2 = Arterial Pressure measured at begining of experimental period .
B4 = Arterial Pressure measured at point of maximum drug effect.
Significance of the regression, p < 0.005
Correlation coefficient (r) = - 0.6
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Figure 5.14. Effect of PGE2 on Strontium Extraction
jug/animal
Significance of the regression, p<0.003
Correlation coefficient (r) = 0.633 .
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Figure 5.16. Change in Bone Vascular Resistance With
PGE2 Treatment
0 20 40 60 80
jiig/animal
V.R.I = Vascular Resistance as estimated from cobalt flow and blood pressure (B1.)
V.R.2 = Vascular Resistance as estimated from tin flow iand blood pressure (B3).
Significance of the regression, p < 0.01.
Correlation coefficient (r) = 0.56
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Figure 5.17. Flow Versus Strontium Clearance in PGE2
Treated Animals
Flow 2 ml/min/g
Significance of the regression, p < 0.0005
Correlation coefficient (r) = 0.77
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y = 77.983 + 24.066x RA2 = 0.007
0.00 0.05 0.10 0.15 0.20
Flow 2 ml/min/g
0.25 0.30
Significance of the regression, p < 0.75
Correlation coefficient (r) = 0.09
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c) Calcitonin
Twenty eight animals were treated with 0, 10, 25, or 50 units of Salmon calcitonin.
Seven rats were unsuitable for inclusion in this study, in four there as insufficient
microspheres in the blood sample or the sample was of an inadequate volume, two
animals died of anaesthetic death and in one there was a question as to the actual dose
received.
The effect of calcitonin on bone blood flow, strontium clearance and arterial pressure
in the remaining 21 animals is detailed in Table 5.9. While Table 5.10 includes themean
values for strontium extraction and bone vascular resistance and Table 5.11. the blood
flow and vascular resistance in muscle. Finally the arterial pressure values are detailed
in Table 5.12.
The only significant action of calcitonin is upon strontium clearance (p<0.03 Figure
5.20a.). However it is only the change at fifty units that causes this effect. At the other
doses a the line of regression ifplotted is almost horizontal with a p value of 0.8 (Figure
5.20b.). This suggests that a higher dose could have been included in the study to see
if the change continues with increased dose. Possibly the dose response curve for
calcitonin is initially flat and then begins to curve upwards. The first two doses may be
on this relatively flat portion with the larger dose on the steeper portion. However the
10U. dose was chosen because Driessens et al (1979) found this, and lower doses had
a significant effect. This study however was in the perfused dog tibia and the rat does
not necessarily exhibit the same dose response.
It is the fifty unit dose that affects the slope of the lines of regression for flow and
vascular resistance change. Initially the flow decreases at 10U flow 2 is 80% of flow 1,
at 25U this falls to 70% but the increase of42% in the 50U dose tends to balance this out
and the regression line is not significant (Figure 5.19.). Vascular resistance exhibits the
opposite pattern initially increasingwith decrease shown at the 50U. dose (Figure 5.24.).
It is at fifty units that the only significant t-values are found in both flow change and
strontium clearance.
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Strontium extraction is dependent upon flow and clearance, a significant change in
either does not necessarily affect it, as is the case here (Figure 5.22). That is strontium
clearance decreases with increasing dose of calcitonin but this is not significant.
Calcitonin has no effect on blood pressure with a mean and standard deviation during
the experimental flow of 121 ± 14 (n=4) for the control and 134 ± 18 (n=14) for the
treated animals (Figure 5.21.) Within each animal the pressure remained constant
during the test period i.e. B2, B3 and B4 are all the same, indicating that the drug has no
effect on the vascular network (Table 5.11.). Similarly there is no significant effect on
either flow or vascular resistance in rat muscle over any of these doses (Table 5.11.).
Analysis of flow versus strontium clearance in the 10-50U. animals is presentedin figure
2 7. There is a correlation between the two variables but this is lower than that of any
other group. Comparison of the slope with that of the control group, PTH experimental
and the PGE2 experimental produces a non significant t value in each case. Thus this
appears to represent a standard effect, that is the relationship is demonstrated in this
range in all animals regardless of drug treatment.
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Table 5.9. Effect of calcitonin on blood flow, strontium clearance and
blood pressure in rat bone
CalcitoninU/animal
Control# 10+ 25 # 50 #
Flow
Cobalt 0.29 + 0.06 0.30 + 0.03 0.45 ±0.11 0.29 ±0.11
Tin 0.28 ±0.07 0.24 ±0.07 0.32 ±0.12 0.41 ±0.12
@Sn - Co -0.01 ±0.08 0.06±0.08 0.13 ±0.11 0.12 ±0.11
* Sr clearance
0.20 ±0.02 0.20 ±0.04 0.19 ±0.05 0.26 ±0.06
Blood Pressure Change
! # ! #
(B4-B2) 1 ±2.5 0 0 1 ± 2.2
@ Paired t-test — All N.S.
* Unpaired t-test (comparison with 0 dose) — 50 U. p < 0.05
All values represent mean ± standard deviation.
Number of animals in each group ! (n) = 4.
# (n) = 5.
+ (n) = 6.
Flow and clearance are measured in ml/min/g.
Blood pressure is measured in mmHg; at two points;
(B2) at the begining of the experimetal run,
(B4) at point of maximum effect.
Sn = Tin. Co = Cobalt.
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Table 5.10. Effect of calcitonin hormone on strontium extraction and
vascular resistance in rat bone
Calcitonin U./animal
Control+ 10# 25+ 50+
*Strontium Extraction
0.72 + 0.1 0.87 ± 0.23 0.68 + 0.26 0.65 ±0.16
Vascular Resistance
Cobalt 461±130 445± 37 339+ 59 548 ±213
Tin 424 ±108 592 ±215 526 + 229 343± 85
@Sn - Co -37 ± 77 152±179 191±189 216 ±240
@ Paired t-test— All N.S.
* Unpaired t-test (comparison with 0 dose) — All N.S.
All values represent mean ± standard deviation.
Number of animals in each group + (n) = 5
# (n) = 6
Vascular resistance is measured in mmHg/min/g (using B1 for calculating the cobalt value
ad B3 the tin value).
Sn = Tin. Co = Cobalt.
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Table 5.11. Effect of calcitonin infusion on blood flow and vascular
resistance in rat muscle
Control 10+ 25# 50!
Flow
Cobalt 0.08 + 0.03 0.11+ 0.05 0.08 + 0.01 0.12 + 0.02
Tin 0.08 + 0.13 0.11 + 0.05 0.08 + 0.03 0.15+0.07
@Sn - Co -0.001+0.04 -0.02 + 0.06 0.001+0.003 -0.02 ± 0.09
Vascular Resistance
i
Cobalt 1520 + 491
Tin 1492 ± 107
@Sn - Co 329 ± 300
All values represent mean + standard deviation.
Number of animals ! (n) = 4.
(n) = 5.
+ (n) = 6.
Flow is measured in ml/min/g.
Vascular resistance is measured in mmHg/min/g. (using B1 for calculation of cobalt
vascular resistance and B3 for tin vascular resistance).
@ Paired t-test — All N.S.
i # i
1736 + 1275 2095 ± 446 1192 + 288
1953 + 1840 2235 ± 1547 1047 ± 400
253 + 546 140 ± 1206 -135 + 600
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Table 5.12. Mean and standard deviation of blood pressure measured at the
four reference points in calcitonin treated animals
Calcitonin U./animal
Control 10# 25+ 50#
Blood pressure
Cobalt B1 122 ±13 135 ±25 151 ±17 141 ± 9
Tin B2}
* B3) 121 ±14 135 ±17 134 ±30 135 ± 3
B4}
Number of animals in each group (n) = 4.
Blood pressure is measured in mmHg.
B1 and B3 Blood pressure at point ofmicrosphere injection used for calculation of
vascular resistance.
B2 Blood pressure at the begining of the experimental run, used for the
calculation of blood pressure change (B4 - B2).
B4 blood pressure at the point ofmaximum drug effect.
* Blood pressure remains constant during infusion thus B2, B3 and B4 measurements are
the same.
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Figure 5.19. Change in Blood Flow During Infusion of Calcitonin
U./ animal
F1 = Control Blood Flow — using Co microspheres.
F2 = Experimental Blood Flow — using tin microspheres.
Significance of the regression , p<0.07.
Correlation coefficient (r) = 0.405.
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Figure 5.20a. Effect of Calcitonin on Strontium Clearance
U./ animal
Significance of the regression, p<0.034.
Correlation coefficient (r) = 0.46.
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Significance of the regression, p<0.8.
Correlation coefficient (r) = - 0.06.
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Figure 5.21. Change in blood pressure with Calcitonin treatment
U./ animal
Four points Three points
Significance of the regresion, p< 0.07
Correlation coefficient (r) = 0.435
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Figure 5.22. Effect of Calcitonin on Strontium Extraction
U./ animal
Significance of the regression, p<0.034.
Correlation coefficient (r) = 0.46
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Figure 5.24. Change in bone vascular resistance in response
to Calcitonin
0 10 20 30 40 50
U./ animal
V.R. 1 = Vascular Resistance as estimated from cobalt flow and blood pressure (B1.)
V.R.2 = Vascular Resistance as estimated from tin flow and blood pressure (B3).
Significance of the regression, p < 0.08.
Correlation coefficient (r) = - 0.042
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Figure 5.25. Flow versus strontium clearance in the Calcitonin
treated animals
Flow 2 ml/min/g
Significance of the regression, p < 0.73
Correlation coefficient (r) = 0.014
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y = 120.32 + 44.440x RA2 = 0.094
-i r" 1 ■-
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Flow 2 ml/min/g
Significance of the regression, p < 0.28
Correlation coefficient (r) = 0.31
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5.6. Discussion
5.6.1. Effect of the calcium regulating hormones
Parathyroid Hormone
In summary PTH treatment resulted in two significant changes.
1. A significant reduction in bone blood flow.
2. A similar decrease in arterial blood . pressure.
Both of these decreases occurred in a dose dependent fashion, that is an increase in
concentration caused a decrease in both flow and pressure. Vascular resistance in bone
is significantly affected at both the 4 and 8pg doses, a reduction when compared to he
control values, however at the 12pg dose the level returns to normal.
Hypotensive action of PTH
Biochemical changes in target tissues in response to PTH can be detected within
minutes. Similarly the change in arterial blood . pressure seen during this study occurs
soon after administration of the hormone and this reflects a vasodilatatory effect which
would cause an increase in systemic blood flow.
The vasodilatatory action of bPTH(l-34) has been demonstrated in the rat by Pang et al
(1980a.), the mean arterial blood pressure was shown to decrease in a dose-related
fashion in the intact animal. This effect lasted approximately two minutes at the lowest
dose and at the higher doses for twenty minutes or longer. This lengthening of recovery
period with increased dose was also noticed in the work presented here. Pang compared
three preparations all showed a dose dependent effect but the extent varied depending
on the product, at the highest dose (about 36 IU. per 350g animal, which is equivalent
to 6pg) the average change was approximately 40mmHg. This value falls between the
the changes shown at 4 and 8pg doses used in this study, this could be expected as the
dose falls between these two values. A later study by Pang et al (1983) investigated
further this hypotensive property comparing its timing with that of the hypercalcemic
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response. The concentrations of PTH used by Pang et al are all less than the than those
used here (i.e. the maximum dose is approximately 1.2pg comparedwith the lowest dose
of 4pg used in this study) but all produced hypotensive effects. The length of this
hypotensive response was only minutes and considered to be separate from the
hypercalcemic effect.
These papers confirm the findings of this work, bPTH(l-34) has vasodilatatory effects, at
least on the general circulation (a reduction in the arterial blood pressure), that is
immediate and the duration of the response depends on the concentration administered.
This dilatation does not occur in the bone vascular bed, which is indicated by the lack of
change in the vascular resistance.
Driessens and Vanhoutte (1981) investigated the response to PTH in a perfused dog
tibia ^ failing to find any significant change in perfusion pressure in response to
treatment and no direct effect on the vascular smooth muscle cells of the bone blood
vessels was observed. Similarly McCarthy et al (1986) found no effect on perfusion
pressure. These authors performed the perfusion at a constant rate and thus perfusion
pressure was proportional tomotor tone. Parathyroid hormone therefore appears to have
no effect on the vascular tone in the canine tibiae even though some bone vessels have
a lining of vascular smooth muscle.
The evidence would suggest that PTH has a vasodilatory action on the peripheral
circulation but not on the bone vascular bed. Vascular resistance in bone remains
constant following PTH treatment indicating that no dilatation or constriction has
occurred. The decrease in bone blood flow seen after PTH can be related to the drop in
arterial blood pressure.
ie. Flow = arterial pressure ~ resistance
Thus this effect on flow reflects a reduction in pressure rather than any constriction of
the blood vessels.
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Hypercalcemic action of PTH
Parathyroid hormone also has an effect on plasma calcium levels, some authors
suggesting that this action is distinct from its effect on blood pressure. The timing of this
response is very different from that of the hypotensive response, the effect taking days
in the rat (Stevenson 198 3). However changes in calcium transport have been detected
within minutes giving rise to hypercalcemia, using perfusion of isolated bone (Parsons
and Robinson 1968).
Strontium-85 has been used as a calcium analogue in this study thus any direct effect of
PTH on calcium will be reflected in a change in strontium clearance. The results of this
study show that clearance in the PTH treated group is flow dependent, a decrease in flow
having an associated decrease in clearance, although this reduction is not significant.
Correlation between flow and clearance is also demonstrated by the untreated animals
and this would infer that the effect on strontium clearance is a normal response to
reduced flow and does not arise independently as a result of PTH treatment.
Shaw and Dacke (1985) have demonstrated that PTH causes an inhibition of calcium
movement into bone at short time intervals. They suggest that the primary hypercal¬
cemic response is mediated by a rapid decrease of calcium exit from blood. This can be
interpreted in terms of inhibition ofcalcium entry into bone rather than by more classical
osteolytic and renal effects. Although these authors suggest that this inhibition could be
reconciled with the plasma calcium pump theory of Talmage they do consider that a
vascular mechanism could be involved.
The findings of the present study suggest that alteration in flow does indeed play a part
in determining the uptake of the calcium analogue. There is however no evidence
supporting the view that PTH acts directly on clearance through an inhibitory mecha¬
nism. Boelkinsetal (1976) demonstrated that changes in blood flow to leg bone in hens,
followingPTH injection parallelled changes in plasma calcium and phosphorus concen¬
trations. Further supporting the idea that a change in calcium levels occurs following
a decrease in blood flow.
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Strontium clearance has been found to vary with flow but the reduction in this is not
significant, suggesting that plasma levels are not greatly increased by this effect. The
elevation ofcalcium levels in hypercalcemic states may occur through a second mecha¬
nism after the initial vasodilatatory action. However the hypotensive action of PTH
results in some change in plasma calcium but either this is insufficient to give rise to
hypercalcemic and/or the kidney is able to compensate for the change. This can be
reconciled with the work of Pang et al. these authors claim that the two actions of the
hormone are distinct and caused by different portions of the hormone and provide
conclusive evidence supporting this. The hypercalcemic action increases calcium levels
in the plasma through mobilisation of calcium from bone, requiring time to develop
while the hypotensive action is immediate with no associated affect on plasma calcium
levels (Pang etal 1983). Here the hypotensive action can be seen to occur in the rat with
no significant effect on strontium clearance, indicating that plasma levels are likely to
be unaffected. Vasodilatation of the peripheral circulation gives rise to a significant
decrease in bone blood flow because of a drop in arterial blood pressure even though the
bone vasculature is apparantly unaffected. This decrease in flow results in associated
reduction in strontium clearance, the two variables correlated to some extent (r=0.83).
Clearance is not significantly affected by PTH treatment. This therefore does not
support the theory of Shaw and Dacke that an inhibition of calcium entry into bone at
short time intervals (beginning at 3 minutes) produces hypercalcemic effects. The lack
of effect on strontium levels suggests that no primary hypercalcemic response is
demonstrated by any of the PTH treated animals in this study. This is in direct contrast
to the decreased net 45-Ca uptake into rat femuronly threeminutes after injection shown
by Dacke and Shaw (1987) using similar concentrations. A decrease in blood flow
should alter the clearance of any tracer, the blood flowing through capillaries at a slower
rate increasing the transit time and allowing larger quantities of the molecule to diffuse
across the wall, assuming that the transport is flow-limited. If however the rate is still
to high to be flow-limited than this transport will be diffusion limited. The control
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animals in this study show a relationship between flow and clearance that appears to be
flow-limited (Figure 3.9.). That is a change in flow is reflected by change in clearance
even at the higher flow rates. The PTH animals demonstrate a similar relationship
(Figure 5.9.) suggesting that any effect on flow will result in a change in clearance
supporting the view that at five minutes any effect on calcium levels arises because of
a vascular effect.
The findings presented here suggest that PTH acts on the peripheral vasculature causing
y
vasodilatation and hypotension. This gives rise to a systemic decrease in blood flow that
is reflected in the decreased arterial pressure. In bone, blood flow is reduced because of
this decrease in arterial pressure while vascular resistance remains unchanged. Clear¬
ance appears to be unaffected by PTH treatment and therefore this work does not support
the theory ofan inhibitory mechanism operating in the uptake ofcalcium by bone during
the hypotensive effect. This mechanismmay play a part in the hypercalcemic action but
this was not seen at the short time intervals of this work.
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Prostaglandin E2
In summary prostaglandin E2 treatment produced a significant effect on:
1. bone blood flow (dose dependent decrease),
2. strontium clearance (similar decrease with increasing dose),
3. arterial blood pressure (reduction),
4. strontium extraction (a dose dependent increase) and
5. vascular resistance (a similar increase).
Hypotensive action
Like PTH it has been demonstrated that PGs have a hypotensive action in most species
and in most vascular beds (McGiff et al 1976, Messina et al 1976) its hypercalcemic
action is however debated, here the former is discussed with reference to the above
findings.
The results of this study agree with the findings of a hypotensive effect. The arterial
blood pressure is decreased at all doses. The range of this indicates that the extent of
effect is similar over the selected concentrations (47% at 20pg to 43% reduction at the
maximum dose). As in the PTH animals the duration of this drop in pressure increases
with dose.
This hypotensive effect has been shown to result from the vasodilatatory actions ofPGE2
(Messina et al 1976). Therefore all things being equal the vasodilatation of blood vessels
should cause an increase in blood flow with a reduction in the systemic vascular
resistance. The present results however show the exact opposite, a significant decrease
in bone blood flow with increasing dose of the agent. Examination of the values for bone
vascular resistance provides an explanation for this. In bone the resistance to flow
increases thereby reducing the flow rate. Thus although there is a drop in arterial blood
pressure as a result of the vasodilatatory action of PGE2 this does not occur in bone. It has
been shown that PGE2 does not cause vasodilation in all cases. In fact constrictor effects
have been noted at selected sites (Goodman and Gillman 1980).
Calcium Regulating Hormones 5-59
Blood flow is measured at only one time period ie. at four minutes as the entrapment of
microspheres is almost immediate, this therefore does not reflect the maximum effect
on blood pressure. At the pointofmicrosphere injection the reduction in pressure is 37%
at the 20 and 40 microgramme doses which increases to 46% at the 60 microgramme
level, but it is only 28% at the highest dose. Therefore the vasodilatator effect on the
systemic circulation requires time to reach it's maximum,The duration of this response
varies with the dose.
Prostaglandins had been shown to have potent vasodilatator effects as early as the 1960's
(Bergstrom etal 1968, Solomon et al 1968), though the quality of this biological action
varies with the individual prostaglandins. The work of Bergstrom et al (1964)
demonstrated that single injections of PGE1, PGE2 and PGE3 all caused a significant
temporary fall in blood pressure during the continuous injection ofnorepinephrine. This
represented a drop of 30mmHg for 5pg PGE2 and 40mmHg for lOpg PGE2 per animal
(approximately 30% and 40% drop in each case). They found that this pressuredrop was
ofa short duration lasting only minutes, unlike its effect on plasma free fatty acids which
lasted for longer periods. These results therefore support the findings of the work
presented here. The variation in the degree ofeffect and duration may reflect the choice
of animals (i.e. Bergstrom used dogs of 14-25kg)and also the different sources of
prostaglandins. When comparing the biological activities of fourprostaglandins Horton
andMain (1963) discuss the effect ofPGE1 andPGE2on blood pressure and blood flow.
In both cases rabbit blood pressure was reduced, a threshold effect occurred at
concentrations of 600ng/kg.
It is clear therefore that certain prostaglandins have depressor actions.This study
highlights the ' vasodilatatory action of PGE2 in the systemic circulation of the rat. This
results in a significant reduction in arterial blood pressure. The peripheral flow does not
however appear to be significantly affected by this action (there is no change in muscle
flow). The bone vascular bed does not exhibit this vasodilatatory response, bone vascular
resistance remains constant. The effect of PGE2 on bone blood flow therefore reflects
the change in the arterial pressure.
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Hypercalcemia effect
Both the hypercalcemia action of PGE2 and its ability to stimulate bone resorption in
vitro have been well established. This would suggest that this agent should be capable
of producing hypercalcemia in vivo.
The results of this study support the theory that PGE2 raises plasma calcium levels, a
change in strontium clearance reflecting the drugs' effect on calcium transport.
Strontium clearance has been shown to be flow dependent in the control animals, a
comparison of the slope of this group (b=0.47) with the PGE2 treated animals (b=0.78)
shows that the two lines are statistically different. Confirming that mineral clearance is
in some way affected by PGE2, the drug having a direct effect on strontium clearance
independent of its action on bone blood flow. These findings can be reconciled with the
work of Shaw and Dacke (1985) who have suggested that PGE2 causes primary hyper¬
calcemia, possibly through inhibition of calcium entry into bone. The doses used in this
paper are comparable with the concentrations used here therefore the reduced clearance
could result from an inhibitiory effect.
Other studies have not found a hypercalcemic reponse to PGE2 treatment. Robertson
and Baylin (1977) failed to produce a hypercalcemic response in the intact rat as did
Klein and Raisz (1970) in parathyroidectomized animals. In both these papers the doses
of PGE that have no effect are less than in the present study but Klein and Raisz did find
a small increase at the 40pg dose (200g rats).
The bone resorptive effects of PGE2 in vitro may be influenced by endogenous
substances in vivo and therefore do not demonstrate so potent an effect in the intact
animals. Or this lack ofeffect could arise because in vivo the levels ofPGE2 are elevated
locally and specific to the site of effect. Thus to have the same action in vivo the blood
levels may be required to be sustained at high concentrations, increasing local levels of
PGE2. Evidence supporting local prostaglandin-stimulated bone resorption in vivo has
been documented by Goodson et al (1974). These authors found that repeated injections
of PGE1 directly on rat calvarium produced changes in bone morphology linked to
increased bone resorption.
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The effects of PGE2 in this work is only examined over a short time period i.e. five
minutes, and the morphological changes require more time to occur. Therefore it is
unlikely that increased bone resorption causes the changes in mineral clearance
observed. The doses used in this study could be adequate to produce the local levels
in bone necessary for action in vivo. Thus the effect on clearance levels may reflect a
hypercalcemic action of the hormone but the calcium levels were not measured in these
animals and thus it was not established that hyperalcemia occured.
Prostaglandin E2 has a direct effect on bone, decreasing strontium clearance independ¬
ent of its effect on bone blood flow. This effect would appear to be flow independent,
but whether this is through action on capillary permeability or osteocyte metabolic
activity is not clear. These results support the suggested ' 'novel" inhibition of calcium
uptake in response to PGE2 but do not confirm any hypercalcemic action of the hormone
in vivo.
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Calcitonin
Administration of calcitonin resulted in only one significant effect, an increase in
strontium clearance. This change is however dependent on the effect shown in the 50U.
group, representing a 30% increase when compared with 0 while at the other doses
clearance remained constant (i.e. 100% and 95% respectively). Similarly an increase in
bone blood flow is shown at the 50U. dose (42% increase) that is not apparent at the other
doses (10U.~ 20% reduction, 25U.— 30% reduction).
Effect on arterial blood pressure
In this study calcitonin has no effect on arterial, blood pressure, the recordings
remaining relatively constant during the entire test period no matter the dose of drug.
This is similar to the findings ofPorter et al with regard to perfusion pressure. These
however differ from those ofDriessens and Vanhoutte (1981), who infused calcitonin
into the isolated tibia after cannulation of the nutrient artery. The doses used in the
present study are comparable to the higher doses used in Driessens experiments but in
an intact animal as opposed to the isolated bone,possibly this gives rise to the different
findings. Comparing the papers of Driessens and Porter the former experiments
involved denervation of the tibia which perhaps increased sensitivity to the hormone
and thus account for the difference in findings.
In the rat calcitonin has no effect on the peripheral circulation indicated by the lack of
effect on arterial blood -pressure. However bone blood flow is reduced at 10and25U.
(p<0.05 DF=16)) suggesting that bone vasculature is in some way affected, possibly
through specific action on bone vascular tone. Therefore although calcitonin does not
appear to affect vascular tone in the general circulation this reduced flow and the
evidence of Driessens and Vanhoutte supports its action in the bone vascular bed,
resulting in a reduction in bone blood flow in the rat. Calcitonin has been shown to cause
receptor loss resulting in an inability to respond to further stimulation. This escape phe¬
nomenon could be what is occurring at the 50U. dose thereby negating the constrictor
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action of the agent seen at the other doses. In vitro this escape occurs between 16-24
hours, this timing is however well out with the duration of the present experiment. The
'escape ' phenomenon may be an important aspect of calcitonin action in vivo but it is
unlikely that it is of importance in this study. Therefore the increase in flow and
strontium clearance shown in this study must arise through another mechanism.
An examination of the pressure traces shows that the heart rate increases with the 50U.
dose this may result from a pharmacological effect and could give rise to a general
increase in blood flow which would in turn elevate the bone blood flow. This could
therefore explain the increased blood flow seen at this dose i.e. a pharmacological effect
causing an increase in the rate of cardiac output elevating the general blood flow rather
than any dilatator effect in the bone blood vessels.
Reviewing the results it appears certain doses of calcitonin affects bone blood flow
thereby increasing bone vascular resistance and this findings agree with those of
Driessens. However as a whole bone blood flow is unaffected by calcitonin because of
the increase shown at the 50U. dose. In order to support the pharmacological effect of
higher doses further work could be done to incorporate higher doses of Calcitonin into
the study.
Plasma calcium levels
Calcitonin has been shown to have hypocalcemic effects, reducing calcium levels in the
blood by retaining the mineral in bone rather than promoting its deposition. There is no
evidence that calcitonin stimulates uptake ofcalcium into bone. The lack of significant
effect on strontium would support the view that calcitonin does not actively increase
calcium uptake. Additionally it is possible that the ratdoes not remodel bone extensively
and in the adult bone turnoverwould be even more limited thus any hypocalcemic effect
would be small and not necessarily appear in these experiments. In the mature animal
it appears that calcitonin inhibits bone resorption but the effect on plasmacalcium is only
seen in situations where bone resorption contributes significantly to the maintenance of
normal serum levels (Martin 1983).
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At the 50U. strontium clearance is increased this reflects the change in flow also seen
at this dose, the increase in flow resulting in an increase in clearance since the calcitonin
animals demonstrate the same relationship between flow and clearance as in the control
animals. In fact examination of the plot of the control animals suggests that a clearance
value of 0.26 would be appropriate for a flow 0.41ml/min/g thus supporting the view
that this increase in strontium clearance results from the change in flow. Strontium
extraction does however decrease in response to increased dose but this is not significant
and at the 10U. dose the mean value is greater than the control mean. Since this is
dependent upon both flow and clearance this reflects the change in flow at the 10 and
25U.doses, and the change in both variables at 50U.
Therefore over the dose range calcitonin appears to have a no direct effect on bone,
though bone blood flow is increased possibly through constriction, specifically in the
bone vascular bed at the 10 and 25U. dose. The agent also has no effect on mineral
transport. At the 50U. dose the effects of the agent on flow are opposite to those at the
other doses, this may arise through an increased cardiac output but because the activity
of the microspheres were not estimated before administration this could not be
confirmed by this study and is an assumption.
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5.6.2. Mechanism of action
All these agents have been shown to affect the production ofcAMP and the role of this
as a secondary messenger in the cellular response of these agents has been widely
investigated. This is of relevance to the transport of minerals but PTH and PGE2 also
has hypotensive actions and therefore this section deals with the mechanism of the
hypotensive response and that of the cellular response.
Mechanism of hypotensive action
Parathyroid hormone.
This work shows that PTH has a vaso-depressor action in the rat; this vasodilatator
effect is dose dependent and causes a reduction in blood pressure. Therefore the action
of this agent on the general circulation and specific capillary beds is important when con¬
sidering the mechanism of this dilatation.
The vasodilatator action of PTH is specific to particular target vascular beds, the
hormone acting directly on the vasculature. Pang et al (1980b.) failed to show dilatation
in the skeletal muscle ofdogs although such vascular beds as the heart, kidney, liver and
stomach did show this response. A further study in 1982 (Pang et al) puts forward the
theor that PTH has a direct vasodilatator action on vascular smooth muscle. The
dilator response in bone to ATP appears to be through action on the vascular smooth
muscle (Gross etal 1979). Ifvascular smooth muscle is involved in the response to PTH
then vasodilatation of bone blood vessels could occur through the same mechanism as
ATP. Parathyroid hormone causes vasodilatation in the general circulation and in
specific vascular beds but in bone this effect is questionable. The systemic pressure
decrease and dilatation of the peripheral blood vessels could lead to a change in blood
flow in the general circulation.
Therefore the question is does PTH cause vasodilatation of the blood vessels in bone?
Parathyroid hormone is a potent vasodilator with specific beds as its target. These
vascular beds all have quite high blood flows rates, and the dilation of their ves sels would
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result in almost an immediate decrease in blood pressure, as seen in this study. The
vascular bed of bone does not fall into this category and this would suggest that the
vasodilaattory action might not occur. The hypotensive action of this hormone is not
significantly diminished in the presence of a and 6 adrenergic,HI and H2 histaminergic
receptor antagonists (Pang et al 1980a, 1980b). Thus the action of PTH on the
vasculature is direct and not mediated by local vasoactive substance. Within bone the
blood vessels have a vascular smooth muscle component until they divide to form
marrow sinusoids. If the PTH causes dilatation of vascular smooth muscle in bone one
would expect this to alter the response of these cells to constriction caused by
noradrenaline, this is not the case (Driessens and Vanhoutte 1979). The evidence of
McCarthy et al (1986) agrees with these findings, although these are in apparent
disagreement with the results ofPanget al. There are numerous explanations that could
account for this. Firstlymostofthe other work has been on systemic vessels and not bone
blood vessels, thus only assumptions can be drawn as to the action of the hormone on
bone vessels without supportive evidence in situ. Secondly it has been previously
demonstrated that vascular smooth muscle cells have heterogenous responses to
vasoactive hormones (Vanhoutte 1978). Thus the response in one vascular bed need not
reflect that in another. Alternatively in vivo PTH may exhert a different action than
when added directly to the bone circulation.
This however does not answer the question, and unfortunately the evidence is not
conclusive as to the effect of PTH on bone vessels in vivo. It is apparent that in the
perfused situation the vascular bed of bone shows no response and the lack of effect on
induced constriction suggests that there is no vasodilatator response. Here the vascular
resistance of bone remains constant indicating that neither a constrictor or dilator effect
occurs in response toPTH. The change in bone blood flow seen in this study reflects the
reduction in arterial blood pressure and this is sufficent to reduce the flow significantly
even though vascular resistance remains constant.
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Prostaglandin E2.
Like PTH this hormone causes a dose dependent reduction in arterial blood pressure.
This occurs because of vasodilatation of the peripheral blood vessels, causing an
increase in systemic blood flow. This systemic vasodilatation however appears to
contradict the fall in bone blood flow. Therefore PGE2, at least at the higher doses, may
have a direct constrictory action in the bone vascular bed thereby reducing flow through
a change in vascular resistance.
Messina et al (1976) reviewed the evidence supporting action of PGE2 in local
circulatory control. They found that the prostaglandins are potent vasoactive substances
in a variety of regional circulations and have the ability to alter vascular reactivity to a
diverse group of vasoconstrictor stimuli, independent of their dilatatory ability. In
particular, PGE2 and PGA1 are effective vasodilatator substances in a number of
vascular beds, including skeletal muscle. Additionally these reduce the vascular
responsiveness to vasoconstrictor agents. The authors infer that the prostaglandins
contribute to the control of vascular reactivity through this mechanism of reduced
response.
McGiff et al investigated this prostaglandin mediated control of vascular reactivity,
finding that prostaglandins are synthesised in the walls of the major resistance vessels,
these authors suggest that prostaglandins directly affect the constrictor state of blood
vessels. The capacity of blood vessels to generate these agents in their walls is directly
related to regulation of vascular tone and reactivity. This would support the view that
in vivo the prostaglandins levels are elevated locally and specific to the target site.
Therefore the concentrations used in any study should be adequate to reflect the local
levels in situ, otherwise the effect may notmirror the actual response to the compound.
Malik et al (1978) show that prostaglandins, in particular PGE2, reduce the vasocon¬
strictor effect of sympathetic nerve stimulation in the vasculature of rat spleen and
pancreas. This vasodilatator response is caused by action on the adrenergic neuroef-
fector units, the effect is not only species dependent but also varies between different
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vascular beds in the same species. This author also noted that the constrictor action of
noradrenaline is inhibited by PGEs', possibly through the same mechanism since the
action of noradrenaline is also through adrenergic receptors in the smooth muscle cells
of the vessel wall.
It appears therefore that prostaglandins contribute to the regulation of vascular tone and
thus arterial pressure through threemechanisms; a) by actingdirectly on smooth muscle,
b) bymodulating the activity of the adrenergic nervous system, and c) by influencing the
activity of other vasoactive substances. In this study the PGE2 administered would act
on the adrenergic nervous system and on smooth muscle. The regulation of this vascular
tone appears to be localised, vascular resistance vessels can generate their own supply.
Although there is no direct evidence that bone blood vessels take part in this regulation
the results of this study would suggests that they do.
Prostaglandin E2 appears to cause vasodilation in the systemic circulation, indicated by
the reduction in the arterial blood pressure but its effect on bone vessels is that of
constriction. Bone blood flow decreases in repsonse to PGE2 and this occurs because
constriction of the vessels increases the bone vascular resistance. The quantities used
here could be sufficient to produce the local levels necessary to cause and maintain
constriction and therefore reflects the systemic doses required for generation of
adequate local concentrations.
Mechanism of cellular action
Of these agents PGE2 is the only drug that significantly affects mineral transport
independent of its effect on bone blood flow. It is not however clear whether this action
is through action on capillary permeability or osteocyte metabolic activity.
Therefore this section deals with the possible mechanism that would give rise to a
cellular action which decreases strontium uptake.
Both PTH and prostaglandin stimulate adenylase cyclase production and increase the
bone cell content of cAMP, and it has been suggested that cAMP acts as a secondary
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messenger in the bone resorption process. However calcitonin also has an effect on
cAMP production in bone cells giving rise to inhibition of resorption. This discrepancy
can be explained by examining the actual cell types upon which these agents act and the
levels of cAMP produced. PTH and PGE2 act on the osteoblast and not the osteoclast,
and calcitonin acts on the osteoclasts but not the osteoblast. High doses of cAMP
produced in response to calcitonin inhibit bone resorption by acting on the bone
resorptive activity of the osteoclast. Further support for this action of calcitonin is
provided by the work ofChambers et al (1982) who demonstrated that calcitonin inhibits
the mobility and bone resorption capacity of the isolated osteoclast. On the other hand
low concentrations of dibutyl cAMP promote bone resorption and unlike PTH, high
concentrations of it inhibits this resorption. Additionally calcitonin inhibits the effect
of PTH when administered at high concentrations (Klein and Raisz 1971). Therefore
the difference in action between calcitonin and the bone resorbing agents can be
explained in terms of the site of the receptors and the levels of cAMP which is required
to produce a response in the osteoclast.
This however does not explain the different effects of PTH and PGE2 therefore the
relationship between these two drugs requires further examination. Initially these
hormones act upon the osteoblast and this action leads to the generation of some signal
which leads to the recruitment, maturation and activation ofosteoclasts (Martin 1983).
The activation of adenylase cyclase and subsequent protein kinase has been well
demonstrated for the osteoblast (Partridge et al 1981, Livesey et al 1982). Whether or
not these hormones cause similar effects on the osteoclast is yet to be demonstrated. The
work ofLivesey suggests that the type of protein kinase isoenzyme stimulated depends
on the hormonal effector, PGE2 andPTH stimulate different types depending on the cell
source. Therefore it could be possible that the elevation of cAMP levels with in the
osteoblast mediates the response of the osteoclast.
Themorphological response toPTH and prostaglandin has been widely investigated and
a comparison of these findings can identify the possible different effect of PTH and
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PGE2 on strontium clearance. The effects of these agents are similar, both compounds
increase the size and number of the osteoclasts as well as the area of ruffled borders
(Hannsjorg et al 1978). Similarly both agents have an effect on the release of lysomal
enzymes from bone. Dietrich and Raisz (1975) studied these morphological effects
attempting to quantify the extent of each compounds effect on these changes. The
administration ofPTH affected the numbers ofosteoclasts more so than their individual
appearances. In contrast PGE2 produced cytological changes that are associated with
increased activity of individual osteoclasts in addition to an increase in cell numbers.
This increase in metabolic activity could result in a change in plasma calcium levels
reflected by the decrease in strontium clearance. McCarthy et al (1986) suggested that
the efflux of certain ions from the exchangeable mineral pool was dependent on the
metabolic activity of bone cells. The use of a metabolic inhibitor significantly affected
the net extraction of strontium-85 but not the maximum instantaneous extraction. This
latter parameter is dependent upon the flux of molecules from blood into bone fluid
therefore the inhibition of metabolic activity does not effect this influx but may effect
the efflux. This is supported by the change in net extraction, strontium does not pass
back to the blood to the same extent as in the controls. If this is the case an increase in
this metabolic activity in response to PGE2 should cause an increase in the efflux thus
decreasing the clearance of strontium.
The above suggests that although PTH and PGE2 stimulates cAMP production in the
osteoblast the signal to, or the signal read by the osteoclasts are different, giving rise to
differences in the morphological effects. Prostaglandins and PTH have similar effects
on bone resorption and the absence of any synergic or inhibitory interaction, and the fact
that no further resorption is obtained when the two compounds are combined indicates
that they act through a common cellularpathway to elevate cAMP concentrations (Klein
and Raisz 1970). Hayes et al (1980) have suggested that different hormones acting via
cAMPmay trigger different chains ofmetabolic events in the same cell. This could arise
because of a possible difference in the regulation of intracellular cAMP levels by PTH
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and the prostaglandins (Rao et al 1977). Alternatively the receptors for PTH and the
prostaglandins could be different (Chase and Obert 1975). Therefore the evidence
supports the view that the actions ofPTH and PGE2 are dependent on the difference in
receptors or in the message transmitted from the osteoblast to the osteoclast. Alterna¬
tively there may be two cAMP activated antagonistical systems regulating bone
resorption, one ofwhich is regulated by the prostaglandins alone (Klein andRaisz 1970).
This theory is however highly speculative.
The activation and increase in osteoclastic activity after PGE2 treatmentwould give rise
to an elevation in plasma calcium levels through increased bone resorption. A similar
rise could result from PTH treatment although the timing of this is likely to reflect the
difference in effect on the osteoclast cell number rather than the increase in activity
which results from PGE2 treatment. The decrease in strontium clearance shown by the
PGE2 treated group could reflect this increased osteocytic activity leading to an increase
in the efflux of strontium. This however is unlikely, the cytological effects require some
time to develop and the plasma calcium levels are not significantly elevated during the
time of this study indicating that the efflux of calcium is not altered to any extent. This
is supported by the evidence from numerous other studies, the hypercalcemic responses
occurring long before the morphological and biochemical changes. Therefore although
PGE2 does appear to affect osteocytic activity this would not cause the decrease in
strontium clearance seen in this experiment but could reflect the changes in plasma
calcium seen at longer time intervals.
Additionally the inhibition of calcium movement into bone can be reconciled with the
calcium pump model of Talmage (1969). The theory is that calcium moves passively
into bone by diffusion through gaps between the surface osteocytes, a transport system
restricted to one side of the cell then pumps the calcium back out of the cell into the
extravascular fluid. With reference to the PGE2 treatment there may be a reduction in
the diffusion of calcium across the osteocyte through a direct inhibitory mechanism
reducing the permeability to the ions. Thus less strontiumwill be cleared because of this
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reduction of ion movement. If the transport mechanism still works efficiently then the
extravascular concentration will increase thereby decreasing the concentration gradient
across the capillary wall further reducing the transport across the capillary.
Calcitonin also elevates cAMP production but this is in the osteoclast itself and results
in the inhibition of bone resorption therefore plasma calcium levels would not be
expected to rise and their would be no associated change in strontium clearance.
5.6.3. The relationship between flow and clearance
Comparison of the plots of flow versus strontium clearance for the control and the
appropriate drug group results in only one significant difference, that for the control
(b=0.47) and PGE2 (b=0.78). This supports the view that PGE2 was having a direct
effect on strontium clearance independent of its effect on bone blood flow. Parathyroid
hormone and calcitonin have lines of regression that are similar to the control animals
and the vasoactive groups. Therefore these two compounds act through the same
vascular mechanism as the vasoactive agents, any change in flow reflected by a change
in clearance.
5.1. Conclusions
Parathyroid hormone and PGE2 causes vasodilatation in the systemic circulation
reducing arterial blood pressure. Vascular resistance in bone remains constant in the
PTH treated animals although there is a fall in bone blood flow. This reduction in flow
reflects the decrease in blood pressure rather than a constrictor effect of PTH.
Prostaglandin E2 significantly affected bone blood flow, resistance and arterial blood
pressure. Therefore it appears that in bone, at least, a constrictor effect increases
resistance thereby reducing flow. Calcitonin has no real effect on the vasculature as flow
is not reduced significantly. Both PTH and calcitonin appear to act through the same
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mechanism as the vasoactive agents, a direct or indirect vascular mechanism. The
significant effectofPGE2 on strontium clearance could be as a result of some inhibitory
mechanism affecting capillary permeability to the ions and so reducing strontium
uptake. It is unlikely that anymorphological effect would occur in the short time interval
of this study which would affect this clearance. But it is obvious that PGE2 has a direct
effect on bone, reducing strontium clearance, independent of its effect on bone blood
flow.
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PLASMA CALCIUM
6.1. Introduction
Examinationof the literature with respect to plasma calcium levels and the effect ofPTH
and PGE2 provides conflicting evidence. There is evidence supporting a hypercalcemic
response but whether this occurs after an initial hypocalcemic effecqand the timing of
the elevation is cause for some controversy.
Firstly the evidence for the effect ofparathyroid hormone. Parsons and Robinson (1971)
suggest that entry ofcalcium into bone occurs very early in response to PTH. Therefore
the plasma calcium concentration is initially lowered but this was then followed by an
elevation in the plasma calcium levels. Boelkins et al (1975) agree with these findings,
the maximum hypocalcemic effect occurring at three minutes followed by a hypercal¬
cemic effect, the maximum effect at thirty minutes. This initial drop in plasma calcium
following PTH administration may be due to a membrane effect of PTH, increasing
permeability to calcium and allowing an initial flux into the cells (Borle et al 1966).
Other authors agree with elevation ofplasma calcium concentration in response to PTH
but disagree with the hypocalcemic effect. Grubb et al (1977) found that with PTH,
plasma calcium concentration rose for approximately twelve hours in thyroparathyroi-
dectomized rats. They concluded that this increase in plasma calcium is caused by an
increase in efflux from the bone compartment which receives calcium from the blood.
On the other hand Shaw and Dacke (1985) found a net inhibition of 45"Ca in response
to PTH and PGE2 (3-30 min) suggesting that this causes the primary hypercalcemic
response. Panget al (1982,83) attempted to separate the hypotensive and hypercalcemic
action of this hormone. These authors found that the hypotensive action was immediate
and that the 24-28a.a. portion was essential for this action. The hypercalcemic
response required time to develop and that the amino acid portion responsible was that
of 1-2.
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Thus these studies support the hypercalcemia action of parathyroid hormone suggesting
that some time is required before elevation of plasma calcium levels are seen.
The evidence with regards to the hypercalcemic effect of PGE2 is even more contra¬
dictory. Vanderweil andTalmage (1979) found that PTH raised plasma calcium levels
significantly but that PGE2 showed no increase. Prostaglandin E2 was found to
duplicate the action ofPTH on osteoclasts but not on plasma calcium control. Similarly
the work ofBeliel et al (1973) does not show any hypercalcemic effect. This is in direct
contrast to the work of Shaw and Dacke (1985) who not only found an elevation in
plasma calcium in response to PGE2 but that the effect was longer in duration than with
PTH.
6.2. Measurement of plasma calcium levels
The aim here is to investigate whether PTH or PGE2 causes hypercalcemia in the intact
animal in the timescale related to the previous experiments. One dose of each was selected
as the test concentration, 8fig of PTH was chosen because it significantly affected
strontium in the earlier experiments and 60pg PGE2 was chosen because it significantly
affected clearance although not extraction. The levels were examined to study whether any
effects of these agents on mineral exchange i.e. strontium clearance in bone could give
rise to hypercalcemia . Additionally the intention was to compare the timing of the
hypotensive effect of these hormones with the hypercalcemic action. Because of
restrictions in my home office licence the duration of the experiment was limited to the
period that the animal was unconscious without causing it undue pain, therefore if the
animal gave any indication of being uncomfortable the experiment was ceased. Thus in
some animals the experimental period was longer and there are more blood samples. The
animals were prepared as set out in 4.4. the only difference is that the tail cannula is not
connected to a withdrawal pump as samples were withdrawn into a 2ml syringe by hand.
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A reference blood sample 1ml was withdrawn two minutes before injection of the test
solution. Further0.5ml samples were taken at a range of intervals, details of these times
are shown in table 6.1. These samples were centrifuged at 3600rpm for fiveminutes and
the supernatant gently removed with another syringe, making sure none of the red blood
cells contaminated this solution. These samples were then used to determine the plasma
calcium levels using absorption spectrometry.
Quantitative, colorimetric determination of calcium in serum (Sigma — Calcium
binding reagent and Calcium buffer reagent)
1. Calcium binding agent, o-Cresolphthalein complexone, 0.006%, 8-hydroxyquino-
line, dimethylsulfoxide (DMSO) and surfactant.
2. Calcium buffer reagent, 2-amino-2-methyl-l-propanol. 450mmol/L.
The calcium assay solution was prepared by mixing equal volumes of the above
reagents. Into two cuvets, labelled test and standard, 4ml of this solution was added. The
absorbance of thesewere then read at 575nm with water as a reference (Unicam SP 600).
This is the initial [A] reading for each. Added to the test cuvet and mixed was 0.05ml
of the serum sample and 0.05ml of the calcium standard solution was added to the
standard cuvet. These samples were then read, with water once again as the reference
at 575nm. This is final [A]. To ensure correct absorbance readings these have to be
completed within 10 minutes.
Calculation of calcium concentration
Final [A] test - Initial [A] test
Calcium (mg/dl) - x 10




The effect of both PGE2 and PTH treatment on plasma calcium levels /\ detailed in
Table 6.1., which also includes the control data.
(a) Control
This group consists of two animals, from which four separate samples were obtained.
Unfortunately one blood sample was lost during the centrifuge process thus the mean
and standard deviations are derived from seven readings. All but one value is within the
range for normal human levels i.e. 8.5 to 10.4mg/dL. Therefore it seems acceptable to
set this as the range for the rat, any values above this would result from raised calcium
levels.
(b) Parathyroid hormone
This group consists of four animals, in two the level at five minutes are above that set
as normal plasma concentration. This may have arisen through contamination of the
samples with red blood cells and examination of the supernatant confirmed the
likelihood that this had occurred. The solution was discoloured to some extent, possibly
through leakage of red blood cells during the centrifuging process, resulting in high
absorption readings. The subsequent values support the view that these are not true
readings, the lack of elevation in concentration at these later time intervals suggesting
that the blood calcium remains relatively constant. In the other two animals the calcium
levels are elevated at forty minutes (in one case this elevation occurs at 20minutes) these
values are even higher than the readings for the contaminated samples. This would
suggest that these values reflect an elevation ofplasma calcium concentration rather than
incorrect readings.
These results suggest that plasma calcium concentrations affected by this dose ofPTH,
at least at forty minutes. Thus during the five minute period of the bone blood flow
experiments it is unlikely that the plasma calcium levels are elevated and this is
supported by the lack of effect on strontium clearance.
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Plasma calcium measured in mg/dl
Assuming a normal range of 8.5 - 10.4mg/dl (acceptable human values) the values in
bold are above this level indicating elevated calcium levels.
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(c) Prostaglandin E2
This group also included four animals with samples taken up to sixty minutes. In
retrospect itwas unfortunate that no sample was taken between fifteen and sixtyminutes
as interpretation of the results is made difficult because of lack of information.
Three of the animals show elevated calcium levels at two minutes if the values are
compared to the rangeof the control animals. The 10.2mg/dL. values are however lower
than the normal human levels and in these animals the readings at seven minutes have
returned to acceptable normal levels. In three of the animals the plasma calcium levels
are raised above the normal human levels (Table 6.1.), suggesting that hypercalcemia
does occur. The timing differs between the animals. Therefore it cannot be conclusively
said that the plasma calcium levels are elevated within the five minute period of the
blood flow experiments. It does however appear that this dose of PGE2 raises plasma
calcium levels in the rat and this supports the decrease in strontium clearance found in




The examination ofplasma calcium levels in four animals shows that the plasmacalcium
concentration is not elevated within the five minute period of the bone blood flow
experiments. This therefore supports the findings of the previous chapter, that is mineral
clearance is not significantly affected by PTH treatment.
This work agrees with the findings of Pang et al (1983) as to the distinct separation of
the hypotensive and hypercalcemic action of the hormone. At the time period of the
bone blood flow work (5 minutes) there is a hypotensive but no hypercalcemic effect.
Reduced uptake of calcium suggested by the slight decline in strontium clearance
(Figure 5.3.) need not give rise to hypercalcemia immediately. The vasodilatatoreffect
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occurs immediately. Thus supporting the theory that the two acts are distinct and occur
through two separate mechanisms. At the time when the hypercalcemic response is
demonstrated (20 - 40minutes) the arterial blood pressure had recovered indicating that
the vasodilatatory action is no longer effective (Figure 6.1.).
Prostaglandin E2
In general the 60pg dose gives rise to elevated plasma calcium levels but the timing of
this hypercalcemic response is questionable.
It is possible that the reduction in strontium clearance shown in the previous section in
response to PGE2 treatment (Figure5.13) could reflect this effect on calcium transport.
However the data from the plasma calcium study suggests that plasma concentration
would be normal during the five minutes of the bone blood flow study. The effect on
transport is thus not sufficient to give rise to a hypercalcemic effectwithin five minutes.
In conclusion this work suggests that in neither the PTH or PGE2 bone blood flow and
mineral clearance studies does hypercalcemia occur. Therefore the decrease in stron¬
tium clearance seen in the PGE2 study does not reflect a significant elevation of plasma
calcium concentration. It may be that this change in calcium levels is so small that no
hypercalcemic response is found and/or the kidney is able to compensate for the change





























This chapter sums up the findings of the previous chapters, drawing together the relevant
facts from each with respect to the objectives set out in the introduction.
Reviewing the introduction the main objectives were ;
1) a review the general vascular supply and architecture of rat bone with particular
reference to the blood supply,
2) to establish a protocol to measure bone blood flow and strontium clearance in the rat
thereby identifying the relationship between drug concentration and response. In
addition to see if any change in blood flow could alter the uptake of minerals or if the
exchange of minerals could be altered independently of flow.
The barium sulphate and histological section details the structure of rat bone and
supports the general nature of the vascular supply (Chapter 2). That is rat bone consists
of cortical and compact bone, with the lamellar bone and Haversian bone present in
approximately equal quantities. The x-rays show details similar to that seen in the work
of Brookes (1971) i.e. the principal nutrient artery and its ascending and descending
branches. The presence of medial canals in the tibia running across the sections is of
importance as this indicates that thematrix and cells have a good blood supply following
secondary osteogenesis than would normally be expected if only the Haversian canals
were present.
After establishing that the blood supply to rat bone allows the use of the microsphere
technique to measure blood flow the next section validates the use of this (Chapter 3).
This chapter basically sums up the problems associated with the method,most of which
arise because of anatomical reasons, i.e. the size of the caudal artery requires a narrow
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cannulawhich can lead to blocking of the cannula or too high awithdrawal rate, resulting
in clamping of the caudal vessel. For future studies the important considerations are;
1. that the microspheres have been shown to trap efficiently,
2. the spheres have no haemodynamic effect,
3. the importance of random choice of animal choice and drug dosage in reducing the
experimental variation.
Additionally this chapter identifies the possible need of a correction factor in the
calculation of flow if the caudal artery is used as a reference sampling point. This work
points to a difference in the haematocrit of bone and caudal artery, the actual extent of
this difference is questionable, it varies depending on the actual haematocrit of the tail
artery in the animal concerned. The suggested cause of this difference is that bone is
richer in plasma and poorer in corpuscles than the caudal blood supply. This would lead
to streaming of the microspheres, an underestimation of flow and over estimation of
strontium clearance. Thus the values for strontium clearance of greater than one in the
first set of control animals can be explained in this context. The work is not conclusive
and therefore it is impossible to encorporate a correction factor into the actual drug
study, only to speculate that one may be required.
The question is therefore: how does the difference in caudal and bone haematocrit
identified by this work affects the main study? All the animals are affected by the
assumption that the two haematocrits are the same and although this may change the
actual results this would not affect the general trends. Thus a 30% correction factor
would increase flow in all animals by the same amount and similarly strontium clearance
would be reduced in each animal by the same amount. This wouldmean that the general
trends and percentage values calculated for flow and clearance would remain the same.
Since the same assumption has been incorporated into each drug group comparisons can
be made between each group. The only variable that would be misinterpreted is
strontium extraction and since this document dealsmainlywith the general trends shown
by the flow and clearance this is not too important.
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Having established the protocol the actual drug experiments were carried out (Chapters
4 and 5). In each case a the line of regression flow, strontium clearance and vascular
resistance in bone along with blood perfusion pressure have been presented. The various
findings are summed up in figure 7.1.
With respect to these, the results show that there is a relationship between bone blood
flow and strontium clearance in the normal rat (Figure 3.9.). That is clearance varies
with flow. The same pattern is shown by the vasoactive agents, ATP and noradrenaline,
parathyroid hormone and calcitonin. This similarity in relationship between the animals
treatedwith these compounds suggests that these act through a similarmechanism. This
appears to be through a vascularmethod either directly or indirectly, any change in flow
reflected by a change in clearance. Indeed the evidence supports the view that ATP and
noradrenaline act directly on the vasculature through alpha adrenoreceptors. Parathy¬
roid hormone also appears to act directly on the vasculature, at least on the smooth
muscle component of the systemic circulation. Calcitonin does not appear to signifi¬
cantly affect blood flow or arterial pressure suggesting that it has little effect on the vas¬
culature. Therefore it is likely that it would demonstrate the same relationship to the
control animals. The increase in flow seen at the 50U. could arise through an increase
in cardiac output and the effect on strontium clearance is similar to that which would be
expected in the untreated animal, supporting the view that this change in clearance is a
direct effect of a change in flow.
Prostaglandin E2 has a direct effect on bone, decreasing strontium clearance independ¬
ent of its effect on blood flow. The possibilty of an inhibitor mechanism, preventing
the uptake of strontium by the bone seems to be the best option causing this effect. The
cytological effect could add to the hypercalcemic effect but this would require hours
before any main affected would be seen. These results therefore support the suggestion
of Dacke and Shaw (1985) that PGE2 causes a novel inhibition of calcium uptake.
This effect therefore questions the use of bone seeking radionuclides such as 85-Sr, 18-
F and Tc-99m in estimating blood flow. Previous work in our laboratory, and by other
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C indicates the direction of the vascular response.
The number indicates the degree of the vascular response i.e. 1* = Primary
2° = Secondary
* Strontium clearance is reduced independently of flow.
Summary 7 -4
authors shows that extraction of bone seeking tracers is flow dependent. The present
study suggests that in addition the metabolic activity of the bone itself can affect this
extraction. This casts doubts on the use of clearance measurements as a method of
estimating bone blood flow.
Chapter six examines the hypercalcemic response to both PTH and PGE2. From this
work its is unlikely that a hypercalcemic response occurs within the five minute period
of the bone blood flow study. Therefore the reduction in clearance seen with PGE2 does
not reflect an elevated calcium concentration and does not infer that hypercalcemia has
occured. It is possible that the effect is too small to produce a noticible effect or that the
kidney is able to compensate for these initail changes in calcium and thus negates the the
effect of an increase.
1.2. Improvements to the experimental protocols
Measurement of bone blood flow and strontium clearance
1. In all the animals only assumptions can be made about the increase in cardiac output.
With the benefit of hindsight measurement of the activity of the microspheres before
and after injection into the animals would have allowed calculation of the dispensed
activity and the cardiac output. This would not only have clarified these assumptions
but ensured that an adequate dose ofmicrospheres were given to each animal.
2.With respect to the calcitonin animals the increase in cardiac output is suggested by
the increase seen in the heart rate at the 50U. dose. There is no indication of this at the
25U. dose therefore in any future studies the use of intermediate doses could be of
importance in establishing the dose atwhich this cardiovasculareffectbegins. Addition¬
ally a larger dose could have been incorporated to study to see if this effect at 50U. is a




This section identifies the possible need for a correction factor to compensate for a
difference in the haematocrits at the two sites. Before this can be established certain
adjustments need to be made to the procedure set out in this document
1. The number of animals needs to be increased substantially to minimise the variation
that occurs between the animals.
2. Here the arterial haematocrit of the tail samples ranges from 40 to 59% with amean
of 49%. This is in disagreement with the 45% value of Brookes (1965). Therefore this
study would have to measure the caudal haematocrit in each animal and use this to
calculate the bone haematocrit.
Plasma calcium levels
Here the study can be improved by increasing both the number of animals and the
numberofblood samples. Ifpossible an extension in duration of the study i.e. over days
rather than hours with possible infusion of the hormone or more than one injection of
the drug would allow better identification of the timing of the hypercalcemic response.
If this was undertaken then the morphological changes could. also be examined allowing
a comparison of the cellular components1 with that of normal rat bone.
7.3 In summary this work presents seven main findings
1. The haematocrit of bone and caudal artery are different but this requires further
investigation before a correction factor can be calculated .
2. Confirmation that a relationship exists between bone blood flow and strontium
clearance in the rat
3. The results show that a change in bone blood flow can alter the uptake of minerals.
Additionally the uptake of minerals can be directly affected independently of blood
flow.
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4. Prostaglandin E2 appears to cause a dose dependent decrease in strontium clearance
independent of its action on blood flow.
5. The PGE2 action could involve a 'novel' inhibition of calcium uptake, possibly
through an effect on capillary permeability.
6. The results add weight to the view that clearance measurements are not appropriate
for the measurement of bone blood flow.
7. The five minute period of the blood flow study is inadequate to allow a hypercalcemic
effect to occur.
7.4. Future work
These experiments highlight the effect of the vasoactive and calcium regulating agents
on bone, for example blood flow, arterial blood pressure, vascular resistance etc, but do
not attempt to consider the mechanisms by which these agents work. In particular this
study shows that the administration ofPTH and PGE2 affects mineral exchange. These
short term effects have however not been observed in any in vivo experiments. Further
studies could therefore be adapted from this work to investigate these effects and the
method by which the drugs cross the bone blood barrier.
The conceptof a 'bonemembrane' has been discussed for some years. Twomechanisms
having been proposed to support the hypothesis of the blood-bone disequilibrium.
Firstly Talmage (1969) suggests that calcium ions are allowed to diffuse down the
concentration gradient (from blood into bone) but these ions are actively pumped out of
bone. Secondly it has been suggested that there is a local concentration gradient of
solubiliser produced by the osteoblasts lining the resting bone surfaces. The reduction
in clearance in response to the PGE2 is independent of blood flow and this can be
reconciled with the calcium pump theory of Talmage.
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Possible future work
The us© ofmetabolic and calcium blocking agents could be used to attempt to identify
the mechanism of these agents action. If active transport is involved in the uptake of
strontium from blood to bone in the response to these preparations then the use of a
metabolic inhibitor should affect this. Further experiments in whole animal prepara¬
tions would be unsuitable for this type of study. The use of cAMP inhibitors or other
inhibitors could have adverse systemic effects thereby complicating the interpretation
of the results even "killing" the animal. In vitro experiments could be used as an
alternative since the metabolic activity would be controlled and there would be no
adverse systemic effects. The removal of the tissue however would likely damage or
interfere with any "membrane" effect. Tibial perfusion would provide the optimum
situation there would be little damage if any to the bone membrane yet the bone could
be experimented on in isolation with the drugs having no general systemic effect. The
rat however would be unsuitable for this type of study thus another animal would have
to be considered. The rabbit is an alternative, the tibial artery can be cannulated
successfully.
Suggested experimental protocol for tibial perfusion technique (rabbit/sheep)
1. This technique requires cannulation of the tibial nutrient artery followed by perfusion
of the tibial cortex with Krebs Ringer buffer.
2. The ipsilateral femoral vein is then cannulated to provide a site for sampling the
venous blood.
3. A bolus of three reference tracers are added via the nutrient artery. These include
a). 125 I-albumin a reference vascular tracer,
b). 14 C-sucrose an inert fluid tracer,
c). 85 Strontium a bone seeking tracer.
Simultaneously, blood is sampled at the ipsilateral vein at 10 second intervals for 5
minutes.
4. One ml aliquots of these blood samples are then measured for activity.
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It is therefore possible to perform two measurements on each animal, the first using
standard buffer as a control measurement and the second after injection of the
appropriate agent and a calcium blocking agent or metabolic inhibitor. Therefore the
results of the animals treated with a metabolic inhibitor or calcium blocking agent and
drug can be compared with those of the drug treated groups only. Interpretation of these
may highlight a possible mechanism of action.
Summary 7-9
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Dose-Dependent Reduction of Bone Blood Flow
and 85Sr Clearance Caused by Prostaglandin E2
E. Cochrane. R. H. Fleming, and I. D. McCarthy
Introduction
Osteolytic effects of series E prostaglandins are well established in vitro and in
vivo (Klein and Raisz 1970; Vanderwiel and Talmage 1979). and it has also
been reported that the injection of massive doses of native prostaglandin E,
(PGE2) into rats can enhance bone mineralisation (Uemo et al. 1984). Recent
reports have claimed that 16-16 dimethyl PGE2 produced inhibition of 45Ca
uptake in chicks. It was suggested that this represented a novel response, but
the possibility of an indirect vascular mechanism was also discussed. In this
paper, we have investigated the relationship between the inhibition of mineral
uptake by PGE, and changes in bone blood flow. This has then been compared
with the response due to the vasoactive effect of noradrenaline.
Materials and Methods
The study involved the use of radioactive microspheres and labelled isotopes
to establish bone blood flow and strontium clearance measurements. After
dissection, a cannula was inserted within the heart via the carotid artery and
a second cannula inserted into the tail artery. Microspheres were inserted into
the carotid cannula and reference blood samples were withdrawn from the tail
cannula. A control flow rate w:as established using 3~Co microspheres. Blood
was withdrawn from the tail artery at a rate of 0.197 ml/min. and 30 s later the
microspheres were injected via the carotid cannula. Withdrawal of blood from
the tail artery ceased after a total of 2 min. A stock solution ofPGE- was made
by dissolving it in ethanol. and this was then made into test solutions of 0. 20.
40. 60 and 80 pg of PGE2 using Krebs-Ringer buffer solution containing 1 %
albumin. Each dose group contained six Sprague-Dawley rats weighing ap¬
proximately 300-350 grams. The test solution was injected via the carotid
cannula. After 30 s blood was withdrawn from the tail artery. I13Sn micro¬
spheres. 15 pm in diameter, and 85Sr were injected via the carotid artery 30 s
later. Withdrawal of blood from the tail artery ceased after a total of 4.5 min.
This method was also followed using noradrenaline as the test solution.
However, due to the properties of noradrenaline and its rate of metabolism in
Appendix 2-1
E. Cochrane el al.
the body the test solution was infused over the experimental period at a rate
of 1.3 pg kg per min and not injected as a bolus. Animals were killed, both
tibiae and femora were removed quickly to minimise post mortem migration,
and bone and blood samples then measured for radioactivity.
Bone blood flow and 85Sr clearance were calculated from the following
equations:
microsphere activity in bone x pump rate
Bone blood flow =
microsphere activity in blood
8"Sr activity in bone x pump rate
Sr clearance=
85Sr activitv in blood
Results
The results presented in Figs. 1 and 2 show that PGE, produced a dose-depen¬
dent reduction of both blood flow and 85Sr clearance. In each dose group the
significance of the effect of PGE2 on bone blood flow was assessed by compar¬
ing the paired values for the First and second flow measurements. This high¬
lighted a general trend, a decrease in bone blood flow with increasing PGE,
concentration. PGE, decreased flow to bone from a control value of 0.3 ml;
min per g to 0.095 ml min per g at PGE, concentration of 80 pg per rat. Using












Fig. 1. Change in flow rate
with injected prostaglandin
E, for rat bone (mean
±~SEM)
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Fig. 2. Change in stron¬
tium clearance with inject¬













Fig. 3. a Change in flow
rate with noradrenaline in¬
fusion for rat bone (mean
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40 and 80 ug PGE, dose groups (P<0.02). Comparison of the control mean'
S5Sr value with each of the PGE, dose group shows the same trend, a dose-de-
pendent reduction of strontium clearance (Fig. 2). Statistical analysis shows
that strontium clearance at 80 pg dose group is significantly different from
control (P<0.01). The effect of noradrenaline infusion on flow and clearance
are shown in Fig. 3. Noradrenaline at a concentration of 1.3 pg/kg per min
decreased both bone blood flow and 85Sr clearance, its effect on flow and
clearance being similar to higher doses of PGE,.
Discussion
The results show a pattern of decreasing bone blood flow and 85Sr clearance
with increasing PGE, concentration, with the one concentration of nor¬
adrenaline having a similar effect. Tothill and Hooper (1984) and Schoutens
et al. (1979) have previously shown clearance is not linearly related to bone
blood flow and that bone clearances become poor indicators of increases of
bone blood flow. The data presented here are in agreement with these results,
suggesting there is no apparent difference between the effects of PGE, and
noradrenaline. If it is assumed that the noradrenaline acts only by increasing
peripheral vascular resistance and reducing blood flow, then it suggests the
reduction of clearance by PGE, is also an indirect vascular effect. There is no
"novel" inhibition of calcium uptake.-The mechanisms of reducing blood flow-
are not necessarily ,the same as PGE, lowers blood pressure, noradrenaline
increases blood pressure.
In summary. PGE, and noradrenaline infusion cause changes in both bone
and 85Sr clearance. The results suggest that changes in 85Sr clearance are
dependent on the effect of the drugs on bone blood flow--.
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APPENDIX 3
Effect of Calcium Regulating Hormones and Vasoactive Substances on Bone Blood
Flow
E. Cochrane and Dr. I.D. McCarthy
Dept. of Orthopaedic Surgery, University of Edinburgh
It is now believed that there is a significant association between skeletal blood flow and
bone turnover. We have been investigating the action of vasoactive substances,
noradrenaline and ATP and calcium regulating agents, PGE2, PTH and calcitonin on
bone blood flow within a five minute period. Radioactive microspheres were used to
estimate blood flow and strontium-85 for strontium clearance in rats weighing approxi¬
mately 350 grammes.
Calcitonin produced no effect on blood flow or pressure but significantly increased
strontium clearance (p<0.03). Administration of PGE2 produced a dose dependent
reduction of blood flow, pressure and strontium clearance (p<0.006). Similarly PTH
significantly reduced blood pressure and blood flow in a dose dependent fashion
(p<0.003). Infusion of noradrenaline resulted in a significant decrease in blood flow
(p<0.01) and an increase in blood pressure (p<0.003). While ATP caused a significant
decrease in blood pressure.
With all groups, there was a significant relationship between blood flow and strontium
clearance, but the slope of regression was significantly different for PGE2 (p<0.01).
This shows that PGE2 was having a direct effect on bone independent of its effect on
blood flow. It also shows that clearance values are not appropriate for themeasurement
of bone blood flow.
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The Effects of vaso-active substances and calcium regulating hormones on bone blood
flow and strontium clearance
I.D. McCarthy, E. Cochrane and S.P.F. Hughes
Department of Orthopaedic Surgery, University of Edinburgh,
Edinburgh EH8 9AG, U.K.
INTRODUCTION: It has been recently reported
that parathyroid hormone (PTH) and prostaglandin
E2 (PGE2) produce a very rapid inhibition of
calcium uptake in chicks (1). In order to investigate
whether this is the result of a vascular effect, or
whether this is a direct effect on bone, the response
of bone blood flow and strontium clearance to
PTH, PGE2 and calcitonin in rats has been
measured. These were then compared with the
responses due to noradrenaline and ATP.
MATERIALS AND METHODS: Sprague
Dawley rats, weighing approximately 300 to 350g,
were used for these experiments. After dissection,
a cannula was inserted within the heart via the
carotid cannula, and a second cannula inserted into
the tail artery. An initial control blood flow
measurement was performed. Blood was
withdrawn from the tail artery at a rate of
0.197ml/min, and thirty seconds after start of
withdrawal microspheres labelled with cobalt-57
were injected via the carotid cannula. Withdrawal
of blood was stopped after 2 minutes. At this point
either PGE2 (20, 40, 60, 80pg), PTH (4, 8, 12pg),
calcitonin (10, 15, 25U.), noradrenaline (1.0, 1.5,
2.0 pg), ATP (10.25, 0.75, 1.25mg) or an equal
volume of Krebs Ringer buffer was administered.
One minute later, blood was withdrawn from the
tail artery, and thirty seconds later, microspheres
labelled with tin-113, together with strontium-85,
were injected via the carotid cannula . Blood was
withdrawn from the tail artery for a period of 4.5.
minutes. The animals were then sacrificed and
both tibiae and femora were removed very
quickly, so that post mortem migration of
strontium into the bones were minimised. The
bones and both blood samples for radioactivity.
The total number of microspheres in the four
bones was normally about 1000. Blood flow and
strontium clearance were calculated from the
radioactivity measurements using the standard
equations.
RESULTS: ATP did not produce any direct effect
on bone. Noradrenaline produced a dose
dependent decrease of bone blood flow (p=0.026),
and a related increase in vascular resistance (p<
0.01). However, there was no change in the
strontium clearance.
PGE2 also produced a dose related decrease of
bone blood flow (p< 0.001) and an increase of
vascular resistance. However, a significant
decrease (p< 0.005) in strontium clearance was
also observed (see Figure 1). Although
administration of PTH resulted in a decrease in
blood flow, this was not associated with any
significant change in vascular resistance or
strontium clearance. Calcitonin, while not having a
significant effect, did slightly increase strontium
clearance (p< 0.03).
The relationship between strontium clearance and
blood flow was generally linear in the range of
values measured. However, there is a significant
difference (p< 0.01) between the slopes of the
regression lines for control rats (0.47) and those
rats given PGE2 (0.78). In all other groups, the
relationship between blood flow and clearance was




Figure 1. The relationship between strontium
clearance and PGE2 concentration.
DISCUSSION: These data show that PGE2 has an
immediate direct effect on hone, in addition to its
effect on blood flow. Previous work has shown that
metabolic activity could alter the immediate
distribution of strontium-85 in bone, either by
controlling access to a compartment or by
increased capacity for binding to bone surfaces (2),
and the present data support that idea.
Clearance measurements have been used for bone
blood flow measurement. However, the extraction
of bone-seeking tracers is flow dependent. The
present work shows that there are additional
factors that control extraction, and great care is
needed in extrapolating from clearance to bone
blood flow.
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